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1 Introduction and aim of the thesis 
Vascular disease generally refers to a pathological state affecting the circulatory 
system of the body. Main risk factors include physical inactivity, hypertension, smoking, 
obesity, dyslipidemia, and hormone status. As its prevalence increases with the rise of 
the average age, vascular disease represents the leading cause of death in 
industrialized nations. Apart from the loss of life years, a diminished quality of life as 
well as enormous direct and indirect medical costs have to be directly associated with 
the occurrence of vascular disease [Kim et al., 2011].  
As a major cause of vascular disease, atherosclerosis defined as the narrowing of the 
arteries by deposition of lipids and fibrous elements on their walls, limits the blood flow 
[Lusis, 2000]. Subsequently, resulting ischemia can lead to substantial functional 
deficits and tissue damage most commonly affecting the heart, brain and lower limbs. 
However, the formation of new blood vessels from pre-existing ones, a process 
designated as angiogenesis, only restrictively occurs in the body, so that a natural 
recovery of the ischemic site is rather unlikely. Therefore, as potential therapies, 
usually anti-thrombotic strategies as well as bypass grafting are pursued. However, 
autologous transplantation of vessels might often not be feasible due to damage and 
pre-existing disease. In contrast, the application of allogeneic or synthetic grafts can 
lead to immunologic and thrombotic problems. Consequently, there is an urgent need 
for appropriate arterial substitutes, tissue regeneration after ischemia, and the 
formation of mature blood vessel networks, which is very actively explored by 
researchers in the context of vascular tissue engineering [Zhang et al., 2007]. 
Tissue engineering, often interchangeably used with the term regenerative medicine 
[Lee et al., 2011], merges principles of life sciences and engineering towards the 
development of biological replacements that restore, maintain or improve tissue 
function. Besides vascular tissue engineering, which aims to create physiologically 
interactive substitutes for diseased or injured vascular tissue [Zhang et al., 2007], 
sufficient vascularization represents an absolute requirement for any other type of 
engineered tissue as well to ensure gas exchange and supply of essential nutrients, 
the removal of metabolites and the establishment of a biochemical communication 
within regenerative approaches [Ko et al., 2007]. Consequently, the development of 
strategies to support effective blood vessel formation is of outstanding general interest 
for almost every therapeutic tissue engineering concept. In this context, therapeutic 
angiogenesis attempts to apply and enforce the natural process of blood vessel 
formation by the provision of bioactive effectors [Zisch et al., 2003b; Zhang et al., 2007] 
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on the molecular (such as angiogenic growth factors) or cellular (such as vessel-
constituting endothelial cells) level [Lee et al., 2001]. 
Inspiration for regenerative approaches originates from the fact that in their natural 
environment cells closely interact with the extracellular matrix (ECM), which represents 
a modular, three-dimensional and intricate scaffold that governs tissue function and 
organization by providing the cells with an adhesive mechanical support and specific 
biomolecular cues such as growth factors [Kleinman et al., 2003]. Following nature’s 
lead, strategies for vascular tissue engineering therefore generally rely on the use of 
polymeric matrices to deliver angiogenic effectors [Zisch et al., 2003b; Zhang et al., 
2007]. As growth factors or cytokines are critically important for determining the cellular 
behavior, many biomaterials were developed to allow for a controlled administration of 
these proteins. However, besides the possibility to effectively store and sustainably 
release the cytokines, for successfully promoting therapeutic angiogenesis, there are 
several additional requirements to be fulfilled by a certain growth factor delivery system 
[Lutolf et al., 2005]. As blood vessel formation is governed by both mechanical and 
biomolecular cues provided by the ECM, scaffolds to be used in angiogenic tissue 
engineering should offer similar, precisely adjustable structural and biological (including 
bioadhesiveness, enzymatic degradability and cytokine-binding ability) recognition 
properties. Moreover, since physiological angiogenesis is characterized by the complex 
interplay of various growth factors, the potential for an independent and adaptable 
parallel delivery of multiple cytokines defines another favorable characteristic of 
angiogenesis-stimulating biomaterials. Finally, in order to specifically meet the intricate 
demands of effective therapeutic angiogenesis, the growth factor provision should be 
tunable in response to local environmental cues or externally applied triggers [Lee et 
al., 2011]. Although several powerful cytokine delivery systems for angiogenic tissue 
engineering were developed to closely mimic mechanical and biomolecular key 
properties of the ECM [Zisch et al., 2003a], to allow for the combined administration of 
several cytokines [Richardson et al., 2001] or to permit the precise triggering of the 
growth factor release [Ehrbar et al., 2008], the integration of all these features into one 
single material represents a challenging, but indispensable prerequisite to further 
enhance therapeutic effectiveness.  
 
Consequently, the aim of this work was to evaluate the potential of a modular biohybrid 
hydrogel composed of star-shaped poly(ethylene glycol) (starPEG) and heparin as a 
delivery system for two major angiogenic cytokines, fibroblast growth factor-2 (FGF-2) 
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and vascular endothelial growth factor (VEGF) [Klagsbrun et al., 1999]. For this 
system, effective administration of the cytokines was based on their reversible affinity-
interaction with heparin, a highly charged glycosaminoglycan capable of complexing 
various different growth factors [Capila et al., 2002].  
After the establishment of appropriate analytical methods, binding and release of both 
cytokines had to be investigated for different heparin-based hydrogel matrices of varied 
mechanical characteristics and degree of biofunctionalization (e.g. with adhesion 
ligands). Moreover, the possibility to deliver distinct concentrations of either single 
growth factors or combinations of FGF-2 and VEGF had to be explored. To evaluate 
the general suitability for pro-angiogenic stimulation, the provision of the cytokines from 
scaffolds differing in physicochemical characteristics and biofunctionalization had to be 
studied using human endothelial cells, the cell type that forms the inner layer of any 
blood vessel [Carmeliet, 2003], in culture. Based on these experiments, matrices most 
effectively stimulating pro-angiogenic cellular responses were to be selected for in vivo 
experiments consisting of the incorporation into the chorioallantoic membrane (CAM) 
system of fertilized chicken eggs, an assay commonly used to quantify the 
vascularization potential of biomaterials in vivo [Auerbach et al., 2003]. After evaluating 
the ability of a growth factor delivery by starPEG-heparin matrices to stimulate 
therapeutic angiogenesis, further options to specifically modulate the growth factor 
release had to be explored to adjust the system for maximal pro-angiogenic response.  
Taken together, this work aimed at investigating the possibility to control immobilization 
and subsequent release of FGF-2 and/or VEGF from starPEG-heparin hydrogels to 
promote angiogenesis in tissue engineering. Using a novel type of biohybrid matrix 
platform, this project set off to generate fundamental insights into the provision of 
functional signaling molecules from polymer scaffolds with far-reaching control over 
structural parameters like stiffness, degradability and adhesive properties. 
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2 Theoretical background 
2.1 Physiological angiogenesis 
2.1.1 The biological process of physiological angiogenesis 
The establishment and maintenance of a vascular supply is an absolute requirement 
for the growth and survival of organs and tissues [Ko et al., 2007]. Depending on the 
size of a particular blood vessel, its composition may vary. While small vascular tubes 
consist only of endothelial cells, larger vessels are surrounded and stabilized by mural 
cells (pericytes in medium-sized and smooth muscle cells in large vessels) [Carmeliet, 
2003].  
Angiogenesis is defined as the formation of new blood capillaries from pre-existing 
vessels [Distler et al., 2003]. While abnormal development of vasculature is associated 
with various diseases such as cancer, arthritis, psoriasis, blindness, obesity, 
artheriosclerosis, asthma and some infections, physiological angiogenesis mainly 
occurs during embryonic development [Carmeliet, 2003]. In the adult organism, it is a 
very rare event usually restricted to wound healing and the female reproductive system 
[Klagsbrun et al., 1999; Liekens et al., 2001; Distler et al., 2003] 
The biological process of angiogenesis (Fig. 1) involves several steps, which are 
controlled by the complex interplay of cells, soluble angiogenic or angiostatic effector 
molecules and the extracellular matrix (ECM) [Liekens et al., 2001]. Upon initiation, 
angiogenic factors such as fibroblast growth factor-2 (FGF-2) or vascular endothelial 
growth factor (VEGF) bind to their receptors on endothelial cells thereby activating 
different signal transduction pathways [Klagsbrun et al., 1999]. One of the first events 
that occur in the following is the vasodilation of the pre-existing blood vessel [Distler et 
al., 2003]. During this step, nitric oxide synthase in endothelial cells is activated by 
FGF-2 [Cuevas et al., 1996; Tiefenbacher et al., 1997] or VEGF [Murohara et al., 1998; 
Garcia-Cardena et al., 1998; Hood et al., 1998; Bouloumié et al., 1999]. In response to 
an increase in the intracellular levels of nitric oxide, guanyl-cyclase synthesizes cyclic 
guanosine monophosphate, which results in a relaxation of mural cells. Moreover, 
VEGF enhances the permeability of endothelial cells by initiating the formation of 
interconnected vesicles and vacuoles [Kohn et al., 1992]. Upon cluster formation, they 
are able to span the whole cytoplasm. As a result of the increased cell permeability 
mediated by these organelles and by inter-endothelial cell junctions [Dvorak et al., 
1995], the transport of plasma proteins such as fibrinogen and plasminogen from the 
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blood stream into the surrounding tissue is highly facilitated. Within the next steps, 
these plasma proteins provide a scaffold for the migrating endothelial cells. However, in 
advance, the removal of mural cells, the disintegration of the endothelial cell basement 
membrane and the remodeling of the perivascular stroma has to occur [Klagsbrun et 
al., 1999; Liekens et al., 2001; Distler et al., 2003]. The key players involved in these 
processes are angiopoietin 2 [Maisonpierre et al., 1997] as well as different proteases 
including plasminogen activators and matrix metallo-proteinases (MMPs) [Mignatti et 
al., 1996]. After the vessel destabilization and matrix degradation, endothelial cells start 
to proliferate and to migrate in response to a gradient of chemotactic molecules 
through the degraded basement membrane into the remodeled and softened 
perivascular space [Klagsbrun et al., 1999; Liekens et al., 2001; Distler et al., 2003]. 
These processes are induced by a variety of different angiogenic effectors such as 
members of the VEGF- [Veikkola et al., 1999; Ferrara, 1999] and FGF-family 
[Bussolino et al., 1996; Presta et al., 2005], angiopoietin 1 [Koblizek et al., 1998; Hayes 
et al., 1999] and 2 [Mochizuki et al, 2002; Lobov et al., 2002], angiogenin [Badet, 
1999], epidermal growth factor (EGF) [Schreiber et al., 1986; Sato et al., 1993; 
Bussolino et al., 1996], CXC-chemokines (containing a cysteine-separating amino acid-
cysteine motif) [Keane et al., 1999] and insulinlike growth factor-1 (IGF-1) [Bar et al., 
1988], while some of them are released by the degraded ECM or different cell types. 
After the endothelial cells have reached the site with decreased vessel density, they 
start assembling in a monolayer and finally build a capillary sprout, which is further 
propagated by proliferating endothelial cells until a lumen is formed [Klagsbrun et al., 
1999; Liekens et al., 2001; Distler et al., 2003]. Among others, different VEGF isoforms 
[Veikkola et al., 1999; Ferrara, 1999] as well as adhesion molecules such as integrin 
αvβ3 [Eliceiri et al., 1998] or E-selectin [Nguyen et al., 1992] are essential for these 
processes. In the last step, the stabilization of the vascular tube by mural cells 
completes the formation of a new vessel [Klagsbrun et al., 1999; Liekens et al., 2001; 
Distler et al., 2003]. For this, mesenchymal cells of the surrounding tissue can be 
recruited in response to effectors such as the platelet-derived growth factor (PDGF) 
isoform PDGF-BB [Lindahl et al., 1997]. Upon these signals, they start to proliferate 
and to migrate to the abluminal surface of the premature vessels [Klagsbrun et al., 
1999; Liekens et al., 2001; Distler et al., 2003]. Here, they either differentiate into 
pericytes, which are found within the basement membrane, or into vascular smooth 
muscle cells, which are located abluminal of the basement membrane [Kurz, 2000]. 
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Fig. 1 Basic steps of the angiogenic process; modified from [Klagsbrun et al., 1999]. (a) Angiogenic 
effectors bind to their receptors on endothelial cells (EC) thereby activating intracellular signaling cascades 
resulting in an increased cell permeability (b) Expression of extracellular matrix (ECM) remodeling 
enzymes such as matrix metalloproteinases (MMPs) leads to the degradation of the basement membrane 
allowing ECs to migrate out of the pre-existing capillary wall and to proliferate. (c) Adhesion molecules 
such as integrin αvβ3 are expressed by ECs facilitating their adhesion to the ECM and their migration. (d) 
Different angiogenic effectors bind to their receptors on ECs thereby stimulating vessel sprouting, pericyte 
recruitment, and/or vessel survival and stabilization. (e) ECs release PDGF-BB, which is a 
chemoattractant for mesenchymal cells. These cells become associated with ECs and differentiate into 
pericytes or smooth muscle cells which stabilize the vascular tube. 
 
 
2.1.2 The angiogenic cytokines fibroblast growth factor-2 (FGF-2) and 
vascular endothelial growth factor (VEGF)  
The term growth factor or cytokine is broadly used to describe a naturally occurring, 
soluble-secreted signaling polypeptide that is able to stimulate a specific cell behavior 
such as survival, proliferation or differentiation in the context of a biological 
environment. After secretion from a producer cell, many growth factors can be stored 
via an interaction with ECM molecules. The function of these proteins is usually 
mediated by an interaction with surface receptors on the target cells which show an 
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intrinsic tyrosine kinase activity. Upon complex cascades involving phosphorylation of 
target proteins, ion fluxes, changes in metabolism, gene expression and protein 
synthesis, the signal created by the growth factor is translated into an integrated 
biological response (Fig. 2) [Lee et al., 2011]. 
In the context of angiogenesis, two of the most important regulators are the angiogenic 
cytokines fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor 
(VEGF) [Klagsbrun et al., 1999; Liekens et al., 2001; Distler et al., 2003]. 
Fig. 2 Basic principle of growth factor signaling; adapted from [Lee et al., 2011]. The producer cell secretes 
soluble growth factors which interact with target cell receptors. This binding event is translated into the cell 
through complex signal transduction pathways leading to a specific biological cellular response. The insert 
illustrates how ECM temporally and spatially governs growth factor presentation. Cell migration towards 
gradients of growth factors, bound to ECM molecules, can be mediated by the ECM. In order to move into 
the direction of these gradients, cells use the integrin adhesion machinery. Upon degradation of ECM 
molecules, attached growth factors become available for cell binding via cell membrane growth factor 
receptors and will finally induce a specific biological cellular response. 
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FGF-2 
FGF-2 belongs to the FGF family [Gospodarowicz, 1975], which contains more than 20 
heparin-binding members [Presta et al., 2005]. It consists of twelve anti-parallel β-
sheets that are organized into a trigonal pyramidal structure and has a hydrodynamic 
diameter of 3.4 to 4 nm [Eriksson et al., 1991; Nugent et al., 2000]. FGF-2 contains four 
cysteine residues with no intramolecular disulfide bonds and two sites (serine 64 and 
threonine 112) that can be phosphorylated. Moreover, a large number of basic residues 
(pI = 9.6) [Bikfalvi et al., 1997] mediate the highly affine (Kd = 23 nM) [Ashikari-Hada et 
al., 2004] electrostatic binding to the negatively charged sulfate groups of heparin. 
Here, two sites (aspartic acid 28, arginine 121, lysine 126 and glutamine 135 as well as 
lysine 27, asparagine 102 and lysine 136) [Faham et al., 1996] interact with the 2-O- 
and N-sulfate groups of the glycosaminoglycan [Habuchi et al., 1992; Turnbull et al., 
1992; Faham et al., 1996], with affinity increasing with heparin chain length [Nugent et 
al., 2000]. Although the heparin 6-O-sulfate groups do not participate in FGF-2 binding, 
they are involved in the enhancement of the protein activity [Pye et al., 1998].  
While larger isoforms (22, 22.5 or 24 kDa) resulting from alternative splicing are 
predominantly localized to the nucleus, the most prominent 18 kDa form of FGF-2 is 
mainly found outside of the cell [Florkiewicz et al., 1991]. As it contains no signal 
sequence for a cellular export, this protein does not progress via the regular secretory 
pathway [Mignatti et al., 1992]. Instead, FGF-2 could be released to the extracellular 
space via non-lethal membrane disruptions as well as cell damage and death [Nugent 
et al., 2000]. In the ECM, FGF-2 is stored upon binding to heparin-like molecules 
[Folkman et al., 1988]. While this interaction protects the protein from proteolytic 
cleavage and heat or acid denaturation, the dynamic FGF-2 binding and release by the 
glycosaminoglycans also controls its diffusional movement and distribution 
[Gospodarowicz et al., 1986a; Dowd et al., 1999]. Here, enzymatic degradation of the 
heparin-like molecules as well as the presence of competitive antagonists, soluble 
glycosaminoglycans, FGF-binding proteins and analogs influence the availability of 
FGF-2 from ECM sites [Nugent et al., 2000].  
Upon release from the glycosaminoglycans, FGF-2 interacts with four different, 
structurally related tyrosine kinase cell surface receptors (FGFR1-4) and their splice 
variants [Zhang et al., 2006]. FGF-2 contains two separate receptor interaction sites, 
which allow a single FGF-2 to bind to two receptor molecules or to interact with one 
receptor molecule at two different sites [Kan et al., 1993]. Upon a binding to heparin or 
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heparan sulfate, the affinity of FGF-2 for its receptors is highly increased [Yayon et al., 
1991], as, due to the presence of a heparin interaction site on FGFR1 [Kan et al., 
1993], a ternary complex of FGF-2, the glycosaminoglycan and the receptor can be 
formed. This cluster might act as a bridge to facilitate FGFR dimerization, which results 
in an activation and the subsequent autophosphorylation of the cytoplasmatic tyrosine 
kinase domain [Nugent et al., 2000]. This event represents the starting point for several 
intracellular signaling cascades including the Ras (derived from “rat sarcoma”), Src 
(derived from “sarcoma”) family tyrosine kinases, phosphoinositide 3-kinase (PI3K) and 
the phospholipase C (PLC) pathway which all lead to a FGF-2 mediated cell response 
[Cross et al., 2001]. After that, FGF-2 is either taken up by the cell bound to the 
glycosaminoglycans in the context of their constitutive internalization and turnover or 
together in the ternary complex with heparin or heparan sulfate and FGFR in order to 
degrade the cytokine in the lysosomes [Nugent et al., 2000]. However, intracellular 
FGF-2 can also translocate to the cell nucleus and directly exert gene regulatory 
functions [Sperinde et al., 1998; Choi et al., 2000; Nugent et al., 2000].  
As the expression of FGF-2 is nearly ubiquitous, it influences the survival, growth, 
differentiation and migration of various cell types being derived from the mesoderm or 
neuroectoderm [Gospodarowicz et al., 1986b] such as fibroblasts, myeloblasts, 
osteoblasts, neural or endothelial cells [Bikfalvi et al., 1997]. Nevertheless, disruption of 
the mouse FGF-2 gene results in mice with decreased vascular tone and low blood 
pressure, but which displayed relatively mild cardiovascular, skeletal, and neuronal 
phenotypes thereby indicating compensatory actions of other FGF family members 
[Dono et al., 1998; Cross et al., 2001]. In contrast, a transgenic over-expression of 
FGF-2 predominantly affects the development and mineralization of bone [Coffin et al., 
1997]. In the context of angiogenesis, cell or ECM-released FGF-2 has been shown to 
stimulate the proliferation, migration and differentiation of endothelial cells both in vitro 
and in vivo [Presta et al., 2005]. Moreover, it is also directly expressed by endothelial 
cells [Schweigerer et al., 1987; Vlodavsky et al., 1987]. Here, FGF-2 induces the 
production of nitric oxide, proteases or adhesion molecules thereby contributing to the 
propagation of the angiogenic process at several levels [Presta et al., 2005]. Besides, 
FGF-2 demonstrates a strong synergistic action together with VEGF. Both in vitro and 
in vivo, this affects the induction of endothelial cell proliferation and migration as well as 
the formation of capillary tubes [Pepper et al., 1992; Goto et al., 1993; Asahara et al., 
1995; Vernon et al., 1999; Yan et al., 2001; Kano et al., 2005]. 
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VEGF 
VEGF belongs to the VEGF family, which currently comprises the six members VEGF-
A (which refers to the VEGF originally identified) [Senger et al., 1983; Ferrara et al., 
1989], placenta growth factor (PIGF), VEGF-B, VEGF-C, VEGF-D and the orf parapox 
virus VEGF, denoted as VEGF-E [Veikkola et al., 1999; Zachary et al., 2001; Robinson 
et al., 2001]. As a result of alternative splicing of the human gene encoding VEGF-A, at 
least six isoforms of 121, 145, 165, 183, 189 and 206 amino acids are generated 
[Robinson et al., 2001]. Out of these variants, VEGF-A165 (from here on denoted as 
VEGF) is the predominant and most biologically active form [Veikkola et al., 1999; 
Zachary et al., 2001]. This protein is glycosylated at asparagine 74 and it contains 16 
cysteine residues that are involved in intra- and inter-chain disulfide bonds [Ferrara et 
al.,1991]. VEGF is typically expressed as a ~ 46 kDa disulfide-linked homodimer, while 
each monomer consists of a four-stranded β-sheet. The protein has a hydrodynamic 
diameter of ~ 6 nm [Muller et al., 1997] and it possesses several basic residues (pI = 
8.5) [Ferrara et al.,1991]. Here, mainly one linear stretch consisting of the amino acids 
arginine 123, and 124, lysine 125 and 140, arginine 145, 149 and 156 with potential 
contributions from lysine 162, as well as arginine 164 and 165 [Fairbrother et al., 1998] 
mediates the electrostatic binding to heparin (Kd = 165 nM) [Ashikari-Hada et al., 
2004]. While this interaction preferentially occurs on 6-O- and N-sulfate groups of the 
glycosaminoglycan, nevertheless also the 2-O-sulfate and the carboxylic acid residues 
of heparin contribute to the overall binding strength [Ono et al., 1999; Robinson et al., 
2006].  
VEGF is a diffusible protein that is secreted into the extracellular medium of the 
producer cell, where it can be associated to the ECM upon binding to heparin-like 
molecules [Houck et al., 1992]. Similar to FGF-2, this interaction protects the biological 
integrity of VEGF [Lee et al., 2005], controls its availability and mediates the action of 
the protein upon modulation of its receptor affinity [Gitay-Goren et al., 1992]. Here, the 
receptor tyrosine kinases VEGFR-1 and VEGFR-2 have been identified as high-affinity 
binding sites for VEGF on the vascular endothelium, while neuropilins modulate the 
VEGF interaction with these two main receptors [Zachary et al., 2001; Robinson et al., 
2001]. Comparable to VEGF itself [Shweiki et al., 1992], the receptor expression is 
regulated by oxygen tension [Tuder et al., 1995; Li et al., 1996]. While VEGFR-1 might 
function as a negative regulator of VEGFR-2, the most important angiogenic effects of 
VEGF are mediated by VEGFR-2 [Zachary et al., 2001; Robinson et al., 2001]. Upon 
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ligand binding, VEGF triggers the receptor dimerization and subsequent auto-/trans-
phosphorylation which finally results in a signal transduction to the nucleus thereby 
leading to a specific cell response. Here, VEGF mainly exert its action via the PLC, 
extracellular signal-regulated kinase (ERK), PI3K/Akt (protein kinase B) or Src family 
tyrosine kinases pathways [Zachary et al., 2001; Cross et al., 2001].  
In normal tissues such as brain, kidney, liver or spleen [Veikkola et al., 1999], VEGF is 
expressed by most of the cell types such as monocytes, macrophages, hepatocytes, 
lymphocytes, keratinocytes, osteoblasts or smooth muscle cells. In contrast to FGF-2, 
VEGF is generally not secreted by its main targets, the endothelial cells [Maharaj et al., 
2007]. Nevertheless, the importance of VEGF in vascular development is highlighted 
by the fact that the loss of only a single VEGF allele already leads to embryonic 
lethality [Carmeliet et al., 1996; Ferrara et al., 1996]. During angiogenesis, VEGF has 
been shown to stimulate the survival, proliferation, migration and differentiation of 
endothelial cells both in vitro and in vivo, while it is not mitogenic for most other cell 
types [Veikkola et al., 1999; Maharaj et al., 2007]. Moreover, it increases vascular 
permeability by stimulating the nitric oxide synthase and enhances basal membrane 
and ECM degradation by supporting the expression of proteases [Distler et al., 2003]. 
Due to their critical roles in the context of vascular development, both FGF-2 and 
VEGF are key players in the concept of therapeutic angiogenesis. 
 
 
2.1.3 Angiogenesis as a therapeutic target 
Although a strong clinical interest has emerged in developing anti-angiogenesis 
reagents for pathological phenomena associated with undesired or enhanced formation 
of new vessels, several strategies also aim to support angiogenesis for the treatment of 
ischemic diseases or for enabling a sufficient vascularization of an engineered implant. 
Ischemia is defined as hypoxia or necrosis of a tissue as a result of an obstruction of 
the arterial blood supply or an insufficient blood flow due to underlying metabolic 
diseases or trauma. Depending on the amount of viable cells remaining in the affected 
tissue, the body is able to spontaneously develop collateral blood vessels to re-supply 
the ischemic area thereby supporting a functional recovery. However, with a few 
exceptions, the body favors a physiological steady-state, in which angiogenesis is 
suppressed. The vascular endothelium therefore remains rather inactive and 
represents one of the tissues with the lowest mitotic rate [Zhang et al., 2007]. 
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Consequently, in order to successfully treat ischemic diseases or to support an 
effective vascularization of an engineered construct for implantation, strategies to 
induce blood vessel formation are required. In this context, the concept of therapeutic 
angiogenesis tries to use and enhance the natural process of blood vessel formation 
upon the administration of bioactive factors. By increasing the blood vessel density, the 
tissue function close to the ischemic site should be preserved or restored [Zhang et al., 
2007]. In contrast, upon the induction of vascularization of an implant, sufficient oxygen 
or nutrient supply, waste removal and the provision of a biochemical communication 
guide within the engineered construct are ensured [Ko et al., 2007].  
Following the strategy of therapeutic angiogenesis, either whole cells or signaling 
molecules (including drugs, proteins or oligonucleotides) could be delivered as the 
angiogenic effectors (Fig. 3). The first concept could use matured endothelial cells [Lee 
et al. 2001], which can be obtained directly from the patient, after which they are 
expanded in vitro and administered to areas of ischemia tissue or to the site of an 
implant, where they should participate in blood vessel formation (Fig. 3, a-c). However, 
these implanted cells might suffer from the lower mitogenic and morphogenic stimuli 
provided by the natural host environment of elderly people thereby leading to extensive 
cell death after introduction to the body and thus leaving cell therapies rather 
insufficient [Uebersax et al., 2009]. In contrast to the first strategy, the application of 
signaling molecules (most commonly recombinant angiogenic growth factors) to the 
ischemic site or the implant area should result in a stimulation of the growth, migration 
and differentiation of cells involved in the process of angiogenesis (Fig. 3, d-f). Here, 
major problems arise from ineffective or undefined dosing and unresponsiveness to the 
angiogenic effectors [Zhang et al., 2007], which often show a short half-life and poor 
bioactivity due to rapid diffusion and denaturation or degradation. As many of these 
factors also act on different tissues, severe adverse effects could occur upon the 
transport of these signaling molecules to adjacent sites. Moreover, angiogenesis is 
tightly controlled by the concentration-dependent, spatially- and temporally-
determinated action of multiple factors [Lee et al., 2011]. Consequently, the success of 
an undefined bolus injection of a single anigogenic signaling molecule might be limited, 
as already indicated by the rather disappointing results of clinical trials with infusions of 
FGF-2 [Simons et al., 2002] or VEGF [Henry et al., 2003]. To overcome these 
problems, more advanced strategies combining either several signaling molecules or 
both whole cells and molecular angiogenic effectors might be required [Zhang et al., 
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2007]. However, to address these challenges, precisely tunable delivery systems are 
needed. 
Fig. 3 Schematic of the two main approaches used in therapeutic angiogenesis; adapted from [Lee et al., 
2001]. Blood vessel formation is either supported by a direct introduction of the target cells (e.g. 
endothelial cells; a) or by the provision of growth factors (d) to the site of interest. The transplanted cells 
form new blood vessels starting at the site of their introduction towards the host tissue, while they might 
also provide stimuli to the existing vessels to grow and sprout into their direction (b). In contrast, soluble 
cytokines promote the growth of existing blood vessels from the surrounding host tissue into the direction 
of their delivery (e). Finally, the combination of new vessels with existing ones creates functional 
vascularization capable of blood flow (c, f).  
 
 
2.2 Angiogenic tissue engineering 
2.2.1 General requirements of biomaterials for an application in 
angiogenic tissue engineering 
Due to the problems associated with the systemic delivery of angiogenic effectors, in 
the context of therapeutic angiogenesis, there is a demand for scaffolds that provide 
the appropriate environment for both cells and signaling molecules [Zhang et al., 2007]. 
In the body, this function is fulfilled by the extracellular matrix (ECM) representing a 
complex, dynamic and critical component of all tissues (Fig. 4). It is composed of 
extracellular structural proteins (e.g. collagen or elastin), proteoglycans (e.g. perlecan 
or aggrecan), glycosaminoglycans (e.g. heparan sulfate or hyaluronic acid) and 
adhesion proteins (e.g. fibronectin or laminin), as well as growth factors (e.g. FGF-2 or 
VEGF), which form an intricate, three-dimensional meshwork [Frantz et al., 2010]. 
Here, the ECM acts as a scaffold for tissue morphogenesis, provides cues for cell 
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growth and differentiation, supports the maintenance of matured tissues and enhances 
the repair response after injury [Kleinman et al., 2003]. Based on these important roles 
of the ECM, the conceptual design of biomaterials to be used for effective tissue 
engineering approaches involves the mimicry of the two most important ECM 
attributes: its structural and its biological recognition (including bioadhesiveness, 
enzymatic degradability and growth factor-binding capacity) properties [Hubbell, 2003]. 
Fig. 4 General composition of the extracellular matrix (ECM); modified from [Frantz et al., 2010]. Depicted 
are the main constituents such as structural proteins like elastin or collagen I (ColI), proteoglycans, 
glycosaminoglycans, adhesion proteins like fibronectin as well as growth factors (GFs) like fibroblast 
growth factor-2 (FGF-2), epidermal growth factor (EGF), transforming growth factor-β (TGF-β) or vascular 
endothelial growth factor (VEGF). These components form an intricate, three-dimensional meshwork. The 
dynamic character of the ECM is represented by the illustration of the enzymatic remodeling of ECM 
proteins by matrix metallo-proteinases (MMPs) and the fluctuations in growth factor localization upon 
binding/release to/from glycosaminoglycans. 
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Structural requirements 
The structural character of the ECM is determined by its fibrillar and viscoelastic 
properties. While the ECM represents a network consisting of tensile components such 
as fibrillar and amorphous structural proteins, it also contains compressive elements 
such as amorphous proteoglycans and glycosaminoglycans [Hubbell, 2003]. Together, 
this composition provides not only support and scaffolding for tissues and cells, but 
also offers an appropriate mechanical strength. Upon the interaction of a substrate with 
the cytoskeleton and cellular adhesion ligands, mechanical forces can be directly 
transduced into chemical signals thereby resulting in a certain cell response [Kleinman 
et al., 2003]. As it has been shown that substrate stiffness critically determines cellular 
behavior [Discher et al., 2005], the mechanical properties of biomaterials used for 
regenerative approaches have to resemble the natural environment of the tissue of 
interest. In the context of angiogenesis, it has been demonstrated that endothelial cell 
adhesion and proliferation is favored on stiff substrates, while due to the fact that their 
requirements for growth and adaptation of an elongated morphology differ, primarily 
differentiate when cultured on a soft matrix that allows for an retraction and 
reorientation of the cell shape [Ingber et al., 1989; Deroanne et al., 2001; Liu et al., 
2005; Saunders et al, 2010]. As there might be an optimal range for balancing both 
parameters, the mechanical characteristics of an engineered matrix for therapeutic 
angiogenesis have to be adapted precisely. Here, mimicking the structural character of 
the natural ECM, biomaterials for tissue engineering are generally either designed as 
fibrillar matrices (e.g. by electrospinning; Fidrikh et al., 2003) or, since the pioneering 
work of [Wichterle et al., 1960], most commonly, as viscoelastic hydrogels defined as 
hydrophilic polymer networks that may absorb up to thousands of times their dry weight 
in water. Hydrogels can be grouped into either physical gels, where the networks are 
held together by molecular entanglements, and/or secondary forces (including ionic, H-
bonding or hydrophobic forces) or into chemical gels when they are covalently 
crosslinked. Here, physical hydrogels can be either formed upon change of 
temperature or pH or by simply combining oppositely charged components. In contrast, 
chemical crosslinking is usually performed via radiation, the addition of chemical 
crosslinkers or the mixing of multi-functional reactive compounds. Generally, in order to 
provide sufficient mechanical strength, hydrogels are often formed out of a diversity of 
synthetic polymers [Hoffman, 2002], as their mechanical properties can be easily 
manipulated at micro- and macroscopic levels by blending, copolymerization, or 
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crosslinking. As an advantage, these molecules can be easily synthesized in large 
amounts with well-defined characteristics such as molecular weight, molecular 
architecture, and microscopic morphology. Moreover, the introduction of various readily 
accessible functional groups at pre-determined polymer sites allows for a versatile 
macromer chemistry [Jia et al., 2008]. Examples of synthetic polymers used for the 
formation of tissue engineering constructs include poly(ethylene glycol) (PEG), poly(L-
lactic acid), poly(glycolic acid), polycaprolactones, polyorthoesters, polyanhydrides and 
polycarbonates [Chan et al., 2008]. 
 
Biofunctional requirements 
Although biomaterials based on synthetic polymers show physicochemical and 
mechanical characteristics similar to those of biological tissues, their biofunctionality is 
often insufficient, thereby limiting their potential. Consequently, numerous research 
groups have turned their attention to mimicking the biological recognition character of 
the ECM in terms of bioadhesiveness, enzymatic degradability and growth factor-
binding capacity by designing materials based on naturally occurring polymers, which 
are analogously assembled into physical or chemically crosslinked gel matrices. These 
biopolymers are purified from the ECM, isolated from microbial cultures or produced in 
recombinant cells [Hubbell, 2003]. Although also non-ECM-derived proteins such as 
albumin or silk fibroin [Uebersax et al., 2009] and polysaccharides such as alginate, 
chitosan or agarose [Lee et al., 2001] represent important examples for building blocks 
used to create biofunctional systems, many materials are based directly on ECM 
components. Once again, both proteins such as collagen or fibrinogen/fibrin and 
polysaccharides such as the glycosaminoglycans heparin/heparin sulfate, hyaluronic 
acid or chondroitin sulfate could be elements of these engineered matrices [Hubbell, 
2003; Uebersax et al., 2009]. To a certain extend, cells are able to interact with these 
naturally derived molecules resulting in increased adhesion to the particular 
biomaterial. Moreover, they may express specific degrading enzymes that permit the 
remodeling of such systems. Due to the interaction of growth factors with the numerous 
functional residues found in biopolymers, also the cytokine-binding ability of the ECM 
can be partially reconstructed. Therefore, to a certain extend, materials based on 
naturally derived polymers are able to mimic the in vivo situation [Lutolf et al., 2005]. 
However, despite their enhanced biofunctionality, there are also some drawbacks of 
these systems. For example, besides limitations concerning the material stiffness, the 
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possibilities to tune and process these biopolymers are restricted compared to 
synthetic molecules [Jia et al., 2008]. 
As a possible solution to overcome these problems, recent approaches rely on the 
creation of biohydrid materials. These systems are composed of both synthetic and 
natural polymer constituents interconnected via chemical or physical means, thereby 
combining the advantages of each single class of polymers. Here, as a structural basis, 
which additionally provides appropriate mechanical properties, synthetic molecules are 
used. Using different chemical modifications, they can be combined with natural 
polymers. However, instead of whole molecules, often low molecular weight peptides, 
which may possess biological activity in certain applications, are incorporated. Most of 
these peptides are truncated versions of naturally occurring proteins, which are 
produced by solid phase synthesis. This results in defined peptides that are slightly 
less biologically active than the complete, native protein, but do not require a specific 
secondary structure to be functional. For example, as they were shown to enhance 
endothelial cell adhesion and proliferation [Wang et al., 2002; Chung et al., 2002], 
peptide sequences containing the arginine-glycine-aspartic acid (RGD) motif of integrin 
ligands such as fibronectin [Ruoslahti et al, 1987] or other ECM proteins are 
incorporated into biohybrid materials. Moreover, also the cell-mediated proteolytic 
degradation and matrix remodeling can be controlled upon addition of peptide 
sequences with the GCRDGPQ-GIWGQDRCG motif (in single-letter amino acid code) 
of common MMP substrates such as collagen, fibronectin or laminin in order to allow 
for endothelial cell migration and scaffold reorganisation [Seliktar et al., 2004; 
Kraehenbuehl et al., 2009]. Beside the support of bioadhesiveness and enzymatic 
degradability, similar to another important molecular recognition property of the ECM, 
biomaterials used for successful tissue engineering approaches have to be capable to 
deliver growth factors. Due to the focus of this work, this particular issue will be 
discussed more in detail. 
 
 
2.2.2 Biomaterials for growth factor delivery in angiogenic tissue 
engineering 
In order to control the spatio-temporal availability of bioactive growth factors, 
therapeutic concepts rely on the presentation of cytokines by polymeric biomaterials. 
For tissue engineering strategies, two different approaches are used to administer 
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these effectors. Here, growth factors are either physically entrapped in the delivery 
matrix or chemically conjugated to the scaffold (Fig. 5). 
Fig. 5 Schematic of the two approaches for growth factor presentation by polymeric biomaterials within the 
context of tissue engineering; adapted from [Lee et al., 2011]. (a) Physically entrapped cytokines can be 
released from the scaffold to target for example specific cells to migrate and direct tissue regeneration. (b) 
Alternatively, growth factors can be chemically bound to the delivery system, making them available to 
cells that infiltrate the material. 
 
Physical growth factor encapsulation 
The former concept of a physical encapsulation is based on the entrapment of growth 
factors during the fabrication of a biomaterial, where hydrophobic or hydrophilic 
interactions among the cytokines and the polymers might facilitate this process. Later 
on, the cytokine release is determined by diffusion out of the network and/or matrix 
degradation. Common processing methods for such delivery systems include solvent 
casting/particulate leaching, freeze drying, phase separation, melt moulding, phase 
emulsion, in situ polymerization and gas foaming, while both synthetic and natural 
polymers are used as building blocks. Materials composed of synthetic constituents 
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could be based on poly(a-hydroxy acids), poly (orthoesters), poly(anhydrides), 
poly(amino acids), dextrin, poly(glycoside), poly(L-lactide) and their copolymers [Lee et 
al., 2011]. Using such systems, it was for instance shown that the sustained delivery of 
VEGF encapsulated in poly(lactide-co-glycolide) (PLG) microspheres can enhance 
vascular density in vivo [Rocha et al., 2008]. Examples for natural polymers applied for 
growth factor encapsulation strategies include silk, keratin, starch, carrageenan, 
cellulose or alginate [Lee et al., 2011]. Here, using alginate, VEGF could be entrapped 
into spherical beads, while its release effectively stimulated endothelial cells in vitro 
[Peters et al., 1998]. Moreover, FGF-2 as well as VEGF-loaded alginate gels promoted 
the formation of new blood vessels in vivo [Lee et al., 2003]. While the growth factor 
delivery can be combined with other biomaterial variables, another advantage of 
physical cytokine encapsulation is the simplicity of the approach, as injectable or 
transplantable systems with relevant mechanical strength, porosity and degradation 
rates can be readily fabricated. However, as the growth factors have to be embedded 
during the fabrication of the materials, the processing conditions could negatively affect 
the bioactivity of the cytokines. Moreover, often additional effort has to be made in 
order to prevent a high initial burst release resulting from the lack of specific chemical 
interactions between the growth factor and the scaffold [Lee et al., 2011].  
 
Chemical growth factor conjugation 
In contrast to the concept of physical cytokine entrapment, the approach of chemical 
immobilization of cytokines into or onto a matrix involves covalent binding or affinity 
interaction between the growth factor and the particular biomaterial. Within the context 
of chemical growth factor conjugation to a certain biomaterial, the strategy of covalent 
immobilization has emerged as a generally important method for cytokine presentation. 
Using this concept, the growth factors may be already active in the bound state or 
could be activated as they are released from the matrix upon cleavage from the 
scaffold or network degradation [Lee et al., 2011]. Most commonly, the proteins are 
either introduced upon a coupling reaction (using water-soluble carbodiimide 
chemistry) or immobilized via UV light (using succinimidyl ester-phenyl azide or 
monoacrylated PEG-succinimidyl ester chemistry). Additionally, in a more advanced 
approach, genetic engineering can be used to generate growth factors with modified 
protein sequences that allow for a covalent coupling to the biomaterial. Applying these 
strategies, cytokines could be chemically linked to both synthetic and natural polymeric 
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matrices. Representatives for synthetic building blocks include PEG, poly(L-lactide) or 
PLG [Masters, 2011]. For example, with PEG hydrogels deployed in the context of 
tissue engineering for therapeutic angiogenesis, covalently immobilized FGF-2 was 
shown to stimulate the proliferation and migration of vascular smooth muscle cells 
[DeLong et al., 2005], while the covalent conjugation of VEGF promoted the tube 
formation of endothelial cells [Leslie-Barbick et al., 2009]. Natural polymeric 
biomaterials used with a covalent growth factor functionalization comprise among 
others chitosan, gelatin, collagen, agarose or fibrinogen/fibrin [Masters, 2011]. In 
angiogenic tissue engineering, for instance fibrin [Zisch et al., 2001], gelatin [Ito et al., 
2005] or collagen [Chiu et al., 2010] matrices were applied for the covalent 
immobilization of VEGF. Performing cell culture experiments, these conjugated 
materials were found to support the proliferation [Zisch et al., 2001; Ito et al., 2005; 
Chiu et al., 2010], migration [Zisch et al., 2001] and tube formation [Chiu et al., 2010] of 
endothelial cells. Generally, a covalent growth factor immobilization to a certain 
biomaterial potentially allows for a more sustained release of the cytokines from the 
scaffolds. Moreover, matrix-conjugated growth factors could be capable to bind and 
activate their cellular receptors but, in parallel, might be subject to slower degradation 
and internalization, thereby prolonging their bioactivity [Lee et al., 2011; Masters, 
2011]. However, there are also some disadvantages of this strategy. For some 
applications, higher initial release rates independent of matrix cleavage or degradation 
could be beneficial. In addition, it might be difficult to determine a specific coupling site 
on the immobilized protein, so that it can be bound in the correct orientation to allow for 
an effective interaction with its receptor. Moreover, the bioactivity of the growth factor 
could be decreased upon conjugation, as biologically relevant protein domains, amino 
acids or functional groups might be damaged or screened [Lee et al., 2011]. 
Another strategy to chemically immobilize cytokines on a certain biomaterial is the 
physical adsorption of the protein based on hydrogen bonding or 
electrostatic/hydrophobic forces between the growth factor and the matrix. This 
approach can be used to provide cytokines which are either directly accessible when 
interacting with the polymeric scaffold or which display their activity after release from 
the material upon diffusion, cleavage from the matrix or degradation of the network. As 
the physical adsorption to biomaterials is based on affinity interaction between the 
growth factor and the scaffolds, following the physiological concept of a reversible 
cytokine storage in the body, usually natural ECM components such as heparin-like 
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molecules, chondroitin sulfate, hyaluronic acid, fibronectin/fibrin, collagen or gelatin 
[Lee et al., 2011] as well as synthetic ECM analogues such as glycosaminoglycan 
mimicking oligosaccharides or protein mimicking oligopeptides [Uebersax et al., 2009] 
are used as building blocks for such polymeric systems. Here, among the earliest 
examples of such materials used in the context of therapeutic angiogenesis, fibrin was 
used as a delivery system for FGF-2 [Fasol et al., 1994; Albes et al., 1994] or VEGF 
[Weatherford et al., 1996] and was shown to effectively promote endothelial cell growth 
in vitro [Fasol et al., 1994; Albes et al., 1994] and vascularization in vivo [Weatherford 
et al., 1996]. In addition, beneficial effects on angiogenesis in animal models were 
observed for the usage of VEGF-functionalized collagen [Tabata et al., 2000] or FGF-2-
modified gelatin [Iwakura et al., 2003] hydrogels. Moreover, due to its high affinity for 
angiogenic growth factors, biomaterials designed for the support of blood vessel 
formation often also include the glycosaminoglycan heparin. In several examples, the 
FGF-2 or VEGF delivery by such systems was found to promote pro-angiogenic cell 
behavior in vitro and vascularization in vivo [Wissink et al., 2000; Tanihara et al., 2001; 
Steffens et al., 2004; Yoon et al., 2007]. Overall, a physical growth factor adsorption to 
biomaterials based on secondary chemical interactions can be considered as a 
compromise between a non-specific entrapment within the matrix and a covalent 
conjugation to the scaffold. Therefore, depending on the particular strength of the 
cytokine affinity to the material, limitations of the concept are either related to a high 
burst release due to weak physisorption forces or to low overall delivery rates because 
of nearly irreversible interactions being almost as strong as in the case of a chemical 
bond. However, this strategy also combines the advantages of a growth factor 
encapsulation and a covalent immobilization approach. Consequently, by designing 
materials with a beneficial intermediate cytokine affinity, such systems might allow for 
optimal release properties thereby delivering the proteins right in the desired 
concentration regime. Moreover, some of the growth factors might exert their action 
already in the bound state, thereby prolonging their bioavailability and, as this 
interaction could protect the proteins from denaturation or degradation, also enhancing 
their bioactivity. Finally, due to the affinity of the cytokines to the biomaterial, it is 
possible to introduce the proteins by adsorption after scaffold processing. As this 
immobilization procedure can be performed under physiological conditions, the 
biofunctionality of the growth factors might be preserved more easily [Lee et al., 2011]. 
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Additional scaffold variables 
Besides all the progress in the field of polymeric cytokine delivery, there are also other 
factors influencing the potential success of a certain biomaterial for the use in 
therapeutic tissue engineering. As discussed earlier, following the example of the 
natural ECM (Fig. 6), the physicochemical and mechanical properties of the scaffold as 
well as the provision of insoluble cues mediating cell adhesion and permitting cellular 
matrix remodeling are key characteristics to govern effective tissue formation and 
regeneration [Hubbell et al., 2003; Lutolf et al., 2005]. Consequently, growth factor 
delivery  systems designed  for  the support of  therapeutic  approaches  should  ideally 
integrate all of these demands. Among the first materials which were developed 
according to this requirement, a synthetic mimetic of collageneous ECM for the delivery 
of a bone morphogenic protein was produced. This scaffold was combined with 
Fig. 6 Illustration of the main ECM characteristics that have to be translated to biomaterials for successful 
tissue engineering; modified from [Mager et al., 2011]. While scaffolds have to provide appropriate 
viscoelastic properties, the presence of insoluble cues mediating cell adhesion and material remodeling as 
well as the supply of diffusible growth factors are unconditional requirements to effectively support 
regenerative approaches. 
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peptides controlling cell adhesion as well as substrates for cell responsive degradation 
and could be successfully applied to repair bone defects [Lutolf et al., 2003].  
Based on this pioneer system, several biomaterials closely mimicking the key 
properties of the ECM were also used in the context of angiogenic tissue engineering 
[Zisch et al., 2003a; Leslie-Barbick et al., 2009; Phelps et al., 2010]. However, in order 
to develop matrices that effectively support angiogenesis, the influence of both the 
viscoelastic properties and molecular signals on the cellular behavior have to be 
explored separately. Here, none of these currently applied biomaterials allow for a far-
going, systematic and independent variation of mechanical and biomolecular 
characteristics [Liu et al., 2005]. 
 
Beside the influence of the viscoelastic ECM properties and the presence of insoluble 
cues controlling cell adhesion and matrix remodeling, the complex process of 
angiogenesis involving cell migration, proliferation and differentiation is also governed 
by the temporally-, spatially- and concentration-dependent interplay of several growth 
factors [Zisch et al., 2003b]. In angiogenic tissue engineering, although the 
administration of either single FGF-2 or VEGF was able to support vascularization in 
animal models, problems associated with the vessel stability were observed [Bruick et 
al., 2001; Komori et al., 2005]. Moreover, as it was shown for FGF-2 and VEGF, 
several growth factors demonstrate considerable cooperative effects on endothelial 
cells in vitro and angiogenesis in vivo [Pepper et al., 1992; Goto et al., 1993; Asahara 
et al., 1995; Vernon et al., 1999; Yan et al., 2001; Kano et al., 2005]. Therefore, in 
addition to the delivery of a single cytokine, simultaneous or sequential provision of 
multiple growth factors was also exploited to enhance the therapeutic efficiency (Fig. 
7). Here, the first single matrix system used to deliver multiple cytokines with distinct 
kinetics was applied for the release of VEGF and PDGF. In an in vivo model, the 
combined provision of both growth factors led to a dramatic increase in the number of 
matured blood vessels compared to the delivery of each single cytokine [Richardson et 
al., 2001]. Despite of this visionary work, only few studies were performed on the 
parallel administration of FGF-2 and VEGF by different biomaterials. Here, these 
systems either physically entrapped the growth factors into biodegradable 
microspheres [Larsen et al., 2010; De Laporte et al., 2011] or relied on the cytokine 
affinity of molecules such as fibrin [Wong et al., 2003; Wilcke et al., 2007; Losi et al., 
2010], gelatin [Ribatti et al., 2001] or heparin [Nillesen et al., 2007] in order to control 
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the storage and release of both effectors. For all these materials, in order to precisely 
adjust the most beneficial conditions for therapeutic angiogenesis, an independent and 
specifically adaptable provision of FGF and VEGF would be advantageous. 
Fig. 7 Schematic of a biomaterial capable to deliver multiple growth factors; inspired from [Lee et al., 
2011]. A scaffold loaded with distinct quantities of two different cytokines can be applied to independently 
provide defined amounts of each single factor. 
 
Biomaterials that effectively mimic the key characteristics of the ECM and which are 
able to provide combinations of several cytokines are appealing cytokine delivery 
systems for an application in therapeutic angiogenesis. However, there might be a 
need for a more far-going adaptation of the growth factor release profiles in order to 
specifically adjust for the versatile requirements of tissue engineering concepts. 
Consequently, recent research turned its attention to the development of materials that 
respond to local environmental signals or externally applied cues in order to control the 
release, so-called ‘release on demand’ systems (Fig. 8). In order to obtain scaffolds 
that are able to provide growth factors upon external triggering, stimuli-responsive 
components are introduced into the delivery matrix, which most commonly respond to 
changes in pH or temperature, the action of proteins such as enzymes releasing the 
cytokines upon cleavage or the application of drugs, ions, light, magnetic fields or 
ultrasound [Lee et al., 2011]. 
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So far, many systems used for cytokine release on demand can be triggered by pH- or 
temperature change. Materials that are responsive to pH are characterized by the 
presence of acidic (e.g. carboxylic and sulfonic acids) or basic (e.g. ammonium salts) 
groups [Bawa et al., 2009], while examples for such pH-sensitive moieties include 
sulphamethazine oligomers, sulphonamide and methacrylic acid [Lee et al., 2011]. 
Upon environmental changes in pH, these groups are able to either accept or release 
protons, while an ionization causes electrostatic repulsive forces. This leads to 
conformational changes of the soluble polymers, resulting in differences in the swelling 
behavior of the hydrogels [Bawa et al., 2009]. By an increase in the mesh size of such 
networks during swelling, growth factors that have been tightly entrapped before could 
get released [Lee et al., 2011]. In contrast, thermo-responsive polymers contain 
moderately hydrophobic groups such as methyl, ethyl and propyl residues that could be 
mixed with hydrophilic elements. For most commonly applied systems such as the 
frequently used synthetic polymer poly(N-iso-propylacrylamide), at lower temperatures, 
hydrogen bonding between the hydrophilic segments and water leads to enhanced 
dissolution; however, as the temperature increases, the hydrophobic segments are 
strengthened, thus resulting in shrinking of the hydrogels due to inter-polymer chain 
associations [Bawa et al., 2009]. Once again, depending on the thermo-responsive 
change in the mesh size of such networks, growth factors can be retained or released 
by such matrices. As one example, by responding to local changes in pH- and 
temperature in an animal model of ischemia, a hydrogel system based on the pH- and 
temperature-sensitive poly(N-isopropylacrylamide-co-propylacrylic acid-co-butyl 
acrylate) provided a prolonged, local delivery of FGF-2, improved angiogenesis, and 
achieved therapeutic effects in regional blood flow and cardiac function [Garbern et al., 
2011]. This study illustrates the advantage of such systems, as the pH and temperature 
conditions are often tissue-dependent, so that responsive materials might provide local 
specificity to the cytokine release. However, as the triggering parameters could only be 
varied within the physiological range, the degree of freedom in designing such 
materials is clearly restricted.  
As another possibility to include stimuli-responsive components into growth factor 
delivery matrices, the incorporation of enzymatically degradable linkers not only allows 
for a cellular remodeling of the scaffolds as discussed before, but also permits the 
release of the immobilized cytokines upon cleavage. Here, the delivery of the growth 
factors can be modulated by modifying the chemical composition of the degradable 
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linker or by changing the scaffold characteristics in order to facilitate or restrict the 
enzymatic accessibility of the cleavable element [Lee et al., 2011]. Studies of [Seliktar 
et al., 2004] are one example for mediating the release of both covalently attached 
VEGF as well as physically entrapped transforming growth factor-β1 (TGF-β1) upon 
network degradation by activated endothelial cells. While the direct release of the 
cytokines in response to the matrix remodeling might be highly beneficial for promoting 
different cellular behavior, there could be also a few applications, where permanent 
matrices are needed. Moreover, in order to effectively release the growth factors upon 
network degradation, the expression of the cleaving enzymes in appropriate quantities 
by the cell types of interest must be guaranteed.  
Depending on the material composition, upon the application of drugs [e.g. Ehrbar et 
al., 2008], ions [e.g. Ehrick et al., 2005], light [e.g. Kloxin et al., 2009], electric/magnetic 
fields [e.g. Jensen et al., 2002/Namdeo et al., 2009] or ultrasound [e.g. Epstein-Barash 
et al., 2010], generally the cytokine delivery can be tuned by a change in the scaffold 
properties (affecting for example the swelling/deswelling behavior or the network 
stability) or, in case of affinity-binding, by modulating the interaction of the growth 
factors and the matrix (thereby leading to a displacement of the proteins from the 
material). Although these systems offer exciting possibilities for precisely tuning the 
cytokine delivery, many of them to date are still prototypes [Lee et al., 2011]. 
Consequently, these materials were often only used to study the release of some 
model drugs and were not applied in any cell culture experiments yet. Examples of 
modular growth factor delivery systems already proven to have the potential for 
supporting therapeutic angiogenesis include hydrogels that release VEGF upon drug-
mediated network dissociation [Ehrbar et al., 2008] or drug-induced volume changes 
due to conformational alterations of the building blocks [King et al., 2010]. With this 
concept, VEGF-induced endothelial cell proliferation could be triggered specifically 
[Ehrbar et al., 2008]. Generally, most advantageous, such smart materials allow for a 
precise and broad modulation of the growth factor release. However, sometimes it 
might be difficult to adapt these cytokine delivery concepts to the in vivo situation, as 
externally applied triggers could negatively affect or, in the case of unphysiological 
parameters, even harm the body. Consequently, there is a need for biomaterials that 
provide options for a precise and far-going modulation of the growth factor release 
under physiological conditions. 
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Fig. 8 Illustration of biomaterials that are tailored to allow for a growth factor release on demand. Upon 
local environmental signals (such as a change in pH) or in response to externally applied triggers (such as 
the application of light), scaffold-immobilized cytokines are released into the environment due to changes 
in the network properties (e.g. upon an increased swelling of the pH-responsive polymeric system) or due 
to a modulation of the interaction between the growth factor and the scaffold (e.g. upon cleavage of the 
cytokine affinity sites within a photo-degradable material). 
 
Taken together, by the usage of both synthetic and natural polymeric biomaterials, 
several different concepts to store and deliver cytokines can be developed. 
Nevertheless, every ideal release system has to balance between a sustained but still 
sufficient growth factor delivery. Moreover, the possibility to independently control the 
physicochemical and mechanical properties of the scaffold as well as the provision of 
insoluble cues mediating cell adhesion and permitting cellular matrix remodeling are 
unconditional parameters for the successful application of a certain biomaterial in the 
context of therapeutic angiogenesis. In addition to the delivery of a single cytokine, 
release systems should also permit an adjustable provision of multiple growth factors in 
order to improve the effectiveness of tissue engineering approaches. As a final 
requirement, for the precise adaptation to different needs in regenerative concepts, the 
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option to modulate the cytokine provision upon the response to local environmental 
cues or externally applied triggers represents a further benefit provided by a certain 
biomaterial. Conclusively, the optimal growth factor delivery system for an application 
in therapeutic angiogenesis should satisfy all of these demands. 
 
 
2.2.3 Tunable biohybrid starPEG-heparin hydrogels as potential growth 
factor delivery systems  
Biohybrid hydrogels composed of four-arm amino-end-functionalized, star-shaped 
poly(ethylene glycol) (starPEG) and heparin were originally developed to aid cell 
replacement therapies for neurodegenerative diseases [Freudenberg et al., 2009]. In 
this study, the starPEG-heparin matrices were shown to support the growth and 
differentiation of primary nerve cells and neural stem cells in vitro and demonstrated 
excellent shape stability together with good histocompatibility after intrastriatal 
transplantations in vivo. Due to these promising results, the application of the hydrogel 
system should be extended towards therapeutic angiogenesis. In this concept, after 
characterization, the biofunctionalized material ideally allows for systematic studies on 
the support of pro-angiogenic behavior of endothelial cells in vitro. Finally, bioactive 
hydrogels should be implanted to a potential target site in vivo and promote the 
effective formation of capillary networks by initiating the growth, migration and 
differentiation of endothelial cells. 
 
Building blocks 
Biohybrid starPEG-heparin hydrogels are formed using the synthetic polymer starPEG 
(Fig. 9, left) and the naturally occurring glycosaminoglycan heparin (Fig. 9, right) as 
building blocks. Generally, PEG represents one of the most common synthetic 
polymers used for the design of biomaterials. Beside its excellent biocompatibility, the 
hydrophilic and uncharged character of PEG effectively repels proteins. Moreover, as 
PEG represents a hydrolytically stable polymer with a good solubility in water and 
many different organic solvents, the possibility to easily modify its terminal functional 
groups opens up perspectives for a versatile PEG macromer chemistry [Tessmar et al., 
2007].  
Heparin and heparan sulfate are sulfated glycosaminoglycans. These linear 
polysaccharides are composed of repeating hexuronic acid-glucosamine disaccharide 
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units, while a number of structural variations of this disaccharide lead to 
microheterogeneties of both glycosaminoglycans (as indicated by the major and minor 
disaccharide repeating units, Fig. 9, right). Generally, heparan sulfate is less sulfated 
but exhibits a higher molecular chain weight and structural variance than heparin. 
Moreover, heparan sulfate can be found attached to core proteins in proteoglycans on 
cell surfaces or within the ECM of nearly all mammalian cells and tissues, while heparin 
is mainly stored in the granules of certain mast cells and in some hematopoietic cells 
[Capila et al., 2002]. Upon release from these cells into the vasculature due to injury or 
immunological activation [Hiromatsu et al., 2003], heparin can either directly initiate 
endothelial cell proliferation and migration [Azizkhan et al., 1980] or release angiogenic 
growth factors from heparan sulfate storage depots in the ECM [Taipale et al., 1997], 
thereby contributing to angiogenesis. In addition, the anticoagulant properties of 
heparin prevent thrombus formation in the new vessels [Hiromatsu et al., 2003]. 
Although heparin is not considered to play a major role in local growth factor storage in 
the ECM, it can be mass produced and it is cheaper than heparan sulfate. Due to this 
fact, besides similar cytokine binding-properties at a smaller structural variance of its 
shorter chains, heparin rather than heparan sulfate is often used as building block for 
biomaterials [Uebersax et al., 2009]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Building blocks of biohybrid starPEG-heparin hydrogel scaffolds. left: structure of four-arm amino 
end-functionalized synthetic starPEG. right: structure of natural heparin with its major and minor 
disaccharide repeating units (X=H or SO3-, Y=Acetyl, SO3- or H); adapted from [Capila et al., 2002]. 
 
 
 
heparin 
 
starPEG 
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Network formation 
In order to covalently combine both starPEG and heparin to generate biohybrid 
hydrogels, the two building blocks are connected by crosslinking of the amino end-
functionalized starPEG with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-
hydroxysulfosuccinimide (EDC/s-NHS)-activated carboxylic acid groups of heparin.  
Upon the addition to heparin, EDC reacts with its carboxylic acid groups to form an 
amine-reactive O-acylisourea intermediate, which may then react with an amino group 
on the starPEG, thereby yielding a conjugate of the two polymers joined by a stable 
amide bond. However, at a neutral pH, the O-acylisourea intermediate is unstable and 
short-lived in aqueous solution, so that it may hydrolyze and regenerate the carboxylic 
acid group. Upon the addition of s-NHS, the EDC can be used to convert the carboxylic 
acid groups to amine-reactive s-NHS esters. As this compound is substantially more 
stable than the O-acylisourea intermediate, the effectiveness of the crosslinking 
reaction under physiological conditions is enhanced substantially [Staros et al., 1986]. 
 
Applying this coupling chemistry, biohybrid hydrogels composed of starPEG and 
heparin can be formed (Fig. 10). As already discussed, such materials combine the 
advantages of a structurally well-defined synthetic polymeric system with superior 
mechanical properties with the benefits of a naturally derived matrix providing 
enhanced biofunctionality. Here, by applying EDC/s-NHS chemistry, RGD adhesion 
Fig. 10 Design of the biohybrid starPEG-heparin hydrogel functionalized with adhesion ligands and growth 
factors. 
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ligands can be covalently coupled to the carboxylic acid groups of heparin. Moreover, 
similar to the natural situation, heparin-binding growth factor such as the angiogenic 
cytokines FGF-2 or VEGF can be reversibly immobilized to the glycosaminoglycan 
upon electrostatic interaction of their basic residues with the sulfate groups of heparin. 
Due to these advantages, several biomaterials designed for the delivery of angiogenic 
growth factors are based on PEG and heparin [Benoit et al., 2005; Cai et al., 2005; 
Andreopoulos et al., 2006; Tae et al., 2006; Nie et al., 2007]. 
 
Design concept 
Conceptually, the network composition of starPEG-heparin matrices goes beyond 
classical strategies since polymer-based hydrogels are often formed via 
interconnecting a polymeric building block with a short crosslinker. In contrast, the 
particular gel design follows a rational concept where starPEG functions as a flexible, 
structural building block, while heparin acts as a stiff, multifunctional crosslinker. The 
14 kDa heparin used in this particular setting carries up to ~ 24 carboxylic acid moieties 
[Capila et al., 2002]. Consequently, by varying the molar ratio of starPEG to heparin (γ) 
from ~ 1.5 to 6, up to six four-arm starPEG molecules could be attached to form a 
dense meshwork. Applying a mean field approach, conditions could be identified, 
where the underlying expansion and retraction forces in the swollen hydrogels 
compensate each other in such a way that in a physiological situation, the 
concentration of the highly charged multifunctional crosslinker (i.e. heparin) stays 
nearly constant. This key property of the starPEG-heparin matrices was theoretically 
predicted and experimentally verified [Sommer et al., 2011]. As a consequence, upon 
the increase of the molar ratio of starPEG to heparin (γ) from 1.5 to 6 in the initial 
reaction mixture, gel types with an enhanced starPEG content (~ 8, 16.8 and 36 mg/ml gel 
for γ = 1.5, 3 and 6), but a constant heparin concentration (~ 8 mg/ml gel for γ = 1.5, 3 and 6) are 
obtained (Fig. 11, top left and Fig. 12, left), while the molar ratio of the building blocks 
defines the degree of crosslinking. 
Moreover, as the synthetic building block represents the component which critically 
determines the viscoelastic properties of the hydrogel matrices, correlating with an 
increasing content of starPEG, less hydrated (volumetric swelling of ~ 53, 30 and 22 for γ = 1.5, 
3 and 6) and stiffer (storage modulus of ~ 1000, 7300 and 14800 Pa for γ = 1.5, 3 and 6) scaffolds 
were produced (Fig. 11, top right and bottom left). This finding is related to a higher 
number of covalent crosslinks, therefore leading to the formation of a denser network, 
32  Theoretical backgrund 
which is more rigid (higher storage modulus) and exhibits restricted water uptake due 
to larger retraction forces caused by the higher number of covalent bridges within the 
gel (lower swelling). Despite of the overall high water content of the materials, varying 
between 95 % (γ = 6) and 98 % (γ = 1.5), all gel types revealed an excellent network 
stability. Rheological measurements demonstrated frequency-independent storage 
moduli in the range of 0.1-10 rad/s to be approximately two orders of magnitude higher 
than the loss moduli (data not shown), which is characteristic for an almost ideal elastic 
behavior of a stable covalently crosslinked material. Moreover, as an elastic hydrogel 
subjected to a small  deformation of less than  20 % will  completely recover  its original 
dimension, the network structure could be analyzed according to the rubber-elasticity 
Fig. 11 Gradual mechanical properties and network characteristics of different starPEG-heparin hydrogels 
determined by the varying content of synthetic starPEG. top left: varying starPEG and constant heparin 
concentration in swollen gels matrices prepared from different molar starPEG/heparin ratios. top right: 
gradual volumetric swelling characteristics of different hydrogel types depending on the starPEG content 
(p < 0.05 for any comparison of the data for γ = 1.5, 3 or 6; ANOVA). bottom left: gradual storage moduli of 
different hydrogel types depending on the starPEG content (p < 0.05 for any comparison of the data for 
γ = 1.5, 3 or 6; ANOVA). bottom right: gradual network mesh sizes of different hydrogel types depending 
on the starPEG content (p < 0.05 for any comparison of the data for γ = 1.5, 3 or 6; ANOVA). All data are 
presented as mean ± root mean square deviation from n ≥ 4. 
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theory to estimate an average mesh size of the networks (for details about the theory 
see “3.3.2 Determination of rheological characteristics” or [Freudenberg et al., 2009]). 
Comparable to that of similar hydrogel systems [Raeber et al., 2005], the pore size of 
starPEG-heparin matrices was found to be in the nm scale and decreased from ~ 16 
over 8.3 to 6.5 nm for γ = 1.5, 3 and 6 (Fig. 11, bottom right) upon increasing the starPEG 
content and therefore the crosslinking degree. Consequently, varying the starPEG to 
heparin ratio allows the production of different gel types with gradual mechanical 
properties.  
However, independent of the different viscoelastic characteristics of the networks, the 
hydrogels contained large quantities of ~ 8 mg heparin per ml gel, which -as already 
discussed- remained approximately constant for scaffolds with different molar ratios of 
starPEG to heparin (Fig. 11, top left and Fig. 12, left). This rationally designed 
characteristic of the hydrogels seems crucial for control and modulation of subsequent 
biomolecular functionalization, as it should principally allow for a decoupling of the 
structural parameters and the biofunctionality. For instance, to mediate cell adhesive 
scaffold properties, integrin-binding cyclic RGDYK (in single-letter amino acid code) 
peptides (RGD-peptides, Fig. 10) were coupled to EDC/s-NHS activated heparin 
carboxylic acid groups by their lysine amino group (Fig. 12, right). Based on the 
constant heparin concentration in hydrogels with varying mechanical characteristics, 
similar amounts of RGD-peptides (~ 0.6 mol RGD/mol heparin) were attached to the 
different gel types as previously demonstrated by [Freudenberg et al., 2009]. 
Fig. 12 Equal RGD concentration of different starPEG-heparin hydrogels determined by the constant 
content of natural heparin. left: varying starPEG and constant heparin concentration in swollen gel 
matrices prepared from different molar starPEG/heparin ratios. right: constant RGD functionalization of 
different hydrogel types depending on the heparin content (p > 0.05 for any comparison of the data for 
γ = 1.5, 3 or 6; ANOVA). All data are presented as mean ± root mean square deviation from n ≥ 3. 
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Consequently, since heparin also represents the basis for a subsequent growth factor 
functionalization of the scaffold, the matrices might represent a system, where the 
cytokine delivery could be adapted independently of structural and mechanical material 
properties.  
Since angiogenesis is critically determined by both molecular signals and the 
viscoelastic characteristics of the surrounding matrix [Ingber et al., 1989; Deroanne et 
al., 2001; Liu et al., 2005; Saunders et al, 2010], this approach offers a way to 
separately explore the influence of both factors on cellular behavior, which might help 
to create optimized scaffolds for an application in angiogenic tissue engineering. 
As a second advantage, compared to many similar systems, starPEG-heparin 
hydrogels are characterized by significantly higher heparin concentrations (up to 0.8 % 
[w/w]) in the swollen matrices. Therefore, as the structural integrity of heparin could be 
preserved up to higher degrees of crosslinking, this attribute might also permit a rather 
unaffected interaction with several heparin-binding growth factors. Consequently, the 
starPEG-heparin hydrogels could represent a promising material for the independent 
and parallel delivery of multiple cytokines as it might be beneficial to aid complex 
regenerative processes such as therapeutic angiogenesis. 
Finally, the design of the biohybrid starPEG-heparin matrices offers several possibilities 
to tune the release of reversibly immobilized growth factors. As it was already shown 
[Tsurkan et al., 2010], upon incorporation of cleavable peptide linkers, enzymatically 
degradable scaffolds can be developed. Besides the option of cellular matrix 
remodeling, this might also offer a way to modulate the delivery of soluble cytokines in 
response to cell-mediated proteolysis. Moreover, as the growth factor immobilization to 
starPEG-heparin hydrogels is based on affinity binding between the cytokines and 
heparin, this interaction might intrinsically represent a parameter that can be modulated 
under physiological conditions. For example, modifying the growth factor binding sites 
of heparin or applying heparin-affine competitor molecules could be ways to tune the 
cytokine release. By this, a precise and far-going modulation of the growth factor 
delivery might open up new perspectives to adapt the cytokine provision to the actual 
requirements of effective angiogenic tissue engineering. 
Following these promising possibilities, in this work, the potential of starPEG-heparin 
hydrogels to provide the angiogenic cytokines FGF-2 and VEGF should be explored. 
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3 Materials and methods 
3.1 Preparation of starPEG-heparin hydrogel networks 
3.1.1 Modification of glass surfaces 
According to their purpose, borosilicate glass surfaces (Carl-Roth GmbH & Co, 
Karlsruhe, Germany) were either functionalized with aminosilane or with 
hexamethyldisilazane. For covalent attachment of starPEG-heparin networks to glass 
cover slips, aminosilanization was used to generate surface-bound amino groups on 
the glass [Pompe et al., 2003] that functioned as anchoring points and enabled a stable 
linkage with the activated heparin carboxylic acid groups in the hydrogel. Alternatively, 
to distribute and cover the liquid starPEG-heparin mixture on plain surfaces, treatment 
of the cover slips with hexamethyldisilazane was used to introduce methyl groups 
resulting in hydrophobic surfaces that prevented sticking to the gel. 
All cover slips were initially pre-cleaned via ultrasonication for 30 min in deionized, 
decarbonized water (MilliQ) followed by a subsequent 30 min ultrasonication step in 
70 % ethanol (VWR International GmbH, Darmstadt, Germany) and rinsing in MilliQ. 
Next, the glass surfaces were freshly oxidized for 10 min at 70 °C in a mixture of 29 % 
aqueous solution of NH3 (Acros Organics, Geel, Belgium), medical extra pure 35 % 
H2O2 (Merck Chemicals KGaA, Darmstadt, Germany) and MilliQ in a ratio of 1:1:5 and 
then two times rinsed in MilliQ.  
Functionalization of glass surfaces was performed according to its purpose either from 
solution or from vapor phase. For aminofunctionalization from solution, samples were 
treated with a 20 mM 3-aminopropyl-triethoxysilane (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) solution in a mixture of isopropanol (Acros Organics) and MilliQ 
(9:1) for 2 h at room temperature. Next, the samples were washed with isopropanol 
and dried with nitrogen. In order to stabilize the coating, cover slips were subsequently 
incubated in the drying oven for 1 h at 120 °C. For  hexamethyldisilazane (Fluka, 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany) treatment from vapor phase, 
cleaned cover slips were dried for 1 h at 120 °C an d then placed in a Petri dish with a 
smaller one containing 100 µl hexamethyldisilazane in the centre for at least 3 h. 
Finally, they were incubated for 1 h at 120 °C. 
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3.1.2 Formation of starPEG-heparin hydrogels 
StarPEG-heparin hydrogels were formed by crosslinking amino end-functionalized four-
arm starPEG with EDC/s-NHS activated carboxylic acid groups of heparin 
[Freudenberg et al., 2009]. For this, a total polymer content of 11.6 % and a 2:1:1 ratio 
of EDC:s-NHS:NH2-groups of starPEG [mol/mol] were used. The molar ratio of 
starPEG to heparin was varied from 1.5 to 6 (for exact composition of the different gel 
types see Tab. 1). 
Heparin (14,000 g/mol; Calbiochem (Merck), Darmstadt, Germany) and starPEG 
(10,000 g/mol Polymer Source, Inc., Dorval, Canada) were each dissolved in one third 
of the total volume of ice-cold MilliQ by ultrasonication and afterwards kept on ice (~ 2-
4 °C). Similarly, s-NHS (Fluka) and EDC (Sigma-Aldr ich) were separately dissolved in 
the sixth part of the total volume of ice-cold MilliQ. Subsequently, s-NHS and EDC 
solutions were added to heparin, mixed well and incubated for 15 min on ice to activate 
heparin carboxylic acid groups. Finally, the star-PEG solution was added to the 
activated heparin and quickly mixed by vortexing (Minishaker MS2, IKA, Staufen, 
Germany).  
For fluorescence microscopy, gels were prepared from heparin spiked with 0.5 % [w/w] 
of heparin labeled with Alexa 488 (Molecular Probes distributed by Invitrogen GmbH, 
Darmstadt, Germany; conjugate synthesized by M. Tsurkan, IPF Dresden; for details 
on preparation and characterization see appendix A). To modulate the interaction 
between the cytokines and the hydrogels, networks were produced using selectively 
desulfated, N-reacetylated heparin (N-; 2-O-; 6-O- + N- or completely desulfated 
heparin; synthesized by A. Röhrich, BCube Dresden; for details on preparation and 
characterization see appendix A). For the preparation of enzymatically degradable 
networks, the common starPEG was substituted by a starPEG-(GPQG↓↑IWGQ, in 
single-letter amino acid code) conjugate with a hydrolytically stable (succinimide-
derivative) bond between the starPEG and the peptide sequence (synthesized by M. 
Tsurkan, IPF Dresden; for details on preparation, characterization and degradation 
studies see appendix A).  
To allow for a practical performance of quantitative growth factor binding/release 
studies and for cell culture experiments, surface bound gels with a final thickness of 
~ 50 µm were prepared. For this, 3.11 µl of the gel mixture per cm² were used. To 
obtain surface immobilized networks, the gel solution was placed on freshly 
aminofunctionalized glass cover slips or directly into aminofunctionalized glass bottom 
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24-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) to allow covalent 
attachment of heparin through its activated carboxylic acid groups. In order to spread 
the solution equally, the mixture on the glass slides was covered with a hydrophobic 
glass cover slip that has been treated with hexamethyldisilazane or by placing an 
ethylen-chlortrifluorethylen-copolymer slide (Goodfellow, Cambridge, England) onto the 
gel solution in the glass bottom wells. For preparation of free-standing gel disks, 
104.7 µl of the liquid gel mixture were placed onto a 1 cm² hydrophobic glass cover slip 
and covered with a second hydrophobic one. To allow for an introduction into an in vivo 
system, small hydrogel clots were prepared by pipetting 1.4 µl of the gel mixture on a 
hydrophobic glass cover slip.  
After polymerization overnight at 22 °C in a humidi fied atmosphere, any hydrophobic 
cover slips were removed. Each gel sample was washed in phosphate buffered saline 
(PBS, Sigma-Aldrich) to remove s-NHS/EDC and any non-bound starPEG/heparin. 
PBS (pH 7.4) was exchanged five times, once per h, and once again after storage for 
24 h. Subsequently, the swollen gels were immediately used for further experiments. 
For cell culture, sterilization was performed by UV-treatment for 30 min. For additional 
treatments, all solutions were sterile unless otherwise indicated. 
 
 Tab. 1 Composition of starPEG-heparin hydrogels. 
            
starPEG/ 
heparin        
ratio (γ) 
[mol/mol] 
starPEG 
[mg] 
heparin 
[mg] 
s-NHS 
[mg] 
EDC   
[mg] 
MilliQ    
[µl] 
1.5 20.69 19.31 3.17 1.80 300 
3 27.27 12.73 4.18 2.37 300 
6 32.43 7.57 4.97 2.82 300 
      
 
 
3.2 Biomodification of starPEG-heparin hydrogels 
The biomodification of starPEG-heparin hydrogels with an adhesion ligand is 
performed by coupling the lysine amino groups of the cyclo(arginine-glycine-aspartic 
acid-D-tyrosine-lysine) (RGD) peptide (Peptides International, Louisville, USA) to 
EDC/s-NHS activated carboxylic acid groups of heparin. For this, surface-bound, 
swollen hydrogels were placed into 24-well plates (TPP, Trasadingen, Switzerland) and 
washed 3 times with ice-cold 1/15 M phosphate buffer (pH 5; 1/15 M Na2HPO4 and 
1/15 M KH2PO4 in a 1:124 mixture; Merck Chemicals KGaA, Darmstadt, Germany). 
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This solution was then exchanged with a s-NHS/EDC mixture (25 mM s-NHS and 
50 mM EDC in 1/15 M phosphate buffer (pH 5)) to activate the carboxylic acid groups 
of heparin. After incubation for 45 min, the scaffolds were washed 3 times in ice-cold 
0.1 M borate buffer (pH 8; 55.85 ml 0.2 M borate stock solution made from boric acid 
(Sigma-Aldrich), 44.15 ml 0.1 M HCl (Acros Organics) and 100 ml MilliQ) to remove 
unbound s-NHS/EDC. Subsequently, the gels were incubated in RGD-solution 
(50 µg/ml; dissolved in borate buffer) for 2 h at room temperature. Finally, all samples 
were washed in PBS 3 times. 
To electrostatically immobilize FGF-2 (Miltenyi Biotech, Bergisch Gladbach, Germany) 
or VEGF165 (PeproTech GmbH, Hamburg, Germany) to the starPEG-heparin 
networks, the respective protein was dissolved in PBS at the desired concentration. 
Unless otherwise indicated, PBS-swollen, pure or RGD-modified gels were placed into 
24-well plates and immersed in the protein solution (200 µl per cm²) at room 
temperature. The cytokines were allowed to penetrate the networks for 24 h followed 
by rinsing twice with an excessive volume of PBS. 
 
 
3.3 Analysis of starPEG-heparin scaffold properties 
3.3.1 Determination of volumetric swelling degree 
Swelling of hydrogels is based on incorporation of liquid into the pores of the gel 
network. Besides this, excessive washing is necessary to remove the activation 
chemicals s-NHS/EDC as well as any unbound starPEG and heparin.  
The initial diameter of the free-standing disks (for preparation see 3.1.2) was measured 
with a digital vernier calliper (MMO, Börnicke, Germany), while the same procedure 
was repeated after swelling in PBS for 24 h at room temperature. Volumetric swelling 
degree Q (change in gel volume after swelling compared to the dry volume of the gels, 
V0) was calculated by Q = (dt/dreact)3 * Vreact/V0, where dt is the diameter of the disk after 
the washing process, dreact is the diameter of the unswollen gel disk (cured reaction 
mixture), Vreact the volume of the cured reaction mixture and V0 = n * vstarPEG + n * 
vheparin. The heparin and RGD content is expressed in relation to the final volume of the 
PBS swollen gel network. 
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3.3.2 Determination of rheological characteristics 
Rheology is defined as the study of the change in form (deformation) and the flow of 
matter, embracing elasticity, viscosity, and plasticity of a material. Two important 
parameters that can be determined by this method are the storage (G’) and loss 
modulus (G’’). In viscoelastic solids they measure the stored energy, representing the 
elastic portion, and the energy dissipated as heat, representing the viscous portion. 
Storage and loss modulus of free-standing starPEG-heparin hydrogel disks (n = 4) 
were determined using oscillating measurements on a rotational rheometer (Ares LN2, 
TA Instruments, Eschborn, Germany) with plate-plate geometry (plate diameter 25 mm, 
gap width 1.2-1.5 mm). Dynamic frequency sweep tests under strain control were 
carried out at 25 °C in a shear frequency range of 10+2-10-1 rad/s. The strain amplitude 
was set to 3 % and storage and loss modulus were measured as a function of the 
shear frequency.  
From the rheological characteristics, pore sizes of the network could be estimated 
according to the rubber-elasticity theory [Rubinstein et al., 2003; Freudenberg et al., 
2009]. As a natural rubber, a hydrogel subjected to a relatively small deformation of 
less than 20 % (here: 3 %), will rapidly and fully recover to its original dimension. 
Following the assumptions that all chains of the polymer network contribute to the 
retraction force after deformation (affine deformation), end effects of single chains are 
neglected and that any influence of physical entanglements is excluded, the mesh   
size ξ (distance between two entanglement points) can be calculated by                                     
ξ = (G’ * NA/R*T)-1/3, where G’ is the storage modulus, NA is the Avogadro constant, R is 
the molar gas constant, and T is the temperature. 
 
 
3.4 Characterization of the biomodification 
3.4.1 Confocal laser scanning microscopy (CLSM) 
Confocal laser scanning microscopy (CLSM) can be applied for acquiring high-
resolution optical images with depth selectivity. This method is based on the application 
of pinholes to produce a point source of light thereby rejecting all scattered light except 
that emitted from the illuminated specimen. For the image acquisition, a galvanometric 
scanning mirror is used that moves laterally line by line over the samples. Moreover, 
also the z-direction can be adjusted by a z-motor replacement. Consequently, CLSM 
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can be deployed to resolve the object of interest into confocal section plains for the 
three-dimensional reconstruction of the observed specimen (xyz-scans). In the context 
of this work, CLSM was used to study the uptake of fluorescently labeled molecules 
into starPEG-heparin hydrogels. 
FGF-2 or VEGF were labeled with tetramethylrhodamine (TAMRA) according to the 
FluoReporter Tetramethylrhodamine Protein Labeling Kit manual (Molecular Probes, 
distributed by Invitrogen). 
TAMRA-FGF-2 or -VEGF (5 µg/ml) were diluted in PBS. The corresponding solutions 
were added to starPEG-heparin gels (n = 2, 200 µl/cm²) that were directly immobilized 
in glass bottom 24-well plates. Fluorescence intensity was quantified using a Leica SP5 
(Leica, Bensheim, Germany) confocal laser scanning microscope with a 40x 
magnification immersion objective (HCxPL APO, Leica) and aperture pinhole set at 
68 µm. The argon-laser (excitation wavelength 488 nm, laser intensity 20 %) was used 
for exciting Alexa 488-labeled gels whereas the diode-pumped solid-state (DPSS) laser 
(excitation wavelength of 561 nm, intensity 20 %) was used for excitation of TAMRA 
labeled proteins. Alexa 488 and TAMRA emission were analyzed in the 500-550 nm or 
570-630 nm range, respectively.  
The time-dependent intensity of the TAMRA-FGF-2 or -VEGF was quantified for the 
solution (supernatant of the gel body) and for the gel body performing an XZ-scan at 
defined intervals. Intensity profiles (XZ-scan) at three different X-positions were 
evaluated for each time point. 
 
 
3.4.2 Radiolabeling studies 
Radiolabeling studies of FGF-2 and VEGF were performed to analyze the uptake and 
release of these proteins by starPEG-heparin hydrogels. For this, the cytokines were 
subjected to iodination, which involves the introduction of radioactive iodine-125 (125I) 
into certain amino acids (usually tyrosines) in the proteins. Quantification of these 
labeled proteins is performed with the help of a gamma counter. As a scintillation 
detector, these counters use crystals with luminescent properties. Upon interaction with 
photons from the gamma rays, the crystals emit light. This light energy is then 
converted into electric energy by a photomultiplier in order to deliver a meaningful 
measure. 
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While 125I-labeled FGF-2 was purchased from Chelatec SAS (Nantes, France), VEGF 
was labeled with 125I using IodoBeads (Pierce, Rockford, USA). These polystyrene 
beads are coated with an oxidizing reagent which converts sodium iodide to its 
corresponding reactive iodine form that spontaneously incorporates into tyrosyl groups. 
For this, 1 mCi Na125I (PerkinElmer Massachusetts, USA) dissolved in 100 µl of PBS 
(pH 7.4) was added to a single IodoBead that had been rinsed with PBS. After 5 min of 
incubation at room temperature, 200 µl VEGF stock (1 mg/ml) was added and allowed 
to react for 20 min. By size exclusion chromatography (NAP-5 column, GE Healthcare, 
Munich, Germany) using PBS as the eluent, unbound iodide was removed yielding 
iodinated protein with less than 2 % free 125I. The resulting protein concentration was 
determined by an UV/vis spectrometer (BioPhotometer Plus, Eppendorf, Hamburg, 
Germany) while the specific activity of the protein solution was analyzed via gamma 
counting (LB 123, Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). 
To perform protein binding and release studies, surface-bound gels (n = 2-4) were 
placed in custom-made incubation chambers that decreased the exposure of the 
protein to surfaces not originating from the hydrogels to a minimum. Native FGF-2 or 
VEGF protein solution was spiked with 125I-labeled FGF-2 or VEGF as a percentage of 
total protein (2.5-100 %). After incubation with mixtures containing 0.5, 1, 5 or 10 µg/ml 
FGF-2 or VEGF, radioactivity was measured twice per sample using gamma counting. 
Immobilized protein was quantified with the help of 125I-FGF-2 or -VEGF standards 
prepared by dropping defined aliquots of a known concentration on glass cover slips.  
After immobilization, FGF-2 or VEGF were allowed to release from these gels (n = 2) at 
22 °C into 250 µl/cm² of serum-free (SF) endothelia l cell growth medium (ECGM; 
Promocell GmbH, Heidelberg, Germany) supplemented with 0.02 % [w/v] sodium azide 
(Fluka). At defined time intervals, the medium was withdrawn and the remaining FGF-2 
or VEGF bound to the gels was monitored twice via gamma counting. An equal volume 
of fresh medium was added back after each measurement. 
 
 
3.4.3 Amino acid analysis via high performance liquid chromatography 
(HPLC) 
High-performance liquid chromatography (HPLC) is chromatographic technique used to 
separate compounds that are dissolved in solution. In this work, it has been applied to 
quantify the amount of RGD or FGF-2 and VEGF in starPEG-heparin hydrogels. For 
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that, peptide bonds were broken down by acidic hydrolysis so that peptides or proteins 
are decomposed into single amino acids. After derivatization with a fluorescent label, 
the different amino acids pass through a chromatographic column at different rates due 
to differences in their partitioning behavior between the mobile liquid phase and the 
stationary phase. Following the separation procedure, they can be detected by their 
fluorescent signal after excitation with a suitable wavelength. 
Quantification of immobilized RGD-peptide (50 µg/ml; n = 4), FGF-2 (10, 25 or 
50 µg/ml; n = 2), or VEGF (10, 25 or 50 µg/ml; n = 2) in the gels was performed by 
acidic hydrolysis and subsequent HPLC analysis as described elsewhere [Salchert et 
al., 2003]. Briefly, gel-coated substrates were subjected to vapor hydrolysis in vacuo 
using 6 M HCl at 110 °C for 24 h and subsequently n eutralized. Extraction of amino 
acids from the samples was accomplished by repeated rinsing with a definite volume of 
50 mM sodium acetate buffer at pH 6.8. The released amino acids were 
chromatographically separated after precolumn derivatization with ortho-
phthalaldehyde (Sigma-Aldrich) on a Zorbax SBC18 column (4.6 × 150 mm, 3.5 µm, 
Agilent Technologies, Boeblingen, Germany) using an Agilent 1100 LC system 
(Agilent) with fluorescence detection (excitation wavelength of 335 nm, emission 
measured at 455 nm). Amino acids were quantified using external standards. 
 
 
3.4.4 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is a biochemical technique used to 
detect the presence of a specific antigen in a sample. In a sandwich ELISA, an 
unknown amount of antigen is affixed to a plate coated with a capture antibody. In the 
next step, a specific detecting antibody is applied over the surface so that it can bind to 
the antigen. After addition of an enzyme-linked secondary antibody that binds to the 
detecting antibody, a chemical substrate is applied which can be enzymatically 
converted to a detectable form (most commonly associated with a color change). By 
comparison to a standard of a defined concentration, the antigen in the sample can be 
quantified. In the context of this work, ELISA was used to analyze the uptake and 
release of FGF-2 or VEGF by starPEG-heparin hydrogels. 
Surface-bound gels (n = 3) were placed in custom-made incubation chambers that 
allowed only minimal interaction of the protein solution with areas not originating from 
the hydrogel. Following the incubation with FGF-2 (0.5, 1, 5 or 50 µg/ml) or VEGF (0.5, 
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1, 5, 10 or 25 µg/ml), the immobilization and washing solutions were collected and 
assayed in duplicates using an ELISA Quantikine kit (R&D Systems, Minneapolis, 
USA). After immobilization, FGF-2 or VEGF were allowed to release from these gels at 
22 °C into 250 µl/cm² of SF ECGM with 0.02 % sodium  azide ± 0.1 % bovine serum 
albumin (BSA; Sigma-Aldrich). For modulation of the growth factor delivery, the 
standard release medium containing 0.1 % BSA was either supplemented with 1 U/ml 
collagenase (Biochrom AG, Berlin, Germany) or 5 mg/ml chitosan (molecular weight 
≈ 10-50 kDa; Chitosan 70/5, Heppe Medical Chitosan GmbH, Halle, Germany). As 
previous studies showed that due to the high heparin excess presumably resulting in a 
dynamic release/-re-binding of the growth factors within the gel, there was no influence 
of changing the frequency of medium replacement on the overall amount of protein 
being released (data not shown), samples were always taken at the same intervals 
(after 3, 6, 24 and 96 h) and stored at -80 °C unti l analyzed by ELISA. An equal volume 
of fresh medium was added back at each time point. 
 
 
3.5 In vitro endothelial cell culture experiments 
3.5.1 Isolation and cultivation of human umbilical vein endothelial cells 
(HUVECs) 
Human endothelial cells were isolated from the umbilical cord vein (human umbilical 
vein endothelial cells - HUVECs) according to the procedure suggested by [Weis et al., 
1991]. Briefly, the vein of umbilical cords that were not older than 20 h was rinsed with 
PBS and filled with sterile collagenase (446 U/ml) in order to proteolytically release the 
cells. After incubation for 20 min at 37 °C, the re action was stopped by adding PBS 
supplemented with 10 % fetal calf serum (FCS, Biochrom). The collagenase solution 
containing the detached endothelial cells was filled into a sterile tube and centrifuged 
(Labofuge 400 R, Heraeus, Berlin, Germany) for 5 min at 1500 rpm. Next, cells were 
resuspended in ECGM and seeded into a tissue culture flask (plastic cell culture flask, 
TPP) coated with 50 µg/ml fibronectin (Roche Diagnostics GmbH, Mannheim, 
Germany). HUVECs were grown to confluence at 37 °C and 5 % CO2, while the 
medium was changed every second day. 
After reaching confluence, a new passage of cells had to be prepared. For this, the 
medium was removed and the culture was rinsed with PBS twice in order to remove 
dead cells, cell debris as well as remnants of old medium. 1 ml of trypsin-EDTA 
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(trypsin-ethylenediaminetetraacetic acid, Sigma-Aldrich) was added per 25 cm² of the 
culture flask for proteolytically detaching the cells during an incubation step for 2 min at 
37 °C. The reaction was stopped by applying 5 ml PB S supplemented with 10 % FCS. 
HUVECs were transferred into a sterile tube and centrifuged for 5 min at 1500 rpm. 
Following resuspension in the corresponding medium, cells were either distributed to 
several culture flaks or directly used for experiments.  
For culture on starPEG-heparin matrices, after one to four passages, ~ 11300 cells per 
cm² surface area were seeded onto the hydrogels, which were pre-equilibrated with SF 
ECGM for 30 min at 37 °C. HUVECs culture was perfor med for three days at 37 °C and 
5 % CO2 on either pure or RGD-treated starPEG-heparin hydrogels, while the RGD 
concentration used for functionalization (50 µg/ml) was selected due to its ability for 
inducing optimized HUVEC growth as determined in pre-experiments (data not shown). 
Such gel matrices were either used without any additional modification or loaded with 
either 1 or 5 µg/ml single FGF-2 or VEGF or with a combination of 1 µg/ml FGF-2 + 
1 µg/ml VEGF. 
 
 
3.5.2 Analysis of cell morphology after adhesion and subsequent culture 
For characterizing cell adhesion, cells were allowed to adhere to the different surfaces 
for 2 h at 37 °C and 5 % CO 2. Light microscopy images were then taken (Olympus 
IX50, Olympus, Hamburg, Germany) at 10x magnification. Resulting cell shapes 
dependent on the culture conditions were analyzed with the help of ImageJ 1.41o 
(developed by W. Rasband, National Institutes of Health, Bethesda, USA) by tracing 
cell boundaries manually. After 3 d of culture, cell morphology was similarly analyzed 
using the circularity calculation within ImageJ. Here, a circularity of ‘1’ corresponds to a 
fully circular object, while a value of ‘0’ represents a straight line. For each condition, 
depending on the cell survival, between ~ 30 and 200 cells were analyzed for up to 13 
different substrates. 
 
 
3.5.3 Survival studies 
Analysis of cell survival was performed via Live/Dead staining as described by [Jones 
et al., 1985] This technique is based on the capability of viable cell to incorporate the 
nonpolar and nonfluorescent compound fluorescein di-O-acetate (FDA). By using their 
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acetyl esterase activity, cells rapidly hydrolyze it to fluorescein, a polar and fluorescent 
compound which is retained within the cell. Nonviable cells no longer have such 
esterase activity and will not be fluorescently stained. However, dead cells are 
susceptible to DNA intercalation of compounds such as ethidium bromide or propidium 
iodide (PI), and can therefore be easily counterstained to differentiate them from viable 
cells in a fluorometric assay. 
After 3 d of culture on the different substrates (n = 2-4), 1.13 ml/cm² of a solution 
containing 0.1 µg/ml FDA  (Fluka) and 2 µg/ml PI (Fluka) dissolved in PBS were added 
to each sample and incubated for 2 min at 22 °C. Th e cells were then immediately 
visualized by fluorescence microscopy (DMIRE2, Leica) using a 10x dry objective 
(HCxPL Fluotar 10x 0.30, Leica). FDA fluorescence was monitored by excitation with 
an argon laser (excitation wavelength 492 nm, emission wavelength 520 nm) whereas 
PI positive samples were excited with a helium-neon laser (excitation wavelength 537 
nm, emission wavelength 566 nm). Both images were combined to generate an overlay 
picture. 
 
 
3.5.4 Proliferation assay 
Cell proliferation was studied with the help of a 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT; Sigma-Aldrich) proliferation assay as described by 
[Supino, 1995]. The MTT test is a colorimetric assay based on the reduction of the pale 
yellow substrate 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) to 
the purple dye formazan by the nucleotide cofactors nicotinamide adenine dinucleotide/ 
nicotinamide adenine dinucleotide phosphate (NADH/NADPH) and is only catalyzed by 
viable cells. Dissolving the resulting crystalline formazan with a solubilization buffer 
permits the convenient quantification of product formation. The intensity of the product 
color, measured at 540 nm, is directly proportional to the number of living cells in the 
culture. 
After 3 d of culture, 283 µl/cm² of a 1/5 mixture of MTT (5 mg/ml in PBS) and SF ECGM 
were added to each sample (n ≥ 3) and incubated for 5 h at 37 °C. Next, the 
supernatant was completely removed from the substrates and 170 µl/cm² dimethyl 
sulfoxide (DMSO; Fluka) was added. The samples were incubated for 20 min at 37 °C 
and 200 µl of the solution were then transferred into a 96-well plate. Absorption was 
subsequently measured in a plate reader (Genios, TECAN, Crailsheim, Germany) at 
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540 nm. Quantification was based on a standard curve from a similar MTT test of 
defined cell numbers seeded on well plates coated with 50 µg/ml fibronectin.  
 
 
3.5.5 Investigation of cell migration 
To study HUVEC migration, the MilliCell modified Boyden chamber (8 µm pores; 
Millipore, Bedford, USA) migration assay was performed [Boyden et al., 1962]. This 
method is based on a chamber of two medium-filled compartments separated by a cell 
permeable membrane, which is generally coated with some ECM component (e.g. 
fibronectin) to facilitate both cell adherence and migration. During this assay, cells are 
placed in the upper compartment and are allowed to migrate through the pores of the 
filter into the lower compartment, in which chemotactic agents are present. After an 
appropriate incubation period, the membrane between the two compartments is fixed 
and stained, and the number of cells that have migrated to the lower side of the filter is 
determined. 
Migration chambers (n = 4-6 for each condition) were prepared by pre-coating the 
upper surface of the polycarbonate membrane with 100 µl/filter fibronectin (50 µg/ml in 
PBS) at room temperature overnight followed by air drying. They were then applied to 
24-well plates containing gel scaffolds either untreated or loaded with 1 or 5 µg/ml 
single FGF-2 or VEGF or a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF as 
described above. As a control, the filters were also introduced to wells without any gel 
networks. All substrates were then coated with 600 µl/filter SF ECGM. To initiate the 
migration assay, HUVECs were added to the upper chamber (20,000 cells in 200 µl SF 
ECGM). After 20 h at 37 °C, the medium was removed from the upper chamber and 
non-adherent cells were washed off using 100 µl/filter PBS. HUVECs still adherent on 
the upper surface of the filter were removed by a cotton tip applicator and the migratory 
cells on the lower membrane surface were fixed by treatment with 600 µl/filter of 70 % 
ethanol for 1 h at room temperature. After rinsing the chamber with PBS, cells were 
stained using 300 µl/filter of 25 % Crystal Violet (Sigma-Aldrich) diluted in MilliQ. Cell 
migration values were determined by elution of the Crystal Violet stain in 400 µl/filter of 
10 % acetic acid (Sigma-Aldrich) for 20 min at room temperature and measuring the 
absorbance at 590 nm.  
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3.6 In vivo experiments using the chicken chorioallantoic 
membrane (CAM) assay 
To assess whether biomodified starPEG-heparin hydrogels could initiate an angiogenic 
response in vivo, experiments using the chicken chorioallantoic membrane (CAM) 
assay were performed. The CAM is a vascular membrane found in eggs of some 
amniotes, such as birds and reptiles. It is formed by the fusion of the chorion and the 
adjacent wall of the allantois. In the shell-free CAM assay, chicken embryos are 
cultured in Petri dishes so that the material of interest can be easily transplanted on the 
membrane. In case of an angiogenic response, the material causes a typical radial 
rearrangement of vessels towards and a clear increase of vessels around the graft 
approximately 1-4 d after onplantation. After this incubation period, angiogenesis can 
be quantified via image analysis or colorimetric detection methods. 
Experiments were performed on chicken embryos grown by the shell-free culture 
method [Auerbach et al., 1974]. Fertile, specific pathogen-free chicken eggs 
(Erzeugergemeinschaft Pharmo-Ei GmbH, Mockrena, Germany) were obtained on 
embryonic day (ED) 0 and, following sterilization with ethanol, incubated under 
conditions of constant humidity (60 %) at 37 °C. On  ED 3, the eggs were carefully 
cracked open and their contents transferred into sterile weighting boats. Subsequently, 
they were incubated for a further 5 d during which blood vessels of CAM vascular 
system developed. The RGD-functionalized starPEG-heparin hydrogels described 
above were either loaded with single 5 µg/ml FGF-2 or VEGF, with a combination of 
5 µg/ml FGF-2 + 5 µg/ml VEGF or were not modified with any cytokines. Each network 
was then placed on the CAM surface at ED 8 and the embryos were returned to the 
incubator (n = 5-16). The untreated CAM served as a control. Analysis of the 
angiogenic response was performed during ED 12. Following Indian ink injection, the 
CAM vasculature was observed under a stereomicroscope (Leica S8AP0) and digital 
micrographs were taken. Quantification was performed by evaluating the amount of 
vessels surrounding the onplant in the proximity of 1 mm from its edge. Results were 
expressed as a ratio of untreated sample. 
 
 
3.7 Data analysis  
Statistical analysis was performed by one-way analysis of variance (ANOVA) and post-
hoc Tukey-Kramer multiple comparison test. P values < 0.05 were considered 
statistically significant. All data are presented as mean ± standard deviation. 
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4 Results and discussion 
4.1 Method establishment for analyzing the interaction of growth 
factors with starPEG-heparin hydrogels 
StarPEG-heparin hydrogels closely mimic the characteristics of the ECM by containing 
large quantities of heparin, which electrostatically bind and stabilize numerous growth 
factors (see Fig. 10). To evaluate the potential of this heparin-rich system, the binding 
and release of FGF-2 and VEGF, two cytokines that are crucial for the process of 
angiogenesis, should be investigated. However, in order to thoroughly characterize the 
interaction of the growth factors with the material, several analytical methods have to 
be applied and compared. For this, detection of fluorescently or radioisotope labeled 
protein, amino acid analysis and ELISA were performed (for details on the 
methodological principles see chapter 3). As all of these approaches are based on a 
distinct detection mechanism, experimental parameters had to be adjusted to the 
requirements of the particular method (Tab. 2). Nevertheless, the combination of all 
four analytical approaches should allow for the characterization of FGF-2 or VEGF 
binding and release over a wide range of concentrations. 
 
     
  CLSM radiolabeling (125I- ) studies HPLC ELISA 
performance well plate immobilization 
chamber well plate 
immobilization 
chamber 
analysis of               
protein 
in gel and 
supernatant in gel in gel in supernatant 
protein labeled yes yes no no 
     
 
The different methods were analyzed with respect to their ability to accurately and 
reliably quantify cytokine binding and release (see appendix B, supplementary results 
and discussion for chapter 4.1) by starPEG-heparin hydrogels. It was found that only 
ELISA experiments could be performed using non-labeled FGF-2 or VEGF under 
conditions minimizing the contact area for non-specific protein interactions with ‘foreign’ 
glass or plastic surfaces. Therefore, this approach was concluded to be advantageous 
Tab. 2 Experimental parameters used for FGF-2 or VEGF binding and release studies with 
heparin-starPEG hydrogels (due to technical reasons, FGF-2 or VEGF release experiments 
were only performed via radiolabeling studies and ELISA); adapted from [Zieris et al., 2010a]. 
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for analyzing growth factor binding and release. For a more detailed discussion of the 
methodological optimization the reader is refered to appendix B. 
 
Parts of the text and the figures of this chapter (including supplementary material) were 
adapted with kind permission from [Zieris et al., 2010a]. Copyright 2009 Springer 
Science and Business Media. 
 
 
4.2 Growth factor binding and release by starPEG-heparin 
scaffolds 
As a main objective of this work, it should be elucidated if starPEG-heparin hydrogels 
could be used as a delivery matrix for the angiogenic cytokines FGF-2 and VEGF. 
Therefore, after evaluation and optimization of different analytical approaches (see 
chapter 4.1), the interaction of FGF-2 or VEGF with distinct starPEG-heparin hydrogels 
differing in their network characteristics (γ = 1.5, 3 and 6) was investigated. Moreover, 
the binding and release of varying concentrations of FGF-2 and VEGF applied as 
single factors (0.5-50 µg/ml) or as different combinations (variation of the FGF-2 to 
VEGF ratio from 0.2-5) were investigated.  
Quantitative protein binding studies were performed using ELISA, radiolabeling studies 
and amino acid analysis via HPLC, while experiments on the release of the cytokines 
were performed via ELISA and exemplarily confirmed by radiolabeling studies. As 
already discussed, quantitative differences determined with these methods might be 
due to experimental conditions. Nevertheless, these techniques were applied because 
all of them delivered the same qualitative results.  
 
 
4.2.1 Uptake and release of FGF-2 or VEGF depending on the 
physicochemical network properties 
First, the influence of the starPEG-heparin network structure on the binding and 
release of FGF-2 or VEGF was investigated for hydrogel types differing in their 
crosslinking degree (γ = 1.5, 3 and 6) and therefore in their mechanical properties (soft, 
intermediate and stiff networks, see Fig. 11). For that, a protein concentration of 
1 µg/ml was used for immobilization. Via ELISA (Fig. 13, top), radiolabeling studies and 
amino acid analysis via HPLC (Fig. B4, left and right, appendix B), it could be shown 
50  Results and discussion 
that similar quantities of both FGF-2 or VEGF were immobilized for each scaffold 
independently of the gel type (for gels with molar ratios starPEG to heparin of γ = 1.5; 3 or 6 ~ 199 
ng/cm² FGF-2 and ~ 197 ng/cm² VEGF as detected by ELISA; p > 0.05). 
In addition to the binding experiments, the FGF-2 or VEGF sequestering depending on 
the meshsize of the particular network was determined for the three different gel types 
over the course of 96 h via ELISA (Fig. 13, bottom left and right) and radiolabeling 
studies (Fig. B5, left and right, appendix B). Both proteins showed an initial burst 
release within the first 6 h. Such burst characteristics are often attributed to surface 
effects [Huang et al., 2001] and could be caused by a FGF-2 or VEGF fraction 
entrapped in the meshwork but not bound specifically to heparin. However, after 24 h, 
the release continued slowly over the course of the entire time period that was 
investigated, indicating the potential of the material for applications with a need for 
long-term delivery profiles of growth factors. Moreover, comparable sequestered 
quantities of FGF-2 or VEGF were found for each scaffold independently of the gel type 
(for gels with molar ratios starPEG to heparin of γ = 1.5, 3, and 6 after four days ~ 1 ng/cm² FGF-2 or 
VEGF released as quantified via ELISA; p > 0.05 for the comparison of the different gel types).  
Based on these findings, results obtained demonstrate that the binding and release of 
the two proteins is independent of the mechanical hydrogel properties. Considering the 
mesh sizes of the matrices with large pores in the range of ~ 16-7 nm for γ = 1.5-6 (see 
Fig. 11, bottom left) and the observations of the qualitative uptake experiments for 
FGF-2 (diameter of ~ 3 nm [Eriksson et al., 1991]) and VEGF (diameter of ~ 6 nm 
[Muller et al., 1997]) performed via CLSM showing no restrictions for penetration of 
both proteins (for details see appendix B), it becomes obvious that the diffusion of the 
cytokines is not affected by differences in the network structure (pore size, hydration 
etc.). Consequently, the FGF-2 and VEGF immobilization and delivery correlates only 
with the constant heparin concentration of the different scaffolds. 
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Fig. 13 Amount of hydrogel-immobilized or -released FGF-2 or VEGF determined for different gel types as 
quantified via ELISA; adapted from [Zieris et al., 2010b]. top: amount of electrostatically bound FGF-2 or 
VEGF per cm² scaffold area for the different gel types γ = 1.5; 3 or 6 (low, intermediate and high 
crosslinking degree, p > 0.05; ANOVA). bottom: cumulative amount of electrostatically bound FGF-2 (left) 
or VEGF (right) released by the different gel matrices γ = 1.5; 3 or 6 (low, intermediate and high 
crosslinking degree, p > 0.05; ANOVA). All data are presented as mean ± root mean square deviation from 
n = 3. 
 
Parts of the text and the table of this chapter (including supplementary material) were 
adapted with kind permission from [Zieris et al., 2010b]. Copyright 2010 Elsevier. 
 
 
 
 
 
Taken together, the starPEG-heparin hydrogels might be used as FGF-2 or VEGF 
storage systems, which can present the growth factors independently of the 
particular structural and mechanical properties of the different scaffolds. 
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4.2.2 Uptake and release of FGF-2 and/or VEGF depending on the protein 
concentration 
Due to their high heparin content, starPEG-heparin hydrogels were shown to bind and 
stabilize both FGF-2 and VEGF. Consequently, they might be promising candidates for 
an application as a delivery system for large cytokine quantities or for the parallel 
provision of several growth factors. Thus, after evaluating the binding potential for high 
concentrations of single cytokines (from 0.5-50 µg/ml), the immobilization and 
subsequent release of FGF-2 and VEGF, introduced to the matrices either as single 
components (1 µg/ml or 5 µg/ml) or as combinations in different ratios (1 µg/ml FGF-2 
+ 1 µg/ml VEGF, 5 µg/ml FGF-2 + 1 µg/ml VEGF or 1 µg/ml FGF-2 + 5 µg/ml VEGF), 
were analyzed.  
First, to evaluate whether the starPEG-heparin hydrogels could be used as efficient 
FGF-2 and VEGF storage system, the capacity of the matrices to take up various 
amounts of the growth factors was investigated for the gel with the intermediate 
crosslinking degree, γ = 3. By analysis via ELISA (Fig. 14, top left), radiolabeling 
studies and amino acid analysis via HPLC (Fig. B6, left and right, appendix B), the 
immobilized quantities at a defined concentration were found to be similar for both 
proteins. Moreover, a linear correlation between the concentration of the incubation 
solution and the amount of immobilized FGF-2 or VEGF within the gel could be found, 
which indicates that no saturation of binding was reached within the concentration 
range monitored. This result correlates well with estimations concerning the maximal 
storage capacity of the applied hydrogel system on the basis of the calculated heparin 
concentration within the swollen network and HPLC-based analysis of immobilization 
experiments with high concentrations of growth factors. Here, even after incubation 
with 50 µg/ml protein the molar ratio of heparin to growth factor was still 26:1 for FGF-2 
and 62:1 for VEGF, respectively. Moreover, as reported for FGF-2 [Arakawa et al., 
1994], each heparin molecule is able to interact with several cytokine molecules, so 
that a saturation of binding will occur only at concentrations much higher than used in 
this study, while due to the small size of FGF-2 and VEGF also no spatial restrictions 
within the gel network should limit the uptake of the proteins.  
While a linear correlation was observed between the concentration of the incubation 
solution and the amount of immobilized cytokine within the gel (~ 199 ng/cm² immobilized 
from a solution of 1 µg/ml and ~ 995 ng/cm² immobilized from a solution of 5 µg/ml as detected by 
ELISA), it could be additionally shown that different combinations of FGF-2 and VEGF 
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(Fig. 14, top right and Fig. B7, appendix B) can be bound to the matrices with the same 
efficiency as determined for the individual factors (p > 0.05 for the immobilized amount of single 
FGF-2 or VEGF and the corresponding concentration used in the combination). Furthermore, the 
immobilized quantities of combinations of FGF-2 and VEGF at a defined concentration 
were found to be similar for both proteins.  
Besides an evaluation of the starPEG-heparin hydrogel binding ability for FGF-2 and 
VEGF, experiments on the release of each single protein as well as of different 
combinations from the matrices were performed via ELISA and exemplarily confirmed 
by radiolabeling studies. Fig. 14 illustrates the cumulative release of either FGF-2 
(bottom left) or VEGF (bottom right) alone (1 or 5 µg/ml) and of different combinations 
of both proteins (1 µg/ml FGF-2 + 1 µg/ml VEGF, 5 µg/ml FGF-2 + 1 µg/ml VEGF or 
1 µg/ml FGF-2 + 5 µg/ml VEGF) measured over 96 h. Irrespective of the immobilized 
concentration or the particular factor considered, the release curves show once again 
the typical burst within the first 6 h followed by a continuous release over time. Similar 
to the trends observed for FGF-2 and/or VEGF immobilization, by ELISA analysis (Fig. 
14, dashed lines), a linear correlation between the amount of gel-bound growth factors 
and the quantities being released was observed for single FGF-2 or VEGF (~ 1 ng/cm² 
released for 1 µg/ml and ~ 6 ng/cm² released for 5 µg/ml), which was exemplarily confirmed via 
radiolabeling studies (single factors, Fig. B8, left and right, appendix B). Additionally, 
different combinations of FGF-2 and VEGF (Fig. 14, continuous lines) could be 
released by the matrices with the same efficiency as for the individual factors (p > 0.05 
for the released amount of single FGF-2 or VEGF and the corresponding concentration used in the 
combination).  
As an explanation, the large excess of heparin appears to prevent any interference 
between the growth factors during their combined application. Moreover, an additional 
advantage of these starPEG-heparin hydrogels is the comparable release of either 
cytokine at a particular loading quantity. Given this finding, the FGF-2 and/or VEGF 
release characteristics can be adjusted by the initial amount of protein loaded, which in 
turn can be tuned over a wide range of concentrations. 
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Fig. 14 Amount of hydrogel-immobilized or -released FGF-2 and/or VEGF determined for different protein 
concentrations as quantified via ELISA; adapted from [Zieris et al., 2010b and 2011]. top (left): uptake of 
single FGF-2 or VEGF in dependence on the protein concentration (0.5-50 µg/ml) in the immobilization 
medium; linear regression, R² (FGF-2) = 0.99999; R² (VEGF) = 0.99999. top (right): amount of 
electrostatically bound FGF-2 and/or VEGF per cm² scaffold area for different protein concentrations (p > 
0.05 for the immobilized amount of single FGF-2 or VEGF and the corresponding concentration used in 
the combination; ANOVA). bottom: cumulative amount of electrostatically bound FGF-2 (left) or VEGF 
(right) released by gels which were loaded with either single cytokines (dashed lines) or different 
combinations of FGF-2 and VEGF (continuous lines) (p > 0.05 for the released amount of single FGF-2 or 
VEGF and the corresponding concentration used in the combination; ANOVA). All data are presented as 
mean ± root mean square deviation from n = 3 (ELISA). 
 
 
 
 
 
In summary, results demonstrate that starPEG-heparin hydrogels could be utilized 
for an independent and modular delivery of both FGF-2 and VEGF over a broad 
range of concentrations. 
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For evaluating the potential of cytokine delivery systems to promote a certain cell 
behavior in vitro, the absence of serum in the cell culture medium might be beneficial, 
as possible interferences of growth factors potentially provided by the serum itself are 
avoided. Consequently, FGF-2 and/or VEGF release experiments performed under 
serum-free conditions are representative for the in vitro HUVEC culture settings 
investigated in this work (see chapter 4.3). However, this environment is significantly 
different from the situation that occurs in vivo. Therefore, the FGF-2 and VEGF release 
from starPEG-heparin hydrogels was additionally analyzed in the presence of the 
serum protein BSA, thereby better corresponding to physiological conditions. 
Exemplarily, Fig. 15 shows the cumulative release of electrostatically bound FGF-2 
(left) or VEGF (right) into SF ECGM ± 1 mg/ml BSA by gels which were loaded with a 
combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF. For a more comprehensive comparison 
of the efficiencies, the data are expressed as percentage of initially bound growth factor 
(see Fig. 14, top right) being released by the starPEG-heparin scaffolds.  
As demonstrated in Fig. 14, both FGF-2 and VEGF release was found to be low in the 
absence of serum proteins in the environment (~ 0.5 %). This effect is most probably 
attributed to the high excess of heparin in the hydrogels, presumably resulting in a 
dynamic release/-re-binding of the growth factors within the scaffold. Nevertheless, the 
amount of cytokines delivered might be sufficient to promote a certain cell response, as 
growth factors already elicit their biological function when present at pico- or nanomolar 
concentrations [Flaumenhaft et al., 1992]. However, despite of similar delivery kinetics, 
compared to the FGF-2 and VEGF release in a serum-free environment, the efficiency 
was increased by magnitudes in the presence of proteins in the medium (~ 9.5 %; p < 0.05 
for comparing released amounts of growth factors into SF ECGM or SF ECGM + 1 mg/ml BSA) as also 
observed by [Gu et al., 2004; Lee et al., 2007]. One reason for this effect could be that 
BSA might displace the cytokines from heparin by reducing their interaction. Moreover, 
BSA might also be able to stabilize FGF-2 and VEGF after they get released into the 
medium, thereby preventing physical loss of cytokine or its activity. 
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Fig. 15 FGF-2 and VEGF release efficiency in dependence on the release medium as obtained by analysis 
via ELISA; adapted from [Zieris et al., 2011]. Plots show the cumulative percentage of electrostatically 
bound FGF-2 (left) or VEGF (right) released into SF ECGM ± 1 mg/ml BSA by gels which were loaded with 
a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF (p < 0.05 for the released amount of growth factors into 
SF ECGM or SF ECGM + 1 mg/ml BSA; ANOVA). All data are presented as mean ± root mean square 
deviation from n = 3. 
 
Parts of the text and the table of this chapter (including supplementary material) were 
adapted with kind permission from [Zieris et al., 2010b and 2011]. Copyright 2010 and 
2011 Elsevier. 
 
 
4.3 In vitro HUVEC response to differently biomodified starPEG-
heparin scaffolds 
After it has been demonstrated that starPEG-heparin hydrogels could be used as 
efficient storage systems for several heparin-binding growth factors going along with 
well adjustable cytokine release characteristics, the potential of starPEG-heparin 
hydrogels for an application as a substrate for in vitro culture of human umbilical vein 
endothelial cells (HUVECs) was investigated. 
For a long time it is known that the process of angiogenesis is tightly controlled by both 
chemical and mechanical cues. Consequently, to gain insight into the complex 
mechanism of its regulation there is a need for in vitro model systems that allow for an 
Taken together, despite the dependence of the release efficiency on the 
environmental conditions, a combination of both FGF-2 and VEGF could be 
delivered by starPEG-heparin hydrogels in similar amounts for several 
experimental settings that are relevant for specific applications.  
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independent investigation of both parameters. Therefore, in this work, endothelial cells 
were cultured on top of hydrogel types that differ in terms of stiffness along with varying 
degrees of biofunctionality. In order to ensure that any effects on HUVECs behavior is 
initiated by these biomodified scaffold rather than by cytokines possibly provided by 
serum-containing cell culture medium, all experiments were performed under serum-
free conditions. 
 
 
4.3.1 Influence of the physicochemical network characteristics 
To analyze the influence of the physicochemical starPEG-heparin network 
characteristics on the behavior of endothelial cells, HUVECs were cultured under 
serum-free conditions on top of hydrogels that differ in terms of their physicochemical 
characteristics (γ = 1.5, 3 and 6; gels with low, intermediate and high crosslinking 
degree and therefore low, intermediate and high stiffness and meshsize, respectively) 
in the presence or absence of the adhesion ligand RGD. For each hydrogel type, the 
amount of introduced adhesion molecules was constant (Fig. 12, right). Concerning 
every culture substrate, differential cellular responses in terms of adhesion, 
proliferation/survival and cell morphology were analyzed. 
 
Cell adhesion 
To allow for cell growth on a particular substrate, the initial process of adhesion to the 
surface is one of the most critical steps. In this study, HUVEC attachment and 
spreading depending on the biomolecular functionalization with adhesion ligands and 
the mechanical properties of the particular matrices was investigated by analyzing the 
cell circularity 2 h after plating them on the hydrogels (Fig. 16). Here, non-adherent 
cells remained circular, (as indicated by a number close to “1”), whereas the circularity 
decreased upon attachment due to spreading. 
Despite their high content of the naturally occurring molecule heparin, poor adhesion 
was observed for all unmodified starPEG-heparin gel types γ = 1.5, 3 and 6 as cells 
cultured on these matrices possessed an almost fully circular morphology. By contrast, 
the different gel scaffolds modified with RGD were able to induce HUVEC attachment 
as indicated by the more elongated morphology (p < 0.05 for the comparison of pure gels or 
gels with RGD for every γ). Consequently, the presence of an adhesion ligand as provided 
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by the introduction of the RGD sequence to the gels was found to be absolutely 
essential to initiate attachment and spreading.  
Beside the major effect of the biomodification, an additional influence on HUVEC 
adhesion could be observed in terms of the substrate stiffness. Due to the poor overall 
attachment to pure starPEG-heparin scaffolds, no significant differences were found 
among the hydrogel types for these particular conditions (cell circularity of 0.988, 0.997 and 
0.998 for γ = 1.5, 3 and 6; p > 0.05 for comparing the different gel types). However, for gel 
substrates treated with RGD, a correlation between the mechanical properties of the 
scaffold and the adhesion of HUVECs was observed (cell circularity of 0.672, 0.634 and 0.604 
for γ = 1.5, 3 and 6; p < 0.05 for the comparison of γ = 1.5 and 6). For matrices with higher degrees 
of crosslinking, cells showed an increased tendency to adhere to these substrates as 
assessed via decreasing cell circularity. This finding is in line with results reported in 
literature, where stiffer, more rigid culture substrates were described to promote 
endothelial cell adhesion [Yeung et al., 2005]. 
Fig. 16 HUVEC adhesion after 2 h culture on different hydrogel types (γ = 1.5; 3 or 6; ± RGD) as accessed 
via cell circularity quantified by the circularity calculation within ImageJ 1.41o. All data are presented as 
mean ± root mean square deviation from n ≈ 40-120 cells quantified on up to 4 different substrates.             
* indicates statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the 
illustrated significant differences, see text. 
Conclusively, significant differences in cell adhesion with respect to the gel type and 
the bioadhesiveness could be observed. While the presence of an adhesion 
ligand was found to be most critical for promotion of an effective cell 
attachment, biomaterials offering a higher stiffness seemed to be more 
advantageous to support the process of HUVEC adhesion. 
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Cell survival/proliferation and morphology 
After successful initial attachment, scaffolds suitable for an application in tissue 
engineering should be able to promote cell survival and proliferation over prolonged 
time periods. Consequently, a live/dead (Fig. 17A) and a MTT (Fig. 17B, left) assay 
were performed after 3 d of culture on starPEG-heparin hydrogels with different 
physicochemical properties in the presence or absence of the adhesion ligand RGD. 
Moreover, materials have to support HUVEC differentiation into less circular and more 
elongated cells in order to form tubular structures during angiogenesis. Therefore, 
HUVEC circularity as it was dependent on the presence of RGD and the structural 
characteristics of the substrate was analyzed after 3 d of culture (Fig. 17B, right). 
For the starPEG-heparin hydrogels it could be shown that coinciding with an advancing 
degree of biofunctionalization, also the HUVEC proliferation/survival rate increased. 
Very low survival with many dead cells in the surrounding medium could be observed 
on pure gels, while the few cells being still viable showed a round shape. This might be 
due to the mainly non-adhesive character of the starPEG therefore leading to the 
detachment of most cells. The very small number of HUVECs that could be found on 
the gel surface was most likely only weakly attached, so that cells were consequently 
not able to proliferate.  
By introducing the adhesion peptide RGD into the starPEG-heparin hydrogels, the 
HUVEC survival rate could be increased significantly (p < 0.05 for the comparison of pure gels 
or gels with RGD for every γ). Under these culture conditions, only very few dead cells were 
found in the medium while the viable HUVECs adapted also a more elongated 
morphology (p < 0.05 for the comparison of pure gels or gels with RGD for every γ). The most 
important parameter for that might be the fact that these substrates were able to 
mediate effective initial cell adhesion. Therefore, HUVECs could successfully spread 
on these scaffolds so that a high number of the primarily plated cells survived. Since 
these results were observed on the RGD-modified starPEG-heparin hydrogels even 
under serum-free culture conditions, these data indicate that the scaffolds do not 
exhibit any toxic effects on the cells and might therefore be generally well suited to 
support growth of HUVECs.  
In addition to the biomolecular functionalization, mechanical matrix parameters of 
engineered materials are important to promote a desired cellular response [Liu et al., 
2005]. For pure gels, where survival due to lacking adhesion ligands was generally 
hardly possible, a change in the mechanical properties did not substantially affect 
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neither HUVEC proliferation/survival (~ 430, 190 and 340 cells/cm² scaffold area for γ = 1.5, 3 and 
6) nor cell morphology (0.996, 0.991 and 0.997 for γ = 1.5, 3 and 6). 
In contrast, for substrates functionalized with RGD, increasing cell numbers were found 
on the gels with a low or intermediate crosslinking degree, indicating that such network 
structures are most beneficial to promote HUVEC proliferation/survival (~ 6200, 5300 and 
3100 cells/cm² scaffold area for γ = 1.5, 3 and 6; p < 0.05 for the comparison of γ = 1.5 or 3 to γ = 6). In  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 Interaction of different hydrogel types (γ = 1.5; 3 or 6; ± RGD) with HUVECs after 3 days of culture; 
modified from [Zieris et al., 2010b]. 17A: representative fluorescence microscopy images after live/dead 
staining of HUVECs (viable cells = green; dead cells = red) on the different substrates (scale bar 130 µm). 
17B (left): HUVEC proliferation/survival as accessed via cell numbers on the different networks quantified 
by an MTT assay. All data are presented as mean ± root mean square deviation from n = 3-5. For statistics 
see supplementary data. 17B (right): HUVEC morphology as accessed via cell circularity on the different 
networks quantified by the circularity calculation within ImageJ 1.41o. All data are presented as mean ± 
root mean square deviation from n ≈ 30-140 cells quantified on up to 4 different substrates. * indicates 
statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the illustrated 
significant differences, see text. 
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terms of the effect on cell morphology, in the case of networks modified with RGD, 
HUVECs cultured on the intermediately crosslinked gel type γ = 3 showed a slightly 
more elongated shape (0.502, 0.416 and 0.575 for γ = 1.5, 3 and 6; p < 0.05 for the comparison of 
γ = 1.5 or 6 to γ = 3). Although it has been described that endothelial cells preferentially 
grow on stiff substrates and, due to the fact that their requirements for proliferation and 
adaptation of an elongated morphology differ, primarily differentiate when cultured on a 
soft matrix that allows for an retraction and reorientation of the cell shape, there might 
be an optimal range for balancing both parameters [Ingber et al., 1989; Deroanne et 
al., 2001; Liu et al., 2005; Saunders et al, 2010]. Results obtained in this study 
demonstrate that with a HUVEC culture on the hydrogel γ = 3 offering an intermediate 
starPEG to heparin ratio going along with a storage modulus in the range of ~ 7000 Pa, 
rather high cell numbers possessing an elongated morphology could be observed. 
 
 
 
 
 
 
 
Parts of the text and the table of this chapter were adapted with kind permission from 
[Zieris et al., 2010b]. Copyright 2010 Elsevier. 
 
 
4.3.2 Influence of the FGF-2 and/or VEGF delivery  
Besides the influence of the physico-chemical properties of the cellular environment, 
also the presence of soluble molecular effectors such as the angiogenic growth factors 
FGF-2 or VEGF is an essential parameter for controlling endothelial cell behavior in 
tissue engineering. Although the administration of one cytokine is not sufficient to 
create well-developed mature blood vessels [Bruick et al., 2001; Komori et al., 2005], 
only a few studies have analyzed the effect of a combined provision of both FGF-2 and 
VEGF by a particular biomaterial [Ribatti et al., 2001; Wong et al., 2003; Nillesen et al., 
2007; Wilcke et al., 2007; Briganti et al., 2010; Larsen et al., 2010].  
Based on its overall beneficial effects on HUVEC adhesion, proliferation/survival and 
differentiation, for investigating the influence of the growth factor delivery by starPEG-
Overall, starPEG-heparin hydrogels functionalized with the adhesion ligand 
RGD are suitable substrates for the culture of HUVECs. It was found that inter-
mediate starPEG to heparin ratios showed beneficial effects on proliferation/ 
survival while in parallel also HUVEC differentiation into tube-like structures could 
be promoted. 
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heparin matrices on the endothelial cell behavior, the intermediately crosslinked 
hydrogel type (γ = 3) was used in this study, while HUVECs were cultured under 
serum-free conditions on top of matrices in the presence or absence of the adhesion 
ligand RGD. These scaffolds were either used without any additional modification or 
loaded with either 1 or 5 µg/ml single FGF-2 or VEGF or with a combination of 1 µg/ml 
FGF-2 + 1 µg/ml VEGF. For every culture substrate, differential cellular responses in 
terms of adhesion, proliferation/survival, cell morphology and migration were analyzed. 
 
Cell adhesion 
As both angiogenic growth factors FGF-2 and VEGF are known to promote endothelial 
cell adhesion [Baird et al., 1988; Hutchings et al., 2003], studies were performed to 
examine cell attachment and spreading on starPEG-heparin hydrogels in the presence 
and absence of these cytokines (applied as single proteins or as a combination) and 
the presence and absence of an additional adhesion ligand (RGD). Once again, cell 
adhesion was assessed by analyzing cell shape (in terms of cell circularity) 2 h after 
plating HUVECs on the hydrogels (Fig. 18).  
As demonstrated in appendix B, the covalent RGD attachment to the heparin 
carboxylic acid moieties does not influence the electrostatic binding (Fig. B9, top, 
appendix B) and release (Fig. B9, bottom, appendix B) of FGF-2 and VEGF. This effect 
is most probably related to the high heparin concentration within the material carrying 
various carboxylic acid groups as potential binding sites for the small RGD ligand, while 
the sulfate groups as main interaction sites for FGF-2 and VEGF are unaffected.  
For analysis of HUVEC attachment, despite the high content of heparin, poor adhesion 
was observed for both pure starPEG-heparin matrices and for gels treated with 1 µg/ml 
or 5 µg/ml FGF-2, as assessed by the high degree of circularity (cell circularity of 0.997, 
0.993 and 0.943, respectively; p > 0.05). In contrast, the HUVEC circularity decreased on 
scaffolds modified with 1 µg/ml or 5 µg/ml VEGF and the combination of both growth 
factors (cell circularity of 0.824, 0.882 and 0.861; p < 0.05 when comparing gels + 1 µg/ml VEGF to pure 
gels or gels + FGF-2). Here, as VEGF is involved in focal adhesion integrity [Abedi et al., 
1997; Hutchings et al., 2003] it is likely that it might exert a slight beneficial effect on 
HUVEC attachment to starPEG-heparin hydrogels, even in the absence of an adhesion 
ligand.   
Nevertheless, the observation of lower cell circularity on starPEG-heparin gels modified 
with RGD (cell circularity of 0.637) alone or in combination with 1 µg/ml or 5 µg/ml FGF-2 
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(cell circularity of 0.639 and 0.558), 1 µg/ml or 5 µg/ml VEGF (cell circularity of 0.635 and 0.665) 
and with FGF-2/VEGF (cell circularity of 0.587) demonstrated that HUVEC adhesion could 
be still enhanced (p < 0.05 for comparing gels with or without RGD for each condition). This 
indicates that despite the supporting effect of VEGF, the presence of an adhesion 
ligand, such as the RGD sequence, is essential for maximal cell attachment and 
spreading. Besides the incorporation of this adhesion peptide, almost no additional 
influence of growth factor modification could be observed (p > 0.05 when comparing gels with 
RGD between the different conditions), which is in line with findings of [Wong et al., 2003]. 
Here, the strong adhesive effect of RGD most probably overrides the cytokine impact 
on HUVEC attachment. However, as an advantage of the RGD decoration, all of the 
samples monitored for their impact on long-term cell culture started with HUVECs that 
similarly adhered to the gel surface.  
Fig. 18 HUVEC adhesion after 2 h culture on the differently biomodified hydrogels (± RGD; with or without 
1 or 5 µg/ml of single FGF-2 or VEGF as well as a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF) as 
accessed via cell circularity quantified by the circularity calculation within ImageJ 1.41o; adapted from 
[Zieris et al., 2011]. All data are presented as mean ± root mean square deviation from n ≈ 50-130 cells 
quantified on up to 5 different substrates. * indicates statistically significant differences (p < 0.05; ANOVA). 
For statistical comparisons apart from the illustrated significant differences, see text. 
 
As a conclusion, effective HUVEC adhesion could be observed depending on the 
modification of starPEG-heparin hydrogels. Although VEGF was found to influence 
cell attachment positively, introduction of the adhesion ligand RGD was still 
necessary to achieve a maximal effect. 
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Cell survival/proliferation and morphology 
As the delivery of cytokines is a crucial material parameter to support endothelial cell 
proliferation/survival and differentiation [Fischbach et al., 2006; Zhang et al., 2007; 
Uebersax et al., 2009], also the effects of FGF-2 and/or VEGF provision by starPEG-
heparin hydrogels on these parameters were investigated using live/dead staining (Fig. 
19A, green/red cells) and a MTT assay (Fig. 19B, left) performed after 3 d of culture on 
the different matrices. Furthermore, cell morphology was analyzed as assessed by 
HUVEC circularity (Fig. 19B, right). As the functionalization of starPEG-heparin 
hydrogels with cytokines alone was not sufficient to support effective cell attachment 
and spreading (Fig. 18), which would be crucial for long term cell cuture (Fig. 17), all 
scaffolds monitored for their effect on HUVEC survival/proliferation and morphology 
were additionally modified with the adhesion ligand RGD.  
After 3 d of culture, substantial HUVEC survival (Fig. 19B, left) was observed for RGD-
functionalized hydrogels (~ 2700 cells/cm² scaffold area) and for RGD-modified matrices 
loaded with 1 µg/ml of single FGF-2 or VEGF (~ 12100 or 10500 cells/cm² scaffold area), 
5 µg/ml of single FGF-2 or VEGF (~ 12200 or 11000 cells/cm² scaffold area) or with a 
combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF (~ 15600 cells/cm² scaffold area). The very 
small number of dead cells in the medium and the typical spindle-shape-like 
morphology of cells grown on the scaffolds (Fig. 19A) indicated once again that the 
introduction of RGD to starPEG-heparin matrices could generate successful HUVEC 
culture substrates. Moreover, in the presence of FGF-2 and/or VEGF in RGD-modified 
hydrogels, cell numbers (Fig. 19B, left) could be further increased (p < 0.05 when 
comparing gels + RGD to scaffolds modified with RGD and cytokines). Despite the positive effect of 
RGD + VEGF on HUVEC survival, after 3 d of culture the presence of RGD + FGF-2 
yielded an even higher cell number than initially applied. However, maximal 
proliferation rates (Fig. 19B, left) were observed when starPEG-heparin hydrogels were 
used for the combined provision of FGF-2 and VEGF (p < 0.05 for comparing gels + RGD and 
one single growth factor to scaffolds + RGD and both FGF-2 + VEGF). Interestingly, increasing 
amounts of single FGF-2 or VEGF released from the matrices (loaded with 5 µg/ml, 
respectively) did not significantly change the HUVEC survival when compared to the 
treatment with lower concentrations (p > 0.05 for the comparison of 1 µg/ml and 5 µg/ml 
cytokine). Nevertheless, the combination of both factors (1 µg/ml FGF-2 + 1 µg/ml 
VEGF) significantly increased cell growth even though this provided a lower total 
amount of cytokine. Thus, the increased proliferation induced by hydrogels modified 
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with FGF-2 + VEGF clearly did not arise from the presence of higher growth factor 
concentrations, but rather seemed to result from a combined action of both cytokines 
as already described by [Goto et al., 1993]. 
In addition to the beneficial effect on cell proliferation/survival, culture on RGD-modified 
starPEG-heparin hydrogels also led to the formation of the typical spindle-shaped 
HUVEC morphology. Here (Fig. 19B, right), the lowest cell circularity representing 
HUVECs with the most elongated shape was observed for starPEG-heparin matrices 
treated with RGD + 1 µg/ml or 5 µg/ml VEGF (cell circularity of 0.34 or 0.35, respectively; 
p < 0.05 when comparing gels with RGD + VEGF to gels with RGD ± FGF-2), while there were no 
significant differences between RGD-functionalized scaffolds with 1 µg/ml or 5 µg/ml 
FGF-2 (cell circularity of 0.43 or 45, respectively) or without any growth factor (cell circularity of 
0.43). However, consistent to the supporting effect of FGF-2/VEGF combinations on in 
vitro tube formation [Pepper et al., 1992; Goto et al., 1993; Sun et al., 2004], also in the 
case of gels treated with the cytokine combination (RGD and FGF-2 + VEGF), 
HUVECs exhibited the tendency to differentiate into more stretched cells (cell circularity of 
0.36; p < 0.05 when comparing scaffolds with RGD + FGF-2/VEGF with gels containing RGD ± 5 µg/ml 
FGF-2; p > 0.05 for the comparison with networks with RGD + 1 µg/ml FGF-2 or 1 or 5 µg/ml VEGF). 
Given the fact that high cell numbers were observed with the parallel delivery of both 
FGF-2 and VEGF, the provision of the cytokine combination by starPEG-heparin 
hydrogels promoted both HUVEC proliferation and differentiation.  
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Fig. 19 Interactions of differently biomodified hydrogels (+ RGD; with or without 1 or 5 µg/ml of single FGF-
2 or VEGF as well as a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF) with HUVECs after 3 d of culture; 
adapted from [Zieris et al., 2011]. 19A: representative fluorescence microscopy images after live/dead 
staining of HUVECs (viable cells = green; dead cells = red) on the different substrates (scale bar 130 µm). 
19B (left): HUVEC proliferation/survival as accessed via cell numbers on the different networks quantified 
by an MTT assay. All data are presented as mean ± root mean square deviation from n = 3-4 (* indicates 
p < 0.05; ANOVA). 19B (right): HUVEC morphology as accessed via cell circularity on the different 
networks quantified by the circularity calculation within ImageJ 1.41o. All data are presented as mean ± 
root mean square deviation from n ≈ 40-200 cells quantified on up to 13 different substrates. * indicates 
statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the illustrated 
significant differences, see text. 
 
 
 
 
A 
B 
In summary, upon the introduction of the RGD adhesion ligand, a FGF-2 
provision by starPEG-heparin hydrogels was able to stimulate HUVEC 
proliferation/survival, while VEGF seemed to promote cell differentiation. 
However, using starPEG-heparin hydrogels as a delivery system for the parallel 
administration of both cytokines, their beneficial effects could be combined to 
obtain high numbers of HUVECs undergoing differentiation. 
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Cell migration 
The biological process of angiogenesis involves the migration of endothelial cells to the 
site where new vessel formation is needed. Therefore, the ability of biofunctionalized 
starPEG-heparin hydrogels to induce directional HUVEC motility was evaluated. In this 
setting, the hydrogels were used as a growth factor delivery matrix to initiate cell 
migration through a fibronectin-coated Boyden filter (upper chamber) towards the site 
of cytokine provision in the lower chamber (Fig. 20A). Results (Fig. 20C) are expressed 
as the relative cell migration compared to wells filled with untreated endothelial cell 
growth medium (ECGM) without any scaffold in the lower chamber (Fig. 20B).  
While unmodified starPEG-heparin matrices were hardly able to support HUVEC 
migration (1.5 % increase compared to wells with untreated ECGM in the lower chamber), hydrogels 
loaded with 1 µg/ml of single FGF-2 or VEGF (11 or 9 % increase in comparison to wells with 
untreated ECGM in the lower chamber, respectively), 5 µg/ml of single FGF-2 or VEGF (15 or 
18 % increase in comparison to wells with untreated ECGM in the lower chamber, respectively) or a 
combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF (28 % increase in comparison to wells with 
untreated ECGM in the lower chamber; p < 0.05 for comparing pure gels to scaffolds modified with 
cytokines) significantly increased cell motility (Fig. 20C). Interestingly, in contrast to the 
other in vitro assays, where cells were directly seeded on the cytokine-loaded 
scaffolds, in this setting, the unaffected release and diffusion of growth factors into the 
medium over a larger distance is required to initiate an effect on HUVEC behavior. 
Consequently, the results obtained indicate the suitability of starPEG-heparin hydrogels 
to function as a cytokine delivery matrix, where the bioactivity of growth factors is 
preserved even after the release from the scaffolds.  
When comparing the migratory cell response to FGF-2 or VEGF at one particular 
concentration, no significant differences where found (p > 0.05 for the comparison of 1 µg/ml 
FGF-2 to 1 µg/ml VEGF or 5 µg/ml FGF-2 to 5 µg/ml VEGF). Although several authors presented 
inconsistent results as whether FGF-2 [Sakomoto et al., 1995; Donohue et al., 2003] or 
VEGF [Yoshida et al., 1996; Castellon et al, 2002] is the most potent initiator of 
endothelial cell motility, these data might suggest that both factors are able to induce 
HUVEC migration in a similar manner. However, compared to the influence on cell 
adhesion, proliferation and morphology, there was clearly a stronger effect of the 
particular cytokine concentration on migration as HUVEC motility generally increased 
with larger growth factor quantities being released by the matrices (p < 0.05 for 1 µg/ml 
FGF-2 versus 5 µg/ml VEGF; 1 µg/ml VEGF versus 5 µg/ml FGF-2 or versus 5 µg/ml VEGF; p > 0.05 for 
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1 µg/ml versus 5 µg/ml FGF-2). These data are consistent with results described in literature 
[Yoshida et al., 1996], where a positive correlation between the endothelial migratory 
response and an increasing concentration of up to 10 ng/ml soluble FGF-2 or VEGF 
was found. However, despite the  effect of  the cytokine concentration, the combination 
of 1 µg/ml FGF-2 + 1 µg/ml VEGF showed the most beneficial influence on cell 
migration (p < 0.05 for comparing the migration towards networks modified with both FGF-2/VEGF to all 
other conditions). Although some authors describe the absence of such an effect on 
endothelial cell motility [Yoshida et al., 1996], in this system FGF-2 and VEGF seemed 
Fig. 20 HUVEC migration in response to differently biomodified hydrogels (with or without 1 or 5 µg/ml of 
single FGF-2 or VEGF as well as a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF) as analyzed by a 
modified Boyden chamber assay; adapted from [Zieris et al., 2011]. 20A and B: representative images of 
HUVECs located on the lower site of the Boyden filter after migration through the membrane towards 
differently biomodified gel matrices (A) or towards the untreated ECGM which served as a control (B) 
(scale bar 100 µm). 20C: quantification of the relative HUVEC migration in relation to differently 
biomodified hydrogels. Data are presented as mean ± root mean square deviation from n = 4-6. * indicates 
statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the illustrated 
significant differences, see text. 
A 
B C 
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to promote migration in a synergistic way as also observed by [Vernon et al., 1999; Yan 
 et al., 2001]. However, as the delivery of both growth factors also significantly 
increased HUVEC numbers after 3 d of culture (Fig. 19B, left), when considering the 
cellular process of migration over 20 h, possible interferences of proliferation should be 
discussed. Since, with regard to a time course of 24 h, no increase in cell numbers 
occurred in standard HUVEC growth curves [Hoshi et al., 1984; Weiss et al., 1990], 
while also the presence of rather high concentrations of FGF-2, VEGF or FGF-2 + 
VEGF had no significant influence on endothelial cell numbers for such short periods of 
culture [Sakomoto et al., 1995], effects observed in this study might be indeed 
attributed to an impact of the growth factors on HUVEC migration rather than 
proliferation. 
 
Parts of the text and the table of this chapter (including supplementary material) were 
adapted with kind permission from [Zieris et al., 2011]. Copyright 2011 Elsevier. 
 
 
4.4 In vivo CAM response to FGF-2 and/or VEGF provision via 
starPEG-heparin hydrogels 
Although in vitro assays using endothelial cells can provide essential information on the 
general suitability of a certain biomaterial for an application in angiogenic tissue 
engineering, the final evaluation of factors which influence angiogenesis is best 
performed by in vivo experiments [Auerbach et al, 2003]. Therefore, to analyze whether 
the provision of FGF-2 or VEGF as single cytokines or in combination by starPEG-
heparin hydrogels could initiate an angiogenic response in vivo, the effects of 
biofunctionalized hydrogel onplants were studied in a CAM assay (Fig. 21). Based on 
the data reported in literature [Wilting et al., 1991 & 1993; Nico et al., 2001], an 
intermediate concentration of either single (5 µg/ml FGF-2 or VEGF) or combined 
growth factors (5 µg/ml FGF-2 + 5 µg/ml VEGF) resulting in ~ 2 µg of every cytokine 
immobilized per scaffold (see Fig. 21) was used, while starPEG-heparin matrices        
In total, cytokine-functionalized starPEG-heparin matrices could be applied as a 
growth factor delivery matrix in order to induce HUVEC directional migration. 
While FGF-2 and VEGF supported cell motility to a similar extent, their 
combined action was found to exert the strongest effect on HUVEC migration. 
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(γ = 3) were generated as clot-like grafts. As the importance of effective cell attachment 
was demonstrated in in vitro cell experiments, all networks were modified with the RGD 
adhesion ligand. After subsequent loading with cytokines, the starPEG-heparin 
hydrogels (Fig. 21A and C) were placed onto the developing CAM at embryonic day 8 
(ED8) until ED12. The untreated CAM (Fig. 21B) served as a reference system. 
As visualized in Fig. 21B, the untreated CAM shows a normal pattern of 
vascularization. The vessels are arranged in an organized manner with regular 
branches of the larger primary blood vessels into secondary vessels and tertiary 
capillaries. This pattern was hardly altered in samples containing onplants without any 
growth factors. However, in the presence of hydrogels loaded with cytokines, the 
onplants were surrounded by an increased number of allantoic vessels that looped 
towards the gel. 
Quantification of any angiogenic response was performed by counting the vessels 
within the site of gel transplantation or the control area of the untreated CAM, 
respectively (Fig. 21C). Here, the starPEG-heparin onplants lacking any growth factor 
only led to a minimal increase in the relative vascularization compared to the untreated 
CAM (~ 4 %). This slightly improved vessel formation might result from the high heparin 
content of the matrices, as this molecule has been shown to induce a moderate 
angiogenic response in the CAM assay [Pacini et al., 2002]. In contrast, a significantly 
enhanced increase in vascularization could be observed in the presence of either 
single FGF-2 or VEGF or with a combination of both cytokines (~ 20 %, 35 % and 40 %, 
respectively; p < 0.05 for comparing gels without any growth factors to cytokine-modified scaffolds). 
Here, similar to the results of [Nico et al., 2001], the administration of single VEGF 
induced a stronger angiogenic effect than that of single FGF-2 (p < 0.05 for the comparison 
of gels modified with VEGF to FGF-2-functionalized scaffolds), while an increased vascularization 
compared to the provision of FGF-2 was also found when both cytokines were applied 
in combination (p < 0.05 for the comparison of hydrogels treated with FGF-2 + VEGF to FGF-2-
modified hydrogels). Although the differences were not statistically significant compared to 
the delivery of single VEGF (p > 0.05 for comparing these two conditions), the parallel 
administration of FGF-2 + VEGF showed the best results on blood vessel formation. 
Thus, it could be concluded that the positive effects observed for the FGF-2 + VEGF 
combination in vitro are similar to the in vivo situation [Chow et al., 2011].  
 
Results and discussion  71 
Fig. 21 Chicken embryo CAM vascularization in response to differently biomodified hydrogels (with or 
without 1 or 5 µg/ml of single FGF-2 or VEGF as well as a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF); 
adapted from [Zieris et al., 2011]. 21A and B: representative images of the CAM vascularization in relation 
to differently biomodified gel matrices (A) or photograph of the untreated CAM which served as a control 
(B) (scale bar 1 mm). 21C: quantification of the relative CAM vascularization in response to differently 
biomodified hydrogels. Data are presented as mean ± root mean square deviation from n = 5-16.                
* indicates statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the 
illustrated significant differences, see text. 
 
 
Parts of the text and the table of this chapter were adapted with kind permission from 
[Zieris et al., 2011]. Copyright 2011 Elsevier. 
 
A 
B C 
Taken together, the administration of FGF-2 and/or VEGF by starPEG-heparin 
hydrogels induced a substantial angiogenic response within the CAM system, 
while the combination of both cytokines tends to increase vascularization most 
effectively. 
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4.5 Modulation of FGF-2 or VEGF release from starPEG-heparin 
hydrogels 
Although the starPEG-heparin scaffolds with their intrinsic growth factor binding/release 
characteristics could be applied to promote pro-angiogenic effects both in vitro and in 
vivo, a more far-going modulation of the cytokine release profiles would be desirable to 
adapt to the requirements of approaches where complex and temporally adjustable 
release profiles are necessary [Uebersax et al., 2009; Lee et al., 2011].  
Therefore, the provision of multiple growth factors by starPEG-heparin hydrogels 
should be easily adaptable and controllable via external triggers. For this, possible 
strategies could be the implementation of cleavable peptide sequences to the hydrogel 
matrices, the use of selectively desulfated heparin as a network building block as well 
as the modulation of the heparin/growth factor interaction via the addition of competing 
highly heparin-affine molecules.  
In order to perform this study under physiological conditions which are relevant for in 
vitro and in vivo applications, all experiments were carried out with SF ECGM + 
1 mg/ml BSA as a release medium rather than in an artificial serum-free environment. 
Since it has been shown that the mechanical properties did not influence the binding 
and release of the growth factors, as a standardized system, gels with an intermediate 
starPEG to heparin ratio were prepared for this study and loaded with 1 µg/ml FGF-2 or 
VEGF. Subsequently, the cytokine binding and release were investigated in 
dependence on the different strategies that could be beneficial to modulate the delivery 
of these growth factors (i.e. modification of the standard hydrogel system with 
cleavable crosslinks or desulfated heparin as a building block as well as the addition of 
competing heparin-affine molecules). As a final goal, the set of available materials 
should be extended towards customized systems capable to provide cytokines “on 
demand”. 
 
 
4.5.1 Incorporation of cleavable peptide linkers 
The enzymatic degradability of a certain biomaterial represents a critical prerequisite 
for effectively mimicking the dynamic natural environment of cells which could be 
rearranged, as it is for instance necessary in the process of wound healing or tissue 
regeneration. However, the incorporation of protease-sensitive building blocks also 
extends the potential of starPEG-heparin hydrogels to function as a growth factor 
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delivery matrix, because the cytokine release might be tunable by the scaffold erosion. 
In this study, enzyme-dependent degradation of the gels was achieved by introduction 
of the MMP-responsive peptide crosslinking unit (GPQG↓↑IWGQ, in single-letter amino 
acid code), which is recognized and cleaved by several proteases, such as MMP1, 
MMP2, MMP3, MMP7, MMP8 and MMP9 [Nagase et al., 1996]. The peptide was 
conjugated to the arms of the starPEG building block by formation of a hydrolytically 
stable amide bond between the maleimide-functionalized starPEG and the thiol group 
of the cysteine within the MMP-cleavable peptide. The gel crosslinking reaction was 
performed analogously to the non-cleavable starPEG-heparin matrices involving the N-
terminus of the PEG-peptide-conjugate and the s-NHS/EDC activated carboxylic acid 
groups of the heparin. 
 
Gel degradation 
In non-cleavable starPEG-heparin hydrogels, the release of the growth factors is only 
based on diffusion. In order to interpret how the network erosion might contribute to the 
overall growth factor release in the case of enzymatically cleavable scaffolds, the 
degradation of the hydrogels was analyzed (Fig. 22). For this, the gels were either 
incubated in pure PBS or in PBS containing 1 U/ml of bacterial collagenase IV. This 
enzyme has been shown to function as a reliable model of MMP activity [Seliktar et al., 
2004]. While the MMP-cleavable gel demonstrated very low degradation in PBS (~ 15 % 
after 96 h), in the presence of the collagenase the main fraction of the network was 
Fig. 22 Decomposition kinetics of the MMP-cleavable hydrogels ± collagenase as monitored by UV-
spectroscopy of the released peptide; modified from [Chwalek et al., 2011]. 
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decomposed within 24 h of incubation (~ 85 %). After 96 h, the scaffold was cleaved 
completely. Based on these degradation kinetics, a significant contribution of the 
enzymatically-triggered hydrogel erosion to the overall growth factor release from 
MMP-cleavable starPEG-heparin networks can be expected. 
 
Cytokine binding 
As with the presence of the MMP-cleavable peptide sequence in the starPEG-heparin 
hydrogels the network composition is changed, it has to be evaluated whether there is 
an influence of this modification on the binding of FGF-2 or VEGF. By ELISA analysis 
(Fig. 23), it could be shown that there was no significant difference in the amount of 
immobilized FGF-2 or VEGF by non-cleavable or MMP-cleavable hydrogels 
(~ 195 ng/cm² scaffold area as determined via ELISA), which could be further validated via 
radiolabeling studies (Fig. B10, appendix B). This finding might be related to the fact 
that both types of scaffolds contain similar amounts of heparin. Moreover, the sulfate 
groups as main interaction sites for FGF-2 and VEGF are unaffected by the 
introduction of the peptide sequence into the network. Consequently, MMP-cleavable 
starPEG-heparin hydrogels could be functionalized with growth factors similarly to the 
standard non-degradable matrices. 
Fig. 23 FGF-2 or VEGF uptake experiments in dependence on the degradability of starPEG-heparin 
hydrogels as quantified via ELISA. Plotted is the amount of electrostatically bound FGF-2 and VEGF per 
cm² scaffold surface for non-cleavable or MMP-sensitive networks (p > 0.05 for the immobilized amount of 
growth factors in non-degradable or MMP-cleavable gels; ANOVA). All data are presented as mean ± root 
mean square deviation from n = 3. 
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Cytokine release 
Starting from similar amounts of cytokines immobilized to non-degradable or 
enzymatically cleavable starPEG-heparin hydrogels, the influence of the network 
degradability on the release of the growth factors was analyzed. While Fig. 24 (top) 
shows the kinetics of the absolute release of FGF-2 (left) or VEGF (right), in the bottom 
part the release efficiency expressed as percentage of initial loading (left) and the 
relative change in the absolute release of the growth factors by cleavable networks 
normalized to non-degradable scaffolds (right) are plotted. 
Similar growth factor release kinetics (Fig. 24, top; release efficiency depicted in Fig. 
24, bottom left) were observed for non-cleavable or enzymatically degradable scaffolds 
in the absence of collagenase. However, a slightly elevated but not significantly 
enhanced release (p > 0.05; ANOVA) found for the MMP-sensitive hydrogels might be 
attributed to the higher non-specific degradation of ~ 15 % in the absence of 
collagenase (see Fig. 22) of the MMP-sensitive scaffolds in PBS (non cleavable-scaffolds: 
20.5 ng/cm² or of 10.3 % for FGF-2 and 22.3 ng/cm² or 11.2 % for VEGF were released after 96 h; MMP-
degradable gels: 24.9 ng/cm² or 12.9 % for FGF-2 and 30.6 ng/cm² or 16.1 % for VEGF were released 
after 96 h).  
The addition of collagenase led to an stronger increase of both FGF-2 (37.1 ng/cm² or 
19.2 %) and VEGF (63.1 ng/cm² or 33.2 %) release from the enzymatically degradable 
starPEG-heparin hydrogels (p < 0.05 for FGF-2 or VEGF release from non-cleavable or 
enzymatically degradable gels under enzyme-free conditions to that of the MMP-cleavable gels upon 
addition of collagenase; ANOVA). As a reason, besides the diffusion-based release of the 
cytokines from the scaffolds, the cleavage of the protease-sensitive peptide crosslinks 
results in the decomposition of the network and, consequently, in an enhanced delivery 
of the growth factors into the medium.  
However, although a significantly higher amount of both FGF-2 and VEGF were 
released upon the addition of collagenase to MMP-cleavable scaffolds, not the entire 
fraction of initially loaded growth factors could be detected by ELISA as expected from 
the complete degradation of the hydrogels after 96 h. The finding is most probably 
related to limitations of the ELISA-technique interfering with high heparin levels. In 
additional experiments, it was shown, that for defined FGF-2- or VEGF-levels in 
medium containing similar concentration of heparin as found in the hydrogels, only 
~ 20-35 % of the original cytokine concentration could be quantified by ELISA analysis 
(data not shown). Consequently, the presence of such high amounts of the 
glycosaminoglycan could disturb the detection of the growth factors by potentially 
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masking their binding sites to the antibody that is used to immobilize FGF-2 or VEGF to 
the ELISA plates. Furthermore, heparin could also directly interfere with the antibody or 
simply sterically hinder its efficient interaction with the cytokines. Additionally, during 
earlier time points, a partial degradation of the networks might also lead to the 
appearance of some gel microclusters in the medium, in which the cytokines could be 
entrapped thereby making them inaccessible for detection via ELISA. While all these 
effects might disturb an efficient quantification of the cytokines, nevertheless FGF-2 
and VEGF released by a proteolytic cleavage of the hydrogels could be preferentially 
available for interaction with cells, as it has been shown that their diffusion is 
decelerated [Taipal et al., 1997], they are stabilized [Saksela et al., 1988; Lee et al., 
2005] and their receptor affinity is even potentiated when they are bound to heparin 
[Roghani et al., 1994; Gitay-Goren et al., 1992]. 
Interestingly, besides this possible methodological issue of a potentially restricted 
detection efficiency via ELISA, also a significantly lower release of FGF-2 from 
enzymatically degradable hydrogels was determined by comparison to VEGF delivery 
(p < 0.05; ANOVA). One explanation for this might be that the heparin binding affinity of 
FGF-2 (Kd = 23 nM) is higher than that of VEGF (Kd =165 nM) [Ashikari-Hada et al., 
2004], while its diameter is even smaller (~ 3 nm for FGF-2 and ~ 6 nm for VEGF) 
[Eriksson et al., 1991, Muller et al., 1997]. Consequently, a greater fraction of FGF-2 
might be strongly attached to the heparin in the release medium or the antibody binding 
sites of such a small cytokine could be shielded more effectively upon this interaction. 
Both effects could thereby disturb the detection via ELISA. However, another possible 
reason for the lower FGF-2 release might be that the protein could get cleaved by 
collagenase [Whitelock et al., 1996], while VEGF does not represent a substrate for 
this enzyme [Keyt et al., 1996]. Although the presence of heparin might protect FGF-2 
from proteolysis [Coltrini et al., 1993] thereby preventing a complete cleavage of this 
cytokine, the smaller release rates determined for FGF-2 could nevertheless result 
from the degradation of a certain protein fraction.  
Overall, there was a significant increase in the release of the growth factors from MMP-
cleavable hydrogels upon addition of the enzyme compared to non-degradable 
scaffolds (~ 80 % increase for FGF-2 or 180 % increase for VEGF; p < 0.05 for the comparison of FGF-2 
or VEGF release from non-cleavable or proteolytically degradable gels under enzyme-free conditions to 
that of the MMP-cleavable gels upon addition of collagenase; ANOVA, Fig. 24, bottom right). As 
expected, in the absence of collagenase differences in the cytokine release between 
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enzymatically cleavable and non-degradable gels were not significant (~ 22 % increase for 
FGF- or 38 % increase for VEGF; p > 0.05 for the comparison of FGF-2 or VEGF release from non-
cleavable or degradable gels to that of MMP-sensitive networks without addition of collagenase; ANOVA). 
Fig. 24 FGF-2 or VEGF release experiments in dependence on the degradability of starPEG-heparin 
networks as quantified via ELISA. top: cumulative amount of FGF-2 (left) or VEGF (right) released by non-
cleavable hydrogels or MMP-degradable scaffolds ± collagenase. bottom (left): cumulative percentage of 
initially bound FGF-2 or VEGF released by non-cleavable hydrogels or MMP-degradable scaffolds ± 
collagenase after 96 h (p < 0.05 for the comparison of FGF-2 or VEGF released by MMP-cleavable gels 
with addition of collagenase; ANOVA). bottom (right): relative change in FGF-2 or VEGF release form 
starPEG-heparin networks functionalized with MMP-cleavable peptide sequences with or without addition 
of collagenase in the medium. Plotted is the percentaged increase of the cumulative absolute amount of 
FGF-2 or VEGF released after 96 h normalized to non-cleavable hydrogels (p < 0.05 for the comparison of 
FGF-2 or VEGF released by MMP-cleavable gels with addition of collagenase; ANOVA). All data are 
presented as mean ± root mean square deviation from n = 3. * indicates statistically significant differences 
(p < 0.05; ANOVA). For statistical comparisons apart from the illustrated significant differences, see text. 
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4.5.2 Selective desulfation of heparin binding sites 
As the starPEG-heparin matrices contain large quantities of the cytokine-binding 
glycosaminoglycan and both FGF-2 and VEGF bind to heparin by electrostatic 
interactions of their basic lysine and arginine residues with the negatively charged 
sulfate groups of this molecule, one way to trigger their potential as a delivery matrix for 
growth factors is the removal of sulfate groups in order to decrease the heparin affinity 
of the cytokines. Although FGF-2 interacts with short sequences that are rich in N- and 
2-O-sulfate [Habuchi et al., 1992; Turnbull et al., 1992; Faham et al., 1996], the 
presence of heparin 6-O-sulfate groups is required for the activation of bound FGF-2 
[Pye et al., 1998]. In contrast, while carboxylic acid groups and 2-O-sulfation also 
contribute to the overall binding strength of VEGF, this protein particularly interacts with 
N- and 6-O-sulfate groups of heparin [Ono et al., 1999; Robinson et al., 2006]. 
Upon desulfation of heparin, not only the overall amount of hydrogel-released cytokine 
should be raised as it could be already achieved by the incorporation of enzymatically 
cleavable peptide sequences into the network. Instead, a selective removal of one or 
more groups involved in the FGF-2 or VEGF binding should also allow for a gradual 
modulation of the growth factor delivery. Therefore, in order to obtain heparins with a 
varying degree of sulfation, a N-, 2-O-, 6-O- + N- as well as a complete desulfation 
treatment was performed, while these modified molecules were used as a building 
block for the formation of starPEG-heparin hydrogels. 
 
Desulfation and gel formation 
Tab. 3 summarizes the sulfate composition of the differently treated heparins. A high 
conversion efficiency was achieved for the N-, 6-O- + N- as well as the complete 
desulfation as determined via FTIR and PCD analysis. In contrast, the yield of the 2-O-
desulfation was rather low. This might be attributed to problems occurring during the 
Conclusively, compared to the standard non-cleavable matrices, for MMP-sensitive 
starPEG-heparin hydrogels similar quantities of FGF-2 or VEGF could be 
bound to the network while the delivered amounts significantly increased as the 
scaffold degrades. Thus, an incorporation of cleavable peptide linkers does not 
only allow for the cellular remodeling of the gel matrix but also extends the potential 
of the matrices to function as an efficient growth factor delivery system. 
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lyophilisation process which led to a partial thawing and re-freezing of this particular 
sample thereby maybe affecting its integrity. As the 2-O-desulfated heparin 
represented the starting material for the preparation of completely desulfated heparin, 
although the exact conversion of each single group cannot be determined, it is very 
likely that most of the remaining sulfate can be found at the 2-O-position of the 
completely desulfated glycosaminoglycan. However, except for the 2-O-sulfate, an 
efficient desulfation could be obtained for all other groups of interest, which offers the 
possibility to use these heparins for the formation of hydrogels with varying degrees of 
sulfation.  
Tab. B1 (see appendix B) summarizes the mechanical properties of gels that were 
prepared out of these differently desulfated heparins. For almost all modifications, 
severe differences resulting in either increased or decreased network stiffness and 
swelling were determined for the gels composed of desulfated heparin when compared 
to those formed out of the standard heparin. Here, a different swelling behavior due to 
a decreased charge density could partially contribute to the observed changes in the 
storage moduli of these hydrogels, but, more likely, altered properties of the desulfated 
heparin could also effect the network formation itself. Referring to this, the desulfation 
of distinct sulfate groups in close proximity to the carboxylic acid moieties relevant for 
crosslinking could lead to an altered ionization (local pK-shift) thereby affecting the 
reactivity [Park et al., 1978]. Besides a direct influence on the ionization of the carboxyl 
groups, conformational changes of the desulfated heparin and therefore altered 
(spatial) accessibility of the carboxylic acid moieties could be a further reason for the 
changed overall reactivity. Depending on the particular sugar ring and the specific 
position relative to the carboxyl groups as well as on the nature of the remaining 
residue, a certain desulfation could therefore either enhance or weaken a reaction of 
the heparin carboxylic acid groups with the amino groups of starPEG thereby leading to 
a higher or to a less efficient crosslinking reaction.  
However, as it has been shown that the mechanical properties of the networks had no 
influence on the growth factor delivery and due to the fact, that the hydrogels contain a 
huge excess of heparin compared to the amount of immobilized cytokines, no effect of 
these differences in the crosslinking degree on either FGF-2 or VEGF binding or 
release are expected. Consequently, any change in the growth factor delivery capacity 
of modified starPEG-heparin hydrogels might be directly related to the modulation of 
the sulfation degree and, therefore, of the ‘primary binding sites’ of the two cytokines. 
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 Tab. 3 Comparison of the sulfate pattern depending on the heparin modification.  
        
heparin 
desulfation 
theoretical 
sulfate      
content [%] 
sulfate content 
determined via 
FTIR and PCD 
analysis [%] 
efficiency of 
conversion [%] 
none 100 100 - 
N- 67 73 81 
2-O- 67 86 41 
6-O- + N- 33 42 87 
complete 0 18 82 
    
 
 Cytokine binding and release 
Due to the lacking stabilization possibility among potentially restricted interaction of 
soluble cytokines with the desulfated starPEG-heparin hydrogels during the 
immobilization procedure, the indirect determination of the growth factor binding via 
detection of remaining protein in the solution via ELISA might be inappropriate for 
analysis of the FGF-2 or VEGF-binding. Consequently, here, the uptake of the 
cytokines was determined performing radiolabeling studies. Generally, due to the 
methodological issues with the lower cytokine binding efficiency detected by 
radiolabeling experiments (see appendix B, supplementary results and discussion for 
chapter 4.1), all immobilization data (Fig. 25) were only expressed as the relative 
percentage of the binding with respect to the standard non-desulfated scaffolds (set to 
100 %) which were analyzed under similar conditions. 
After it was evaluated whether a selective desulfation of heparin could decrease the 
affinity of FGF-2 or VEGF to starPEG-heparin hydrogels during immobilization studies, 
the influence of the variation in the sulfation degree on the release of the cytokines was 
determined by ELISA. Consequently, Fig. 26 (top) illustrates the kinetics of the 
absolute release of FGF-2 (left) or VEGF (right). For a comparison of the efficiency, in 
the bottom part the release from the scaffolds was plotted as percentage of initial 
loading (left), which was calculated based on the immobilization data shown in Fig. 25. 
Finally, the relative change in the absolute release of the growth factors by desulfated 
hydrogels normalized to non-desulfated matrices (right) are plotted.  
 
Concerning the effect of a selective desulfation of heparin on the binding of FGF-2 or 
VEGF to starPEG-heparin hydrogels (Fig. 25), no significant change could be 
demonstrated for the interaction of FGF-2 or VEGF with matrices formed out of           
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2-O-desulfated heparin (91.7 % binding for FGF-2 or 100 % binding for VEGF compared to non-
desulfated hydrogels; p > 0.05; ANOVA). Similarly to the uptake experiments, considering the 
absolute (Fig. 26, top) or relative (Fig. 26, bottom left) amounts of FGF-2 (20.5 ng/cm² or 
10.3 %) or VEGF (22.3 ng/cm² or 11.2 %) released by non-desulfated scaffolds after 96 h, 
for the 2-O-desulfated hydrogels, analogously no substantial increase in cytokine 
release could be determined (24.1 ng/cm² or 13.1 % for FGF-2 or 22.7 ng/cm² or 11.4 % for VEGF; 
p > 0.05 for comparing the protein release from non-desulfated networks to that from 2-O-desulfated 
scaffolds; ANOVA). Since the 2-O-sulfate plays a major role in mediating the interaction of 
heparin with FGF-2, this finding might be related to the low efficiency of the 2-O-
desulfation procedure (see Tab. 3). As the biohybrid hydrogels contain huge quantities 
of heparin, a sufficiently large fraction of 2-O-sulfate groups might be still present which 
allows for an efficient binding of the cytokines. 
In contrast, a significant reduction of the FGF-2 or VEGF immobilization to                   
N-desulfated heparin-containing matrices was observed (69.4 % binding for FGF-2 and 
86.1 % binding for VEGF compared to non-desulfated hydrogels; p < 0.05 for comparing the FGF-2 or 
VEGF binding to non-desulfated hydrogels to the binding to N-desulfated matrices; ANOVA). Similarly 
to the trends determined during the growth factor immobilization studies, a moderate 
increase in the FGF-2 (35.7 ng/cm² or 25.7 %) or VEGF (29.8 ng/cm² or 17.5 %) release was 
found for the N-desulfation of the hydrogels (p < 0.05 for comparing the cytokine release from N-
desulfated heparin-containing matrices to that observed for any other type of scaffold; ANOVA). 
The strongest reduction of the FGF-2 or VEGF immobilization could be demonstrated 
for 6-O- + N- (35.9 % binding for FGF-2 and 62.5 % binding for VEGF compared to non-desulfated 
hydrogels) as well as for the completely (33.8 % binding for FGF-2 and 68.6 % binding for VEGF 
compared to non-desulfated hydrogels) desulfated heparin-containing hydrogels (p < 0.05 for 
comparing the FGF-2 or VEGF binding to non-desulfated hydrogels to the binding to 6-O- + N- or 
completely desulfated heparin-containing scaffolds; ANOVA). Consequently, with the usage of    
6-O- + N- (60.7 ng/cm² or 84.4 % for FGF-2 or 40.9 ng/cm² or 33 % for VEGF) or completely 
desulfated scaffolds (50.8 ng/cm² or 75.3 % for FGF-2 or 42.2 ng/cm² or 31 % for VEGF), also the 
quantities of delivered protein could be even further elevated (p < 0.05 for the comparison of 
the growth factor release from 6-O- + N- or completely desulfated matrices to that observed for any other 
type of hydrogels; ANOVA).  
As this finding was expected for VEGF, which mainly binds to 6-O- and N-sulfate 
groups of heparin, the further reduction of the FGF-2 affinity to 6-O- + N-desulfated 
matrices compared to only N-desulfated hydrogels is particularly interesting as the 
heparin 6-O-sulfate is not described to represent a key interaction site for FGF-2 
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[Habuchi et al., 1992; Turnbull et al., 1992; Faham et al., 1996]. However, [Ishai-
Michaeli et al., 1992] found that an over-sulfation of heparin groups originally not acting 
as major FGF-2 binding sites led to a substantial compensation of the lacking main 
interaction group and therefore to a significant restoration of the protein binding 
capacity of this particular heparin. In line with this effect, especially in the heparin-rich 
biohybrid hydrogels other groups than the primary important 2-O sulfate residues could 
enhance the intrinsic FGF-2 binding capacity. Therefore, the heparin interaction with 
the cytokines might rather correlate with the overall sulfate content of the scaffolds than 
with the presence of particular binding sites.  
Besides this finding, with regard to Fig. 25 and 26, it is also obvious that no significant 
differences in the reduction of the FGF-2 or VEGF affinity to 6-O- + N- desulfated 
compared to the completely desulfated scaffolds were observed (p > 0.05 for comparing the 
FGF-2 or VEGF binding/release to/from 6-O- + N-desulfated networks with that to/from completely 
desulfated hydrogels; ANOVA). This might be due to the fact, that because of the low 
conversion efficiency observed for the 2-O-desulfation, for the completely desulfated 
heparin probably most of the remaining sulfate can be found at the 2-O-position of the 
glycosaminoglycan. Consequently, the variation in the overall sulfation pattern of        
6-O- + N- desulfated heparin-containing matrices compared to completely desulfated 
hydrogels might be small, which could explain the similar data obtained for these two 
gel types. Moreover, the remaining sulfate content of ~ 20 % for scaffolds, which were 
composed of the heparin that had undergone each of the desulfation procedures for 
the N-, 2-O- and 6-O-sulfate groups, might be the reason for the fact that still a certain 
fraction of FGF-2 and VEGF could interact with matrices composed out of such 
heparin. 
Generally, despite the same tendencies were observed for FGF-2 or VEGF binding and 
release to the starPEG-heparin hydrogels with different degrees of sulfation, for FGF-2, 
a significantly stronger reduction in the immobilization and a substantially higher 
increase in the release was determined for N-, 6-O- + N- or completely desulfated 
scaffolds when compared to the interaction of VEGF with these gel types (p < 0.05 for 
comparing the FGF-2 binding/release to/from N-, 6-O- + N- or to/from completely desulfated hydrogels to 
that of VEGF; ANOVA). The reason for this effect might be that, beside the main interaction 
sites at the N- and 6-O-position, the 2-O-sulfation and even the carboxylic acid groups 
of heparin contribute to the overall binding strength of VEGF [Robinson et al., 2006], so 
that more functional groups of heparin mediate its affinity to VEGF than in the case of 
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FGF-2. Consequently, there might be a stronger compensatory effect for the removal of 
key binding sites of VEGF. Moreover, the larger diameter of this protein (~ 6 nm) 
[Muller et al., 1997] compared to that of FGF-2 (~ 3 nm) [Eriksson et al., 1991] could 
result in a more efficient sterical entrapment within the hydrogel networks thereby 
supporting an immobilization even in the case of a reduced specific heparin affinity. 
After discussing the effect of a selective heparin desulfation on the FGF-2 or VEGF 
binding and release separately for each desulfated group, for the general release 
kinetics (Fig. 26., top), it could be determined that, upon desulfation of heparin, no 
substantial change in the general appearance of the FGF-2 and VEGF release profile 
was observed. Here, also for the desulfated hydrogels more loosely entrapped protein 
showing no specific heparin interaction got released during an initial burst. Due to the 
removal of the growth factor binding sites, this effect is a bit more pronounced in the 
case of the desulfated matrices as indicated by the initial steep incline of the 
corresponding curves. After the burst release, a slow delivery of the growth factor 
fraction that showed a rather strong interaction with the remaining binding sites of 
heparin within the matrices was determined over the course of 96 h.  
 
Considering these data, the selective desulfation of heparin turned out to be an 
appropriate tool to modulate the cytokine binding and release from starPEG-heparin 
hydrogels. Except for the 2-O-desulfated heparin suffering from low turnover rates 
(~17 % increase for FGF-2 or 2 % for VEGF p > 0.05 for the comparison of FGF-2 or VEGF release from 
non-desulfated or from 2-O-desulfated hydrogels; ANOVA), significantly higher absolute growth 
factor quantities (Fig. 26, bottom right) could be gradually delivered by selectively 
desulfated heparin-containing scaffolds (N-desulfation: ~ 74 % increase for FGF-2 or 34 % 
increase for VEGF; 6-O- + N-desulfation: ~ 196 % increase for FGF-2 or 84 % for VEGF; complete 
desulfation: ~148 % for FGF-2 or 90 % increase for VEGF; p < 0.05 for the comparison of FGF-2 or VEGF 
release from non-desulfated or from N-, 6-O + N- or completely desulfated hydrogels; ANOVA). This 
effect still holds true, if the overall lower amount of FGF-2 or VEGF that could be 
immobilized to desulfated starPEG-heparin hydrogels is considered.  
As a reason, upon removal of the ‘specific’ growth factor interaction sites on heparin, 
the equilibrium might be shifted rather from the protein binding towards the release. 
This weakens the ability of the cytokines to re-bind to heparin so that they might be 
preferentially available in the surrounding environment, as it is required for many in 
vitro and in vivo cell applications. Another main advantage of using desulfated heparin 
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to form customized starPEG heparin matrices is that cell-secreted soluble effectors 
would remain accessible in the medium rather than that they might get entrapped by 
the gels upon interaction with heparin. Moreover, as the growth factor release could be 
gradually modulated by changing the overall sulfate content of the networks, a specific 
desulfation degree can be chosen in dependence on the particular requirements of a 
certain application. Consequently, as a large fraction of the immobilized cytokine was 
released within 96 h, the use of highly desulfated starPEG-heparin hydrogels could be 
interesting for any application, where a boosted release of growth factors is beneficial 
towards the therapeutical approach. In contrast, in need of long-term protein delivery 
profiles, non- or low desulfated heparin-containing scaffolds should be deployed. These 
matrices efficiently store and protect growth factors via heparin-effector interactions, so 
that loading-related quantities of FGF-2 or VEGF could be released constantly over the 
course of several weeks (tested for up to four weeks, data not shown). 
 
 
 
 
 
Fig. 25 Relative FGF-2 or VEGF binding experiments in dependence on the desulfation of starPEG-
heparin hydrogels as quantified via radiolabeling studies. Plotted is the percentage of electrostatically 
bound FGF-2 or VEGF with respect to the immobilization to scaffolds prepared out of non-desulfated 
heparin which was set to 100 % (p < 0.05 for the comparison of FGF-2 or VEGF released by N-, 6-O- + N- 
or completely desulfated networks; ANOVA). All data are presented as mean ± root mean square deviation 
from n = 3. * indicates statistically significant differences (p < 0.05; ANOVA). For statistical comparisons 
apart from the illustrated significant differences, see text. 
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Fig. 26 FGF-2 or VEGF release experiments in dependence on the desulfation of starPEG-heparin 
networks as quantified via ELISA. top: cumulative amount of FGF-2 (left) or VEGF (right) released by 
hydrogels prepared out of non-desulfated or selectively desulfated heparin. bottom (left): cumulative 
percentage of initially bound FGF-2 or VEGF released hydrogels composed out of non-desulfated or 
selectively desulfated heparin after 96 h (p < 0.05 for the comparison of FGF-2 or VEGF released by N-, 6-
O- + N or completely desulfated networks; ANOVA). bottom (right): relative change in FGF-2 or VEGF 
release form starPEG-heparin networks prepared out of selectively desulfated heparin. Plotted is the 
percentaged increase of the cumulative absolute amount of FGF-2 or VEGF released after 96 h 
normalized to hydrogels composed of non-desulfated heparin (p < 0.05 for the comparison of FGF-2 or 
VEGF released by N-, 2-O-, 6-O- + N- or completely desulfated networks; ANOVA). All data are presented 
as mean ± root mean square deviation from n = 3. * indicates statistically significant differences (p < 0.05; 
ANOVA). For statistical comparisons apart from the illustrated significant differences, see text. 
In summary, the interaction of FGF-2 or VEGF with starPEG-heparin hydrogels 
could be significantly weakened upon desulfation of heparin. Although this 
resulted in a reduction of the protein binding to the scaffolds, nevertheless higher 
absolute amounts of both cytokines could be released. As this effect is 
gradually depended on the overall sulfate content of the modified hydrogels, the 
growth factor delivery system can be adapted to applications that require 
materials with different sets of protein release characteristics. 
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4.5.3 Application of competing highly heparin-affine polyelectrolytes 
Upon variation of the network degradability or the heparin sulfation, it was shown that 
the overall amount of starPEG-heparin hydrogel-delivered FGF-2 and VEGF could be 
gradually increased in a defined manner. However, for different therapeutic approaches 
in tissue engineering, not only the quantities of growth factors provided by a certain 
biomaterial should be adjustable but also the cytokine release profiles have to be 
adaptable to the particular requirements [Uebersax et al., 2009; Lee et al., 2011]. As an 
optimum, a growth factor delivery system should be selectively tuneable, so that the 
soluble effectors could be provided at different, well-defined time points. Therefore, it 
was evaluated whether the release kinetics of starPEG-heparin-associated FGF-2 and 
VEGF could be modulated. In these studies, the temporarily defined addition of highly 
heparin-affine molecules should allow to competitively displace the growth factors from 
their binding sites, thereby resulting in a “triggered” cytokine release from the matrices. 
Conceptually, such modulator molecules can be directly used upon addition to any in 
vitro setting or upon injection close to the implanted starPEG-heparin scaffold in 
particular in vivo applications. As a more advanced approach, entrapment within carrier 
nanoparticles with defined decomposition kinetics could allow for a direct integration 
into the hydrogel matrix thereby permitting a combined administration. However, before 
the mode of application for such modulator molecules could be optimized, this work 
should deliver more general conceptual insights into the possibility to specifically trigger 
the FGF-2 and VEGF release from starPEG-heparin matrices. 
 
Chitosan as heparin-affine molecule 
For realizing the approach of a competitive growth factor displacement after interaction 
with heparin, the polysaccharide chitosan was chosen as the modulator molecule. 
Chitosan represents a copolymer of glucosamine and N-acetylglucosamine. It is 
usually derived upon partial deacetylation of chitin from crustacean shells and may 
differ in its degree of deacetylation (40-98 %), its viscosity (1 % chitosan in 1 % acetic 
acid < 2000 mPas) and its molecular weight (up to 2000 kDa) [Illum, 1998]. In order to 
modulate the growth factor release from starPEG-heparin hydrogels, this molecule 
fulfils several important requirements. As biocompatibility is an indispensable 
prerequisite for a latter in vitro or in vivo application, its very safe toxicity profile already 
resulting in an extensive usage of chitosan as an excipient in the pharmaceutical 
industry [Illum, 1998] constitutes a great advantage. Moreover, at neutral and acidic 
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conditions, the amine groups of the deacetylated polysaccharide are protonated. 
Accordingly, the polymer is positively charged in solution, which represents the basis 
for a sufficient affinity to the negatively charged heparin. As another requirement, 
although the molecular weight of the modulator should not restrict its network 
penetration, the dimensions of the molecule should be at least comparable to those of 
the immobilized cytokines to allow for an effective spatial displacement of these 
proteins. While chitosan is commercially available within a large range of molecular 
weights (from enzymatically derived oligomers with ~ 2 kDa up to naturally occurring 
polymers with ~ 2000 kDa), for this study a polysaccharide of an intermediate size 
(~ 10-50 kDa) was chosen. Together with a moderate degree of deacetylation (70 %) 
resulting in a more compact, coiled conformation [Illum, 1998], this molecular weight 
goes along with a rather low viscosity ( ~ 7 mPas) which ensured a good solubility of 
this chitosan up to a pH of ~ 6.7 being close to the physiological pH. Consequently, this 
molecule represents an appropriate candidate to modulate the growth factor release 
from starPEG-heparin hydrogels.  
As the matrices were loaded with FGF-2 or VEGF according to the standard procedure, 
they displayed the well known immobilization efficiencies for both cytokines (see 
chapter 4.2). For a modulation of the release, the chitosan was added later upon a 
medium exchange at different time points. For all these studies, a molar ratio of 
0.19 mol/mol of applied chitosan to the heparin content in the gel was used. 
Considering the larger dimensions of this polysaccharide compared to heparin, this 
corresponds to an effective molecular weight ratio of 0.53 kDa/kDa. These chitosan 
quantities were chosen, because in pre-experiments, upon continuous concentration 
increase in the release medium, they represented the lowest amount of the 
polysaccharide introduced which could induce a significant enhancement of the FGF-2 
or VEGF release from starPEG-heparin hydrogels (data not shown).  
Upon an application of chitosan, the release kinetics should be modulated in a way that 
either a more constant delivery profile – via elongation of the initial burst release by 
chitosan addition right after this period (3 h, modulation type A) – or a belated, boosted 
release – via chitosan addition at a later time point (24 h, modulation type B) – could be 
obtained. Additionally, these two temporally different ways of modulating the kinetics of 
the FGF-2 and VEGF delivery by starPEG-heparin hydrogels should be compared with 
a continuous application of the polysaccharide over the whole course of the release 
experiment (addition already after 0 h, modulation type C). 
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Cytokine release 
As upon a temporally-defined chitosan addition especially the growth factor release 
profiles should be modulated, for a clear illustration, in this study, the non-cumulative 
FGF-2 or VEGF release efficiencies are plotted in Fig. 27 (middle) separately for each 
particular time point. For reasons of transparency, the absolute quantities of FGF-2 or 
VEGF released under standard conditions in the absence of chitosan are plotted in a 
separate graph (top). For the standard cumulative illustration of the cytokine delivery, 
the reader is referred to (Fig. B11, appendix B). Moreover, any relative change in the 
overall protein amount that is delivered by the scaffolds upon chitosan addition 
compared to the application of standard release medium is illustrated in Fig. 27 
(bottom).  
Due to the different way of data presentation, the FGF-2 and VEGF release kinetics will 
be discussed additionally for the standard release medium without any application of 
chitosan (Fig. 27, top). Here, the curves for both proteins show a steep incline for the 
first 3 h clearly attributed to the burst release of the loosely entrapped factors. The 
slightly higher dimensions of this peak for FGF-2 might result from its smaller diameter 
thereby initially leading to a more rapid diffusion out of the network (for details see 
appendix B, supplementary results and discussion for chapter 4.1). This initial period is 
followed by the release of the cytokine portion which interacts with heparin. Thus, a 
tremendously decreased release of both growth factors was observed as represented 
by the distinct decline of the curves within the overall time frame of 6 h. The still higher 
VEGF release, as indicated by the more moderate slope of the curve compared to the 
FGF-2 relase profile, might be caused by the lower heparin affinity of this cytokine 
(Kd =165 nM) compared to that of FGF-2 (Kd = 23 nM) [Ashikari-Hada et al., 2004].  
After the initial burst release, the amounts of FGF-2 or VEGF delivered by starPEG-
heparin hydrogels remain rather constant for the residual time course of the 
experiment. However, as indicated by the small decline of the FGF-2 release curve, 
slightly higher quantities of VEGF were released after 96 h in contrast to FGF-2 most 
probably attributed to the already mentioned differences in heparin affinity. Considering 
the overall experimental time course of 96 h, the total amounts of both proteins are 
equalized again (see Fig. B11, appendix B).  
Modulation type B: For an application of chitosan-containing medium (Fig. 27, middle) 
after 24 h, a strong incline of the release curves was observed for FGF-2 (left) and 
VEGF (right). This increase could be attributed to a certain protein fraction being 
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actively displaced by competing chitosan molecules. Interestingly, compared to FGF-2, 
the VEGF release in response to the application of this heparin-affine polyelectrolyte 
was enhanced more effectively as indicated by the steeper rise of the graph. Most 
probably, due to its lower heparin affinity (see discussion above), VEGF could be 
displaced more easily by an interaction of heparin with chitosan than FGF-2. 
Consequently, under this condition, overall also higher cumulative amounts (Fig. 27, 
bottom) of VEGF were delivered when compared to FGF-2 (chitosan application after 24 h: 
42.3 % increase for FGF-2 or 116.6 % increase for VEGF; p < 0.05; ANOVA). 
Modulation type A: Addition of chitosan-containing medium after 3 h resulted in a 
continuous increase for both FGF-2 and VEGF release (as indicated by the steady rise 
of the graphs up to 24 h), therefore preventing the transition from the burst to the 
slower release as observed in the absence of chitosan. Again, the slightly steeper 
increase –and therefore stronger release– was found for VEGF, encouraging once 
again the discussion about the differences in heparin affinity as a reason for this 
behavior. 
Nevertheless, results show that with an addition of chitosan-containing medium, both 
growth factors could be delivered in a more continuous manner within the time frame of 
24 h. In the following, although still substantial amounts of both FGF-2 and VEGF were 
delivered by the hydrogels, the cytokine release slightly drops. A reason for this effect 
could be that upon addition of chitosan a fraction of protein bound in close proximity to 
the starPEG-heparin hydrogel surface was released nearly completely. After this 
portion is gone, the protein molecules that are bound in layers distant from the surface 
of the matrices have to be liberated and to diffuse through the network to the surface. 
Due to the high heparin content of the scaffolds, this diffusion process is most probably 
superimposed by a dynamic re-binding and release of the cytokines to adjacent 
heparin molecules within the scaffold. Consequently, the delivery of this fraction might 
be slower and could therefore explain the decrease in the FGF-2 and VEGF release 
curves. Cumulatively, with a provision of more chitosan at further time points, the 
release of both proteins could be additionally enhanced (chitosan application after 3 h: 
202.4 % increase for FGF-2 or 164.3 % increase for VEGF). As an explanation, with the 
introduction of higher total quantities of the heparin-affine polyelectrolyte to the system, 
more cytokine molecules could be displaced from their heparin binding sites in the gel 
network. 
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Modulation type C: Upon a continuous application of chitosan over the whole course 
of the experiment starting at 0 h, the shape of the FGF-2 and VEGF release graphs 
resemble that ones determined in the complete absence of the polyelectrolyte. In 
detail, an initial burst effect, a smaller continuous release up to 24 h and a following 
decrease in the cytokine quantities being delivered by starPEG-heparin hydrogels, 
were observed. Nevertheless, cumulatively, highly elevated FGF-2 or VEGF quantities 
could be delivered (continuous chitosan application: 334.4 % increase for FGF-2 or 168.4 % increase 
for VEGF; p < 0.05; ANOVA).  
Although VEGF could be displaced from its heparin binding sites more easily (see 
discussion above), the maximum improvement of the growth factor delivery by 
starPEG-heparin hydrogels was observed for FGF-2 rather than for VEGF. The reason 
for this finding could be that chitosan was found to effectively protect FGF-2 from 
inactivation or degradation via heat, proteolysis or acid [Masuoka et al., 2005; results of 
own stability tests, data not shown] via complex formation between negatively charged 
sites of the protein and positively charged amino groups of the chitosan. As such effect 
was not determined for VEGF, upon a continuous presence of the polyelectrolyte in the 
medium, an increased FGF-2 stability could superimpose the stronger ability of 
chitosan to displace VEGF. 
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Fig. 27 FGF-2 or VEGF release experiments in dependence on the presence of chitosan in the release 
medium at different time points as quantified via ELISA. Plots show the non-cumulative percentage of 
electrostatically bound protein released under standard conditions (top) or FGF-2 (middle, left) or VEGF 
(middle, right) delivered upon the application of chitosan to the medium at different time points. The red 
symbol indicates the first addition of chitosan (rhomb: application after 0 h; square: application after 3 h; 
pentagon: application after 24 h). At the bottom, the relative change in FGF-2 or VEGF release form 
starPEG-heparin networks in dependence on the addition of chitosan in the medium at different time points 
is depicted. Plotted is the percentaged increase of the cumulative absolute amount of FGF-2 or VEGF 
released after 96 h normalized to the standard release medium without any chitosan (p < 0.05 for the 
comparison of FGF-2 or VEGF released upon the continuous application of chitosan or an addition after 24 
h; ANOVA). All data are presented as mean ± root mean square deviation from n = 3. * indicates 
statistically significant differences (p < 0.05; ANOVA).  
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In conclusion, with this study it was shown that the release kinetics of FGF-2 or 
VEGF from starPEG-heparin hydrogels could be modulated in direct response to 
addition of chitosan-containing medium at different time points, while in parallel 
also the overall delivery effectiveness for both cytokines could be increased.  
In detail, upon an early chitosan addition (e.g. after 3 h), prolonged constant 
release rates of both growth factors were achieved which could be beneficial 
towards applications where high initial doses are required.  
In contrast, a chitosan application at later time points (e.g. after 24 h) created a 
peak-like upregulation of the cytokine release. Therefore, besides the fact that 
the overall cumulative growth factor delivery was increased, the commonly occurring 
flattening of the FGF-2 or VEGF release profiles determined in the absence of 
chitosan (see plateau range in Fig. 27, top) could be prevented. Thus, a later 
chitosan application allows for the gentle upregulation of the cytokine delivery over 
extended time periods and for temporally higher release upon request.  
Finally, exploiting the FGF-2 or VEGF release upon continuous chitosan addition 
could be advantageous for applications where at a given growth factor 
functionalization of the hydrogel matrices the delivery of both proteins should be 
maximised while in parallel release profiles similar to the standard curves would be 
beneficial.  
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5 Summary and future perspectives 
5.1 The potential of starPEG-heparin hydrogels as a growth factor 
delivery matrix 
Provision of soluble pro-angiogenic effectors is one of the key requirements for 
biomaterials in tissue engineering. Therefore, the aim of this work was to investigate 
the potential of starPEG-heparin hydrogels to deliver the angiogenic growth factors 
FGF-2 and/or VEGF, while heparin was utilized for a reversible, electrostatically 
controlled conjugation of both proteins.  
 
By using optimized detection methods, the binding and release of the growth factors 
was analyzed depending on the physico-chemical network characteristics of gels with 
different crosslinking densities, the applied cytokine concentration and on the presence 
of cytokine mixtures to be delivered by the material. Fig. 28 summarizes the results of 
these studies.  
The variation of the network properties (Fig. 28, left) did not influence the efficiency of 
FGF-2 or VEGF delivery. As a reason, by changing the starPEG to heparin ratio, the 
hydrogels can be modified in their mechanical characteristics while the heparin 
concentration of scaffolds differing in their density of crosslinks remains constant. Since 
heparin is the base for any subsequent biomodification, this key property of the hybrid 
material also allows for similar functionalization with various effectors. This fact and the 
significant dimensional difference between FGF-2 or VEGF and the pore size of the 
hydrogel network explains that both proteins could be equally bound and released by 
hydrogels with different crosslinking density.  
Besides this finding, the applied concentration of FGF-2 or VEGF did not affect the 
growth factor delivery by starPEG-heparin matrices (Fig. 28, middle). Due to the fact 
that the hydrogels are characterized by a high heparin content and, furthermore, one 
heparin molecule has the ability to interact with several cytokine molecules, there is an 
excess of available binding sites within the network capable of immobilizing huge 
amounts of growth factor. Consequently, different concentrations of FGF-2 or VEGF 
can be bound and released with the same efficiency, so that the delivered cytokine 
quantities can be adapted upon a variation of the initial protein amounts applied during 
the immobilization procedure.  
As another advantage, an introduction of FGF-2 and VEGF in parallel showed also no 
influence on the binding or release efficiency of either protein (Fig. 28, right). Here, 
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once again both the large excess of heparin as well as the sufficiently large mesh size 
of the network appears to prevent any interference between the cytokines during their 
combined delivery by the hydrogels. Thus, with an alteration of the growth factor ratio 
or concentration used for immobilization, FGF-2 and VEGF can be released in any 
constellation of quantities.  
Taken together, the usage of starPEG-heparin hydrogels as a delivery matrix for the 
angiogenic cytokines FGF-2 and VEGF allows for the parallel provision of both 
effectors in any desired concentration independent of the physical network properties. 
These results open up new prospects for their application in the context of angiogenic 
tissue engineering, as demonstrated by cell culture experiments using the matrices as 
a growth factor delivery system. 
Fig. 28 Key characteristics of starPEG-heparin hydrogels allowing for effective growth factor delivery. 
 
However, despite of all these advantages, there are also restrictions of the starPEG-
heparin hydrogel system in its function as a cytokine delivery matrix. First, the high 
content of heparin permits a very effective immobilization of huge growth factor 
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quantities, but at the same time it represents also the reason for the limited overall 
release efficiency which is presumably mainly influenced by a dynamic protein 
release/re-binding from/to heparin. Besides that, the release of the cytokines is only 
based on diffusion, so that it always follows the same pre-determined kinetics. 
Consequently, new strategies were developed and applied to control both the overall 
amounts of soluble growth factors available upon release into the medium as well as 
the kinetics of the protein delivery by starPEG-heparin hydrogels. For this, either the 
network design was changed to modulate the heparin-protein interactions 
(incorporation of cleavable peptide sequences or of selectively desulfated heparin) or 
the release of heparin-conjugated growth factor molecules was stimulated via 
competitive interactions of highly heparin-affine molecules. For each concept, Fig. 29 
depicts the main impact on the cytokine release and illustrates exemplarily the potential 
effect on a specific cell behavior. 
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Fig. 29 Modulation of cytokine delivery from starPEG-heparin hydrogel system and its effects on the 
growth factor release and the cell behavior. 
Summary and future perspectives  97 
Upon an introduction of cleavable peptide linkers to the starPEG-heparin networks (Fig. 
29, left), due to the fact that the heparin composition of the hydrogels was not affected, 
no change in the FGF-2 or VEGF binding efficiency was observed. However, with an 
addition of protease, the scaffolds were degraded going along with an increased 
cytokine release as the network gets fragmented and heparin is released. The 
advantage of this cleavable hydrogel system is that high quantities of growth factors 
can be delivered in direct response to the cellular remodeling of the matrix. While the 
cytokines might be still attached to the released heparin, this could represent an 
additional benefit, as growth factors that are bound to this glycosaminoglycan          
were found to have an increased bioactivity [Roghani et al., 1994; Gitay-Goren et al., 
1992]. 
Minimizing the available cytokine binding sites within starPEG-heparin hydrogels 
utilizing selectively desulfated heparin for gel formation (Fig. 29, middle), the 
immobilization efficiency of the growth factors was reduced gradually. Here, due to the 
high heparin content of the scaffolds, potentially non-specific FGF-2 or VEGF binding 
regions could exert compensatory effects on the removal of the actual interaction sites. 
Consequently, the reduced cytokine immobilization efficiency rather correlated with the 
remaining overall sulfate content of the hydrogels. Interestingly, although lower 
amounts of FGF-2 or VEGF were immobilized when the scaffolds were composed out 
of desulfated heparin, nevertheless even the absolute quantities of growth factors 
being released could be gradually enhanced correlating with a decreasing degree of 
heparin sulfation. Consequently, the quantities of cytokines available for a delivery after 
immobilization to the desulfated hydrogels can be adapted to the particular 
requirements of a certain application and a more efficient cytokine administration can 
be achieved. Moreover, a further advantage of this system is that both the growth 
factors being released as well as medium/body fluid components and cell-secreted 
soluble effectors might be preferentially accessible for an interaction with cells in their 
direct surrounding, because they have a reduced opportunity to (re-)bind to the heparin 
sulfate groups.  
Another possibility to decrease the FGF-2 or VEGF affinity to starPEG-heparin 
hydrogels is to apply competitive, highly-heparin affine molecules as the polyelectrolyte 
chitosan (Fig. 29, right). Upon addition with the release medium, this polysaccharide 
was shown to displace the growth factors from their heparin binding sites thereby 
resulting in an increased protein delivery. As chitosan could be introduced at different 
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time points, also the growth factor release kinetics were found to be tunable, so that 
distinct delivery profiles could be adapted to a certain application. Therefore, in 
response to the temporally defined addition of chitosan, the boost in the cytokine 
delivery might be beneficial to trigger a certain cell behavior just at a desired time point.  
 
Taken together, due to the opportunity to adapt the growth factor binding and release 
by starPEG-heparin hydrogels to almost any specific requirement being crucial for a 
certain application, this material represents a unique cytokine delivery system. In 
particular, the capability to adjust complex, time-resolved multi-factor release profiles 
from matrices with precisely and independently adaptable physical and biomolecular 
composition is not only expected to support therapeutic angiogenesis but similarly to 
promote a wide variety of advanced tissue engineering concepts. 
 
 
5.2 The potential of biofunctionalized starPEG-heparin hydrogels 
to support pro-angiogenic effects in vitro and in vivo 
Although starPEG-heparin hydrogels were found to represent effective and tunable 
growth factor delivery systems, it still had to be demonstrated whether they could be 
applied in the context of angiogenic tissue engineering. Therefore, scaffolds that 
differed in their physicochemical characteristics and their degree of biofunctionalization 
were used to study the behavior of endothelial cells in vitro. Based on these 
experiments, the matrices that were most effective in inducing pro-angiogenic cell 
responses were selected for further investigation in in vivo experiments by introducing 
them to the CAM of fertilized chicken eggs.  
 
For the pre-selective in vitro cell culture experiments, the endothelial cell behavior was 
compared in terms of adhesion, survival/proliferation, differentiation and migration 
depending on the characteristics of differently biomodified starPEG-heparin hydrogel 
networks. As the starPEG-heparin hydrogel system allows for the decoupling of its 
mechanical properties from the biomolecular functionalization, the influences of the 
viscoelastic characteristics and the complexity of the biomodification on the endothelial 
cell response were investigated independently. For this, different types of soft, 
intermediate and stiff gel matrices were either used without any modification or were 
functionalized with the RGD adhesion ligand. Moreover, different FGF-2 or VEGF 
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quantities as well as a combination out of both cytokines were provided via the 
hydrogels. 
In terms of endothelial cell adhesion, starPEG-heparin hydrogels with a higher stiffness 
are more beneficial for effective cell attachment. While the presence of VEGF positively 
affects cell adhesion, the introduction of the adhesion ligand RGD is the most critical 
material parameter for supporting successful cell attachment. 
Based on the indispensable requirement of the RGD peptide for effective initial cell 
adhesion, the functionalization of starPEG-heparin hydrogels with this ligand 
represents also an inevitable prerequisite for mediating endothelial cell growth and 
differentiation. Besides that, matrices offering an intermediate network stiffness with a 
storage modulus of ~ 7000 Pa provide the optimal mechanical characteristics to 
balance cellular demands for both survival/proliferation and adaptation of the pre-
tubular, elongated morphology. In addition, combining the impact of FGF-2 on cell 
growth and the influence of VEGF on cell differentiation, the parallel delivery of both 
growth factors results in increased numbers of endothelial cells adapting a highly 
elongated shape. 
The evaluation of endothelial cell migration in response to gel type- and RGD-
independent cytokine release from starPEG-heparin hydrogels revealed that FGF-2 
and VEGF similarly promote cell motility, but both growth factors act synergistically to 
further enhance migratory behavior.  
Over all the parameters monitored, gels with an intermediate stiffness functionalized 
with the adhesion ligand RGD and a combination of the growth factors FGF-2 and 
VEGF were found to induce the most effective pro-angiogenic endothelial cell behavior 
and therefore represented promising candidates for studying the effect on 
vascularization in vivo. Here, in the CAM system of fertilized chicken eggs the provision 
of single FGF-2 or VEGF by intermediately stiff, RGD-decorated starPEG-heparin 
hydrogels induced a substantial angiogenic response. Also, a tendency towards further 
enhanced blood vessel formation was observed in these experiments upon the 
administration of the cytokine combination. Conclusively, these results demonstrate the 
suitability of biofunctionalized starPEG-heparin hydrogels as growth factor delivery 
systems for the support of angiogenesis in vivo.  
 
In summary, starPEG-heparin hydrogels providing controlled release of pro-angiogenic 
cytokines can be successfully applied in angiogenic tissue engineering. For that, the 
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possibility to decouple their mechanical properties from the biofunctionalization is 
advantageous to precisely adjust various different material parameters, with the option 
to deliver several growth factors in parallel being of particular benefit for therapeutic 
angiogenesis. 
 
 
5.3 Outlook 
While growth factor delivery from starPEG-heparin hydrogels was shown to offer 
unprecedented opportunities for regenerative therapies, additional studies may further 
extend their applicability. 
 
To deepen the understanding of starPEG-heparin hydrogels as a growth factor delivery 
matrix, the distribution of cytokines within the gel matrices due to the dynamic release 
from and re-binding to heparin within the network should be further investigated. Here, 
a microscopic analysis of the protein diffusion through macroscopic channels filled with 
the gel is ongoing. As this particular setting allows the examination of the growth factor 
distribution at a substantially larger scale (mm instead of µm dimensions), the 
information obtained would be of general significance for drawing conclusions about 
the cytokine distribution within bulk gel matrices to be used for an implantation into 
living systems. 
Moreover, besides FGF-2 or VEGF, the possibility to immobilize and release also other 
angiogenic effectors should be analyzed. In this context, experiments with molecules 
lacking specific heparin binding sites would additionally increase the knowledge about 
the mechanisms of protein-network interactions and could help to extend the options 
for effectively governing therapeutic angiogenesis via the provision of further supportive 
factors. 
While the possibility to tune the FGF-2 or VEGF release from starPEG-heparin 
hydrogels was already successfully demonstrated, in vitro and in vivo cell studies 
concerning the effect of a triggered growth factor delivery have to be performed in 
order to explore the suitability of a modulated cytokine provision to induce pro-
angiogenic cellular effects and to broaden the information about the most beneficial 
parameters to stimulate therapeutic angiogenesis. Based on these results, also several 
ways to trigger the FGF-2 and/or VEGF delivery from starPEG-heparin hydrogels could 
be combined to adjust the system to the particular requirements of angiogenic tissue 
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engineering. Moreover, using these options to extend the set of precisely tunable 
material characteristics and based on the fact that also many other cytokines posses 
heparin-binding sites which allow for an interaction with the gel scaffolds, starPEG-
heparin matrices might not only be applicable for angiogenic tissue engineering but 
could represent a promising candidate to support a number of different therapeutic 
strategies. Here, one potential application might be the usage of the gel system in the 
treatment of neurodegenerative disorders such as Parkinson’s disease, which is 
characterized by a continuous and selective loss of dopaminergic neurons in the brain 
region substantia nigra with a subsequent reduction of neurotransmitter release mainly 
in the striatum [Meyer et al., 2010]. In this context, the in vitro expansion and 
differentiation of neural stem cells into dopaminergic neurons as a target cell type for 
direct transplantation into the brain could be supported by starPEG-heparin matrices 
with optimized mechanical properties, adhesive characteristics and functionalization 
with relevant cytokines such as FGF-2 and glial-derived neurotrophic factor (GDNF). 
As a more advanced approach, by bridging the gap between the substantia nigra and 
the striatum with biomodified hydrogels directly in the brain, a cytokine release from the 
matrices could also promote the proliferation and oriented outgrowth of dopaminergic 
extensions/axons from the substantia nigra towards the striatum [Meyer et al., 2010]. 
Other examples being currently explored include the application of starPEG-heparin 
hydrogel scaffolds as a growth factor delivery system to stimulate progenitor cells in 
kidney or cardiac regeneration. 
 
Besides that, the growth factor delivery should be similarly analyzed for starPEG-
heparin matrices produced by different gel formation schemes. Here, by applying 
conditions, which permit the introduction of micro-dimensional pores into the matrices 
upon cryogelation, interconnecting structures should facilitate a scaffold penetration by 
diffusional processes, thereby leading to an enhanced and accelerated provision of 
different factors via starPEG-heparin hydrogels. In addition, also increased network 
accessibility for molecular components or even for whole cells could be enabled by 
such porous matrices. Furthermore, using different crosslinking mechanisms which 
allow for gelation under physiological conditions, the starPEG-heparin hydrogels should 
be producible in situ for the entrapment of both growth factors and cells. In the context 
of in vitro and in vivo studies, with the application of the porous scaffolds or the in situ 
forming hydrogels, the ECM as the natural, three-dimensional cellular environment 
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could be mimicked even more closely. Moreover, apart from the provision of molecular 
effectors, the possibility to deliver whole cells via starPEG-heparin hydrogels might 
open up new perspectives for the usage of this material in versatile approaches for 
regenerative therapies. 
Finally, besides an optimization of the crosslinking mechanism for preparing starPEG-
heparin hydrogels, further options to precisely trigger the delivery of different factors 
under physiological conditions could be established. For example, photo-degradable 
matrices that can be cleaved upon the illumination by light within the harmless infrared 
range should be developed. In potential therapeutic concepts, such scaffolds could 
release immobilized effectors in response to this external trigger that can be directly 
applied to the body just within the desired local and temporal context. 
 
Conclusively, together with the presented data and the already established starPEG-
heparin hydrogel as an efficient growth factor delivery system, these further 
experiments and additional optimization procedures could lead to an increased general 
knowledge about the provision of therapeutic effectors via polymeric biomaterials and 
pave the way for the widespread medical application of such modular and thoroughly 
tunable materials to rekindle regeneration processes in diseased or injured tissues and 
organs of the mammalian organism. 
References  103 
References 
Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine 
phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and 
paxillin in endothelial cells. J Biol Chem 1997;272(24):15442-15451. 
 
Albes JM, Klenzner T, Kotzerke J, Thiedemann KU, Schäfers HJ, Borst HG. 
Improvement of tracheal autograft revascularization by means of fibroblast growth 
factor. Ann Thorac Surg 1994;57(2):444-449. 
 
Andreopoulos FM, Persaud I. Delivery of basic fibroblast growth factor (bFGF) from 
photoresponsive hydrogel scaffolds. Biomaterials 2006;27(11):2468-2476. 
 
Arakawa T, Wen J, Philo JS. Stoichiometry of heparin binding to basic fibroblast growth 
factor. Arch Biochem Biophys 1994;308(1)267-273. 
 
Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner 
JM. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth 
factor on angiogenesis in vivo. Circulation 1995;92:365-371. 
 
Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of 
growth factor-binding structures in heparin/heparan sulfate using an octasaccharide 
library J Biol Chem 2004;279(13):12346-12354. 
 
Auerbach R, Kubai L, Knighton D, Folkman J. A simple procedure for the long-term 
cultivation of chicken embryos. Dev Biol 1974;41:391-394. 
 
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical 
overview. Clin Chem 2003;49(1):32-40. 
 
Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates 
migration of capillary endothelial cells in vitro. J Exp Med 1980;152(4):931-944. 
 
Badet J. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and 
structural properties. Pathol Biol (Paris) 1999;47:345-351. 
 
Baird A, Schubert D, Ling N, Guillemin R. Receptor- and heparin-binding domains of 
basic fibroblast growth factor. Proc Natl Acad Sci U S A 1988;85:2324-2328.  
 
104  References 
Bar RS, Boes M, Dake BL, Booth BA, Henley SA, Sandra A. Insulin, insulin-like growth 
factors, and vascular endothelium. Am J Med 1988;85:59-70. 
 
Bawa P, Pillay V, Choonara YE, du Toit LC. Stimuli-responsive polymers and their 
applications in drug delivery. Biomed Mater 2009;4(2):022001 (15 pp). 
 
Benoit DS, Anseth KS. Heparin functionalized PEG gels that modulate protein 
adsorption for hMSC adhesion and differentiation. Acta Biomater 2005;1(4):461-470. 
 
Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. 
Endocr Rev 1997;18:26-45. 
 
Bos GW, Scharenborg NM, Poot AA, Engbers GHM, Beugeling T, van Aken WG, 
Feijen J. Proliferation of endothelial cells on immobilized albumin-heparin conjugate 
loaded with basic fibroblast growth factor. J Biomed Mater Res 1999;44(3):330-340. 
 
Bouloumié A, Schini-Kerth V, Busse R. Vascular endothelial growth factor up-regulates 
nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999;41:773-780. 
 
Boyden SV. The chemotactic effect of mixtures of antibody and antigen on 
polymophonuclear leukocytes. J Exp Med 1962;115:453-466. 
 
Bruick RK, McKnight SL. Building better vasculature. Genes Dev 2001;15:2497-2502. 
 
Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G. Role of 
soluble mediators in angiogenesis. Eur J Cancer 1996;32A:2401-2412. 
 
Cai S, Liu Y, Zheng Shu X, Prestwich GD. Injectable glycosaminoglycan hydrogels for 
controlled release of human basic fibroblast growth factor. Biomaterials 
2005;26(30):6054-6067. 
 
Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 
2002;41(3):391-412. 
 
 
 
 
References  105 
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, 
Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, 
Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking 
a single VEGF allele. Nature 1996;380(6573):435-439. 
 
Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-660. 
 
Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. Effects of 
angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 
2002;74(4):523-535. 
 
Chan G, Mooney DJ. New materials for tissue engineering: towards greater control 
over the biological response. Trends Biotechnol 2008;26(7):382-392.  
 
Chiu LL, Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for 
vascularization of engineered tissues. Biomaterials 2010;31(2):226-241. 
 
Choi J, Ko MK, Kay EP. Subcellular localization of the expressed 18 kDa FGF-2 
isoform in corneal endothelial cells. Mol Vis 2000;6:222-231. 
 
Chow LW, Bitton R, Webber MJ, Carvajal D, Shull KR, Sharma AK, Stupp SI. A 
bioactive self-assembled membrane to promote angiogenesis. Biomaterials 
2011;32(6):1574-1582. 
 
Chung TW, Lu YF, Wang SS, Lin YS, Chu SH. Growth of human endothelial cells on 
photochemically grafted Gly-Arg-Gly-Asp (GRGD) chitosans. Biomaterials 
2002;23:4803-4809. 
 
Chwalek K, Levental KR, Tsurkan MV, Zieris A, Freudenberg U, Werner C. Two-tier 
hydrogel degradation to boost endothelial cell morphogenesis. Biomaterials 
2011;32(36):9649-9657. 
 
Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn II GW, Lightfoot P, 
German R, Howles PN, Kier A, O’Toole BA, Sasse J, Gonzalez AM, Baird A, 
Doetschaman T.  Abnormal bone growth and selective translational regulation in basic 
fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell 1995;6:1861-1873. 
 
106  References 
Coltrini D, Rusnati M, Zoppetti G, Oreste P, Isacchi A, Caccia P, Bergonzoni L, Presta 
M. Biochemical bases of the interaction of human basic fibroblast growth factor with 
glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem 
1993;214(1):51-58. 
 
Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling 
pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 
2001;22(4):201-207. 
 
Cuevas P, Garcia-Calvo M, Carceller F, Reimers D, Zazo M, Cuevas B, Munoz-Willery 
I, Martinez-Coso V, Lamas S, Gimenez-Gallego G. Correction of hypertension by 
normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase 
in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1996;93:11996-12001. 
 
De Laporte L, des Rieux A, Tuinstra HM, Zelivyanskaya ML, De Clerck NM, Postnov 
AA, Préat V, Shea LD. Vascular endothelial growth factor and fibroblast growth factor 2 
delivery from spinal cord bridges to enhance angiogenesis following injury. J Biomed 
Mater Res A 2011;98(3):372-382 
 
DeLong SA, Moon JJ, West JL. Covalently immobilized gradients of bFGF on hydrogel 
scaffolds for directed cell migration. Biomaterials 2005;26(16):3227-3234. 
 
Deroanne CF, Lapiere CM, Nusgens BV. In vitro tubulogenesis of endothelial cells by 
relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc Res 
2001;49(3):647-658. 
 
Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their 
substrate. Science 2005;310:1139-1143. 
 
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and 
angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 
2003;47(3):149-161. 
 
Dono R, Texido G, Dussel R, Ehmke H, Zeller R. Impaired cerebral cortex 
development and blood pressure regulation in FGF-2-deficient mice. EMBO J 
1998;17(15):4213-4225. 
 
 
 
References  107 
Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, 
Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor 
that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc 
Biol 2003;23(4):594-600. 
 
Dowd CJ, Cooney CL, Nugent MA. Heparan sulfate mediates bFGF transport through 
basement membrane by diffusion with rapid reversible binding. J Biol Chem 
1999;274:5236-5244. 
 
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular 
endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J 
Pathol 1995;146:1029-1039. 
 
Edelman ER, Mathiowitz E, Langer R, Klagsbrun M. Controlled and modulated release 
of basic fibroblast growth factor. Biomaterials 1991;12(7): 619-626. 
 
Ehrbar M, Schoenmakers R, Christen EH, Fussenegger M, Weber W. Drug-sensing 
hydrogels for the inducible release of biopharmaceuticals. Nat Mater 2008;7(10):800-
804.  
 
Ehrick JD, Deo SK, Browning TW, Bachas LG, Madou MJ, Daunert S. Genetically 
engineered protein in hydrogels tailors stimuli-responsive characteristics. Nat Mater 
2005;4(4):298-302. 
 
Epstein-Barash H, Orbey G, Polat BE, Ewoldt RH, Feshitan J, Langer R, Borden MA, 
Kohane DS. A microcomposite hydrogel for repeated on-demand ultrasound-triggered 
drug delivery. Biomaterials 2010;31(19):5208-5017.  
 
Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of 
human basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991;88(8):3441-3445.  
 
Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and 
interactions with basic fibroblast growth factor. Science 1996;271(5252):1116-1120. 
 
Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. Solution 
structure of the heparin-binding domain of vascular endothelial growth factor. Structure 
1998;6(5):637-648. 
 
108  References 
Fasol R, Schumacher B, Schlaudraff K, Hauenstein KH, Seitelberger R. Experimental 
use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the 
heart. J Thorac Cardiovasc Surg 1994;107(6):1432-1439. 
 
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth 
factor specific for vascular endothelial cells. Biochem Biophys Res Commun 
1989;161:851-858. 
 
Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial 
growth factor family of polypeptides. J Cell Biochem 1991;47(3):211-218. 
 
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, 
Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted 
inactivation of the VEGF gene. Nature 1996;380(6573):439-442. 
 
Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr 
Top Microbiol Immunol 1999;237:1-30. 
 
Fridrikh SV, Yu JH, Brenner MP, Rutledge GC. Controlling the fiber diameter during 
electrospinning. Phys Rev Lett 2003;90:144502-1-4. 
 
Fischbach C, Mooney DJ. Polymeric systems for bioinspired delivery of angiogenic 
molecules. Adv Polym Sci 2006;203:191-221. 
 
Flaumenhaft R, Rifkin DB. The extracellular regulation of growth factor action. Mol Biol 
Cell 1992;3:1057-1065. 
 
Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and 
cell surface localization. Growth Factors 1991;4:265-275. 
 
Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-
binding angiogenic protein --basic fibroblast growth factor-- is stored within basement 
membrane. Am J Pathol 1988;130:393-400. 
 
Freudenberg U, Hermann A, Welzel PB, Stirl K, Schwarz SC, Grimmer M, Zieris A, 
Panyanuwat W, Zschoche S, Meinhold D, Storch A, Werner C. A starPEG-heparin 
hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. 
Biomaterials 2009;30(28):5049-5060. 
 
References  109 
Garbern JC, Minami E, Stayton PS, Murry CE. Delivery of basic fibroblast growth factor 
with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted 
myocardium. Biomaterials. 2011;32(9):2407-2416.  
 
Garcia-Cardena G, Fan R, Shah V Sorrentino R, Cirino G, Papapetropoulos A, Sessa 
WC. Dynamic activation of endothelial nitric oxide synthase by Hsp 90. Nature 
1998;392:821-824. 
 
Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial 
growth factor to its receptors is dependent on cell surface-associated heparin-like 
molecules. J Biol Chem 1992;267:6093-6098. 
 
Goodman OB Jr, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, Nanus 
DM. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol 
Chem 2006;281(44):33597-33605. 
 
Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol 
Chem 1975;250:2515-2520. 
 
Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J 
Cell Physiol 1986a;128:475-484. 
 
Gospodarowicz D, Neufeld G, Schweigerer L. Molecular and biological characterization 
of fibroblast growth factor, an angiogenic factor which also controls the proliferation and 
differentiation of mesoderm and neuroectoderm derived cells. Cell Differ 1986b;19:1-
17. 
 
Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial 
growth factor and basic fibroblast growth factor on the proliferation and cord formation 
of bovine capillary endothelial cells within collagen gels. Lab Invest 1993;69(5):508-
517. 
 
Gu F, Amsden B, Neufeld R. Sustained delivery of vascular endothelial growth factor 
with alginate beads. J Control Release 2004;96(3):463-472. 
 
Habuchi H, Suzuki S, Saito T, Tamura T, Harada T, Yoshida K, Kimata K. Structure of 
a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. 
Biochem J 1992;285(Pt 3):805-813. 
 
110  References 
Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its 
receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival 
of endothelial cells. Microvasc Res 1999;58:224-237. 
 
Henry, T. D. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, 
Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, 
Fine J, McCluskey ER, VIVA Investigators. The VIVA trial: vascular endothelial growth 
factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365. 
 
Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003;60(1):64-
69. 
 
Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;54(1):3-
12. 
 
Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, 
protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-
H1058. 
 
Hoshi H, McKeehan WL. Brain- and liver cell-derived factors are required for growth of 
human endothelial cells in serum-free culture. Proc Natl Acad Sci U S A 
1984;81(20):6413-6417. 
 
Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular 
endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol 
Chem 1992;267:26031-26037. 
 
Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-
controlled drug delivery systems. J Control Release 2001;73(2-3):121-136. 
 
Hubbell JA. Materials as morphogenetic guides in tissue engineering. Curr Opin 
Biotechnol 2003;14(5):551-558. 
 
Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial 
growth factor promotes endothelial cell adhesion, migration and survival through 
integrin ligation. FASEB J 2003;17:1520-1522. 
 
Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 
1998;15(9):1326-1331. 
 
References  111 
Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation 
during fibroblast growth factor-stimulated angiogenensis in vitro: role of extracellular 
matrix. J Cell Biol 1989;109:317-330. 
 
Ishai-Michaeli R, Svahn CM, Weber M, Chajek-Shaul T, Korner G, Ekre HP, Vlodavsky 
I. Importance of size and sulfation of heparin in release of basic fibroblast growth factor 
from the vascular endothelium and extracellular matrix. Biochemistry 1992;31(7):2080-
2088. 
 
Ito Y, Hasuda H, Terai H, Kitajima T. Culture of human umbilical vein endothelial cells 
on immobilized vascular endothelial growth factor. J Biomed Mater Res A 
2005;74(4):659-665. 
 
Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, Tabata Y. 
Intramyocardial sustained delivery of basic fibroblast growth factor improves 
angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003;18:93-
99. 
 
Jensen M, Birch Hansen P, Murdan S, Frokjaer S, Florence AT. Loading into and 
electro-stimulated release of peptides and proteins from chondroitin 4-sulphate 
hydrogels. Eur J Pharm Sci 2002;15(2):139-148. 
 
Jia X, Kiick KL. Hybrid multicomponent hydrogels for tissue engineering. Macromol 
Biosci 2009;9(2):140-156. 
 
Jones KH, Senft JA. An improved method to determine cell viability by simultaneous 
staining with fluorescein diacetate - propidium iodide. J Histochem Cytochem 
1985;33:77-79. 
 
Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding 
domain in the fibroblast growth factor receptor kinase. Science 1993;259(26):1918-
1921. 
 
Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa 
K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement 
of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118(Pt 16):3759-3768. 
 
Keane MP, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis. 
Chem Immunol 1999;72:86-101. 
 
112  References 
Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The 
carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for 
its mitogenic potency. J Biol Chem 1996;271(13):7788-7795. 
 
Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic 
heart disease. Circulation 2011;124(3):314-923.  
 
King WJ, Pytel NJ, Ng K, Murphy WL. Triggered drug release from dynamic 
microspheres via a protein conformational change. Macromol Biosci 2010;10(6):580-
584. 
 
Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999;6(8):R217-224. 
 
Kleinman HK, Philp D, Hoffman MP. Role of the extracellular matrix in morphogenesis. 
Curr Opin Biotech 2003;14:526-532. 
 
Kloxin AM, Kasko AM, Salinas CN, Anseth KS. Photodegradable hydrogels for 
dynamic tuning of physical and chemical properties. Science 2009;324(5923):59-63. 
 
Ko HCH, Milthorpe BK, McFarland CD. Engineering thick tissues - the vascularisation 
problem. Eur Cell Mater 2007;14:1-19. 
 
Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces 
sprouting angiogenesis in vitro. Curr Biol 1998;8:529-532. 
 
Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer 
transport across venules and small veins. Structural basis for the hyperpermeability of 
tumor blood vessels. Lab Invest 1992;67:596-607. 
 
Komori M, Tomizawa Y, Takada K, Ozaki M. A single local application of recombinant 
human basic fibroblast growth factor accelerates initial angiogenesis during wound 
healing in rabbit ear chamber. Anesth Analg 2005;100:830-834. 
 
Kraehenbuehl TP, Ferreira LS, Zammaretti P, Hubbell JA, Langer R. Cell-responsive 
hydrogel for encapsulation of vascular cells. Biomaterials 2009;30(26):4318-4324.  
 
Kurz H. Physiology of angiogenesis. J Neurooncol 2000;50:17-35. 
 
 
 
References  113 
Larsen M, Willems WF, Pelzer M, Friedrich PF, Yaszemski MJ, Bishop AT. 
Augmentation of surgical angiogenesis in vascularized bone allotransplants with host-
derived a/v bundle implantation, fibroblast growth factor-2, and vascular endothelial 
growth factor administration. J Orthop Res 2010;28(8):1015-1021. 
 
Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general 
approaches and a review of recent developments. J R Soc Interface 2011;8(55):153-
170.  
 
Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev 2001;101(7):1869-
1879. 
 
Lee KY, Peters MC, Mooney DJ. Comparison of vascular endothelial growth factor and 
basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release 
2003;87:49-56. 
 
Lee M, Chen TT, Iruela-Arispe ML, Wu BM, Dunn JC. Modulation of protein delivery 
from modular polymer scaffolds. Biomaterials 28 2007;10:1862-1870. 
 
Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by 
matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J 
Cell Biol 2005;169(4):681-691. 
 
Leslie-Barbick JE, Moon JJ, West JL. Covalently-immobilized vascular endothelial 
growth factor promotes endothelial cell tubulogenesis in poly(ethylene glycol) diacrylate 
hydrogels. J Biomater Sci Polym Ed 2009;20(12):1763-1779. 
 
Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and 
flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 
1996;270(5 Pt 2):H1803-1811. 
 
Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. 
Biochem Pharmacol 2001;61(3):253-270. 
 
Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm 
formation in PDGF-B-deficient mice. Science 1997;277:242-245. 
 
Linemeyer DL, Kelly LJ, Menke JG, Gimenez G, DiSalvo J, Thomas KA. Expression in 
Escherichia coli of a chemically synthesised gene for active bovine acidic fibroblast 
growth factor. Biotechnology 1987;5:960-965. 
114  References 
Liu WF, Chen CS. Engineering biomaterials to control cell function. Mater Today 
2005;8(12):28-35. 
 
Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF dependent modulation 
of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 
2002;99:11205-11210. 
 
Losi P, Briganti E, Magera A, Spiller D, Ristori C, Battolla B, Balderi M, Kull S, Balbarini 
A, Di Stefano R, Soldani G. Tissue response to poly(ether)urethane-
polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic 
growth factors. Biomaterials 2010;31(20):5336-5344.  
 
Lusis AJ. Atherosclerosis. Nature 2000;407(6801):233-241. 
 
Lutolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Müller R, Hubbell JA. 
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. 
Nat Biotechnol 2003;21(5):513-518.  
 
Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 
2005;23(1):47-55. 
 
Mager MD, LaPointe V, Stevens MM. Exploring and exploiting chemistry at the cell 
surface. Nat Chem. 2011;3(8):582-589.  
 
Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74(2-
3):100-113.  
 
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, 
Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, 
Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo 
angiogenesis. Science 1997;277:55-60. 
 
Masters KS. Covalent growth factor immobilization strategies for tissue repair and 
regeneration. Macromol Biosci 2011;11(9):1149-1163. 
 
Masuoka K, Ishihara M, Asazuma T, Hattori H, Matsui T, Takase B, Kanatani Y, Fujita 
M, Saito Y, Yura H, Fujikawa K, Nemoto K. The interaction of chitosan with fibroblast 
growth factor-2 and its protection from inactivation. Biomaterials 2005;26:3277-3284. 
 
References  115 
Meyer AK, Maisel M, Hermann A, Stirl K, Storch A. Restorative approaches in 
Parkinson's Disease: which cell type wins the race? J Neurol Sci. 2010;289(1-2):93-
103. 
 
Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of 
secretory signal sequence, is released by cells via a pathway independent of the 
endoplasmic reticulum-Golgi complex. J Cell Physiol 1992;151:81-93. 
 
Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in 
angiogenesis. Enzyme Protein 1996;49:117-137. 
 
Mochizuki Y, Nakamura T, Kanetake H, Kanda S. Angiopoietin 2 stimulates migration 
and tube-like structure formation of murine brain capillary endothelial cells through c-
Fes and c-Fyn. J Cell Sci 2002;115:175-183. 
 
Müller M, Kessler B, Richter S. Preparation of monomodal polyelectrolyte complex 
nanoparticles of PDADMAC/poly(maleic acid-alt-r-methylstyrene) by consecutive 
centrifugation. Langmuir 2005;21:7044-7051. 
 
Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular 
endothelial growth factor: crystal structure and functional mapping of the kinase domain 
receptor binding site. Proc Natl Acad Sci USA 1997;94(14):7192-7197. 
 
Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular 
endothelial growth factor / vascular permeability factor enhances vascular permeability 
via nitric oxide and prostacyclin. Circulation 1998;97:99-107. 
 
Nagase H, Fields GB. Human matrix metalloproteinase specificity studies using 
collagen sequence-based synthetic peptides. Biopolymers 1996;40(4):399-416. 
 
Namdeo M, Bajpai SK, Kakkar S. Preparation of a magnetic-field-sensitive hydrogel 
and preliminary study of its drug release behavior. J Biomater Sci Polym Ed 
2009;20(12):1747-1761. 
 
Nico B, de Falco G, Vacca A, Roncali L, Ribatti D. In vivo absence of synergism 
between fibroblast growth factor-2 and vascular endothelial growth factor. J 
Hematother Stem Cell Res 2001;10(6):905-912. 
 
116  References 
Nie T, Baldwin A, Yamaguchi N, Kiick KL. Production of heparin-functionalized 
hydrogels for the development of responsive and controlled growth factor delivery 
systems. J Control Release 2007;122(3):287-296.  
 
Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH. 
Increased angiogenesis and blood vessel maturation in acellular collagen-heparin 
scaffolds containing both FGF2 and VEGF. Biomaterials 2007;28(6):1123-1131.  
 
Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 
2000;32(2):115-120. 
 
Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M. Structural features in heparin that 
interact with VEGF165 and modulate its biological activity. Glycobiology 1999;9(7):705-
711. 
 
Pacini S, Gulisano M, Vannucchi S, Ruggiero M. Poly-L-lysine/heparin stimulates 
angiogenesis in chick embryo chorioallantoic membrane. Biochem Biophys Res 
Commun 2002;290(2):820-823. 
 
Park JW, Chakrabarti B. Optical characteristics of carboxyl group in relation to the 
circular dichroic properties and dissociation constants of glycosaminoglycans. Biochim 
Biophys Acta 1978;544(3):667-675. 
 
Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular 
endothelial growth factor and basic fibroblast growth factor in the induction of 
angiogenesis in vitro. Biochem Biophys Res Commun 1992;189(2):824-831. 
 
Peters MC, Isenberg BC, Rowley JA, Mooney DJ. Release from alginate enhances the 
biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed 
1998;9:1267-1278. 
 
Phelps EA, Landázuri N, Thulé PM, Taylor WR, García AJ. Bioartificial matrices for 
therapeutic vascularization. Proc Natl Acad Sci U S A 2010;107(8):3323-3328.  
 
Pompe T, Zschoche S, Herold N, Salchert K, Gouzy MF, Sperling C, Werner C.  Maleic 
anhydride copolymers - a versatile platform for molecular biosurface engineering. 
Biomacromolecules 2003;4:1072-1079. 
 
References  117 
Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth 
factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor 
Rev 2005;16(2):159-178.  
 
Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. Heparan sulphate 
oligosaccharides require 6-O-sulphation for the promotion of bFGF mitogenic activity. J 
Biol Chem 1998;273:22936-22942.   
 
Raeber GP, Lutolf MP, Hubbell JA. Molecularly engineered PEG hydrogels: a novel 
model system for proteolytically mediated cell migration. Biophys J 2005;89:1374-1388. 
 
Ribatti D, Nico B, Morbidelli L, Donnini S, Ziche M, Vacca A, Roncali L, Presta M. Cell-
mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor 
onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J 
Vasc Res 2001;38(4):389-397. 
 
Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth 
factor delivery. Nat Biotechnol 2001;19(11):1029-1034. 
 
Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor 
(VEGF) and their receptors. J Cell Sci 2001;114(Pt 5):853-865. 
 
Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding sites within 
heparan sulfate encompass two highly sulfated domains and can be liberated by K5 
lyase. J Biol Chem 2006;281(3):1731-1740.  
 
Rocha FG, Sundback CA, Krebs NJ, Leach JK, Mooney DJ, Ashley SW, Vacanti JP, 
Whang EE. The effect of sustained delivery of vascular endothelial growth factor on 
angiogenesis in tissue-engineered intestine. Biomaterials 2008;29:2884-2890. 
 
Roghani M, Mansukhani A, Dell'Era P, Bellosta P, Basilico C, Rifkin DB, Moscatelli D. 
Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not 
required for binding. J Biol Chem 1994;269(6):3976-3984.  
 
Rubinstein M, Colby RH. Polymer physics. Oxford, New York: Oxford University Press, 
2003. 
 
Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion - RGD and 
integrins. Science 1987;238:491-497. 
 
118  References 
Sakamoto T, Ishibashi T, Kimura H, Yoshikawa H, Spee C, Harris MS, Hinton DR, 
Ryan SJ. Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial 
cells. Invest Ophthalmol Vis Sci 1995;36(6):1076-1083. 
 
Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan 
sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. 
J Cell Biol 1988;107:743-751. 
 
Salchert K, Pompe T, Sperling C, Werner C. Quantitative analysis of immobilized 
proteins and protein mixtures by amino acid analysis. J Chromatogr/A 2003;1005:113-
122. 
 
Sato Y, Okamura K, Morimoto A, Hamanaka R, Hamaguchi K, Shimada T, Ono M, 
Kohno K, Sakata T, Kuwano M. Indispensable role of tissue-type plasminogen activator 
in growth factor-dependent tube formation of human microvascular endothelial cells in 
vitro. Exp Cell Res 1993;204:223-229. 
 
Saunders RL, Hammer DA. Assembly of human umbilical vein endothelial cells on 
compliant hydrogels. Cell Mol Bioeng 2010;3(1):60-67. 
 
Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more 
potent angiogenic mediator than epidermal growth factor. Science 1986;232:1250-
1253. 
 
Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. 
Capillary endothelial cells express basic fibroblast growth factor, a mitogen that 
promotes their own growth. Nature 1987;325:257-259. 
 
Seliktar D, Zisch AH, Lutolf MP, Wrana JL, Hubbell JA. MMP-2 sensitive, VEGF-
bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res A  
2004;68(4):704-716. 
 
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells 
secrete a vascular permeability factor that promotes accumulation of ascites fluid. 
Science 1983;219(4587):983-985. 
 
Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by 
hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-845. 
 
References  119 
Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, 
Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment 
of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, 
randomized, controlled clinical trial. Circulation 2002;105:788-793. 
 
Sommer JU, Dockhorn R, Welzel PB, Freudenberg U, Werner C. Swelling Equilibrium 
of a binary polymer gel. Macromolecules 2011;44:981-986. 
 
Sperinde GV, Nugent MA. Heparan sulfate proteoglycans control intracellular 
processing of bFGF in vascular smooth muscle cells. Biochemistry 1998;37(38):13153-
13164. 
 
Staros JV, Wright RW, Swingle DM. Enhancement by N-hydroxysulfosuccinimide of 
water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 
1986;156(1):220-222. 
 
Steffens GC, Yao C, Prével P, Markowicz M, Schenck P, Noah EM, Pallua N. 
Modulation of angiogenic potential of collagen matrices by covalent incorporation of 
heparin and loading with vascular endothelial growth factor. Tissue Eng 2004;10(9-
10):1502-1509. 
 
Sun X-T, Ding Y-T, Yan X-G, Wu L-Y, Li Q, Cheng N, Qiu YD, Zhang MY. Angiogenic 
synergistic effect of basic fibroblast growth factor and vascular endothelial growth 
factor in an in vitro quantitative microcarrier-based three-dimensional fibrin 
angiogenesis system. World J Gastroenterol 2004;10(17):2524-2528. 
 
Supino R. MTT assays. Methods Mol Biol 1995;43:137-149. 
 
Tabata Y, Miyao M, Ozeki M, Ikada Y. Controlled release of vascular endothelial 
growth factor by use of collagen hydrogels. J Biomater Sci Polym Ed 2000;11(9):915-
930. 
 
Tae G, Scatena M, Stayton PS, Hoffman AS. PEG-crosslinked heparin is an affinity 
hydrogel for sustained release of vascular endothelial growth factor. J Biomater Sci 
Polym Ed 2006;17(1-2):187-197. 
 
Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 
1997;11(1):51-59. 
 
120  References 
Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of 
basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of 
heparin and alginate. J Biomed Mater Res 2001;56(2):216-221. 
 
Tessmar JK, Göpferich AM. Customized PEG-derived copolymers for tissue-
engineering applications. Macromol Biosci 2007;7:23-39. 
 
Tiefenbacher CP, Chilian WM. Basic fibroblast growth factor and heparin influence 
coronary arteriolar tone by causing endothelium-dependent dilation. Cardiovasc Res 
1997;34:411-417. 
 
Tsurkan MV, Chwalek K, Levental KR, Freudenberg U, Werner C. 
Modular starPEG-heparin gels with bifunctional peptide linkers. Macromol Rapid Comm 
2010;31:1529-1533. 
 
Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF 
receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation 
of gene expression by nitric oxide. J Clin Invest 1995;95(4):1798-1807. 
 
Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. Identification of the basic 
fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 
1992;267(15):10337-10341. 
 
Uebersax L, Merkle HP, Meinel L. Biopolymer-based growth factor delivery for tissue 
repair: from natural concepts to engineered systems. Tissue Eng Part B Rev 
2009;15(3):263-289. 
 
Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 
1999;9:211-220. 
 
Vernon RB, Sage EH. A novel, quantitative model for study of endothelial cell migration 
and sprout formation within three-dimensional collagen matrices. Microvasc Res 
1999;57(2):118-133. 
 
Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J,  Klagsbrun 
M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into 
subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987;84:2292-2296. 
 
References  121 
Wang DA, Ji J, Sun YH, Shen JC, Feng LX, Elisseeff JH. In situ immobilization of 
proteins and RGD peptide on polyurethane surfaces via poly(ethylene oxide) coupling 
polymers for human endothelial cell growth. Biomacromolecules 2002;3:1286-1295. 
 
Weatherford DA, Sackman JE, Reddick TT, Freeman MB, Stevens SL, Goldman MH. 
Vascular endothelial growth factor and heparin in a biologic glue promotes human 
aortic endothelial cell proliferation with aortic smooth muscle cell inhibition. Surgery 
1996;120(2):433-439. 
 
Weis JR, Sun B, Rodgers GM. Improved method of human umbilical arterial endothelial 
cell culture. Thromb Res 1991;61:171-173. 
 
Weiss TL, Selleck SE, Reusch M, Wintroub BU. Serial subculture and relative transport 
of human endothelial cells in serum-free, defined conditions. In Vitro Cell Dev Biol 
1990;26(8):759-768. 
 
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human 
endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by 
stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 
1996;271(17):10079-10086. 
 
Wichterle O, Lim D.  Hydrophilic gels in biologic use. Nature 1960:185:117-118. 
 
Wilcke I, Lohmeyer JA, Liu S, Condurache A, Krüger S, Mailänder P, Machens HG. 
VEGF (165) and bFGF protein-based therapy in a slow release system to improve 
angiogenesis in a bioartificial dermal substitute in vitro and in vivo. Langenbecks Arch 
Surg 2007;392:305-314. 
 
Wilting J, Christ B, Bokeloh M, Weich HA. In vivo effects of vascular endothelial growth 
factor on the chicken chorioallantoic membrane. Cell Tissue Res 1993;274(1):163-172. 
 
Wilting J, Christ B, Bokeloh M. A modified chorioallantoic membrane (CAM) assay for 
qualitative and quantitative study of growth factors. Studies on the effects of carriers, 
PBS, angiogenin, and bFGF. Anat Embryol (Berl) 1991;183(3):259-271. 
 
Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. 
Improved endothelialization of vascular grafts by local release of growth factor from 
heparinized collagen matrices. J Control Release 2000;64(1-3):103-114. 
 
122  References 
Wong C, Inman E, Spaethe R, Helgerson S. Fibrin-based biomaterials to deliver 
human growth factors. Thromb Haemost 2003;89(3):573-582. 
 
Yan Q, Li Y, Hendrickson A, Sage EH. Regulation of retinal capillary cells by basic 
fibroblast growth factor, vascular endothelial growth factor, and hypoxia. In Vitro Cell 
Dev Biol Anim 2001;37(1):45-49. 
 
Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like 
molecules are required for binding basic fibroblast growth factor to its high affinity 
receptor. Cell 1991;64:841-848. 
 
Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, Funaki M Zahir N, Ming W, 
Weaver V, Janmey PA. Effects of substrate stiffness on cell morphology, cytoskeletal 
structure, and adhesion. Cell Motil Cytoskel 2005;60:24-34. 
 
Yoon JJ, Chung HJ, Park TG. Photo-crosslinkable and biodegradable Pluronic/heparin 
hydrogels for local and sustained delivery of angiogenic growth factor. J Biomed Mater 
Res A 2007;83(3):597-605. 
 
Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation 
to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 
1996;13(1-2):57-64. 
 
Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of 
the vascular endothelial growth factor family. Cardiovasc Res 2001;49(3):568-581. 
 
Zhang G, Suggs LJ. Matrices and scaffolds for drug delivery in vascular tissue 
engineering. Adv Drug Deliv Rev 2007;59(4-5):360-373. 
 
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor 
specificity of the fibroblast growth factor family. The complete mammalian FGF family. 
J Biol Chem 2006;281(23):15694-15700.  
 
Zieris A, Prokoph S, Welzel PB, Grimmer M, Levental KR, Panyanuwat W, 
Freudenberg U, Werner C. Analytical approaches to uptake and release of hydrogel-
associated FGF-2. J Mater Sci Mater Med 2010a;21(3):914-923. 
 
Zieris A, Prokoph S, Levental KR, Welzel PB,Grimmer M, Freudenberg U, Werner C. 
FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate 
biomolecular and physical cues of angiogenesis. Biomaterials 2010b;31(31)7985-7994. 
References  123 
Zieris A, Chwalek K, Prokoph S, Levental KR, Welzel PB, Freudenberg U, Werner C. 
Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin 
hydrogels. J Control Release 2011, in press (doi:10.1016/j.jconrel.2011.06.042). 
 
Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA. Covalently 
conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001;72(1-
3):101-113. 
 
Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmökel H, 
Bezuidenhout D, Djonov V, Zilla P, Hubbell JA. Cell-demanded release of VEGF from 
synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J 
2003a;17(15):2260-2262.  
 
Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth 
factors. Cardiovasc Pathol 2003b;12(6):295-310. 
 
 
Acknowledgements  125 
Acknowledgements 
I wish to express my sincere gratitude to all those, who contributed to the completion of 
this work. 
 
First of all, I would like to thank Prof. Dr. Carsten Werner for being always interested 
and available as well as for providing me with valuable advices and scientific expertise. 
I really appreciated the opportunity to work on this exciting topic. 
 
I also thank Prof. Dr. Matthias Lutolf, Ecole Polytechnique Fédérale de Lausanne, for 
reviewing this thesis as a second referee. 
 
Furthermore, I am very grateful to the members of my thesis advisory committee, Prof. 
Dr. Elly Tanaka and Prof. Dr. Martin Bornhäuser, for their guidance, assistance and 
cooperation during the course of this work. I would also like to acknowledge the 
support of the Dresden International Graduate School for Biomedicine and 
Bioengineering. 
 
Particularly, I would like to thank my direct supervisor Dr. Uwe Freudenberg for his 
unconditional help, encouragement, understanding, patience and faith. Moreover, my 
special thanks go to Dr. Petra Welzel for all her support and the stimulating 
suggestions that helped me throughout the time of research and writing of this thesis.  
 
I am deeply indebted to my colleagues of the “Biofunctional Polymer Materials” 
department for their encouragement and assistance. I especially thank Silvana 
Prokoph for her outstanding collaboration, advices, moral support, loyalty and 
friendship in every situation. PhD Kandice Levental, Dr. Manfred Maitz and Dr. Philipp 
Seib are particularly thanked for their help concerning experimental questions. Besides, 
I am indeed very grateful to Dr. Mikhail Tsurkan for preparing fluorescently labeled 
heparin and for the synthesis of enzymatically degradable peptide conjugates. I also 
particularly thank Dr. Anika Röhrich for the desulfation of heparin and Dr. Martin Müller 
for characterizing the sulfate content of these samples. For performing the in vivo CAM 
studies, I am highly indebted to Karolina Chwalek. Lisa Naujox is specially thanked for 
her contributions to the experiments of the growth factor release modulation via 
chitosan addition. My sincere gratitude goes also to Milauscha Grimmer for introducing 
126  Acknowledgements 
me into the gel preparation and performing HPLC analysis as well as to Juliane Drichel 
and Tina Lenk for advice on radioisotopic studies and for labeling VEGF. For the 
pleasant and amicable atmosphere within the research group I would like to thank 
Marion Fischer, Marina Prewitz, Katja Schneider and Babette Lanfer. 
 
Finally, I want to thank my family and friends for their unfailing support and 
encouragement. I especially thank Christian Schulze for his help related to the design 
of this thesis. 
Appendix A – Supplementary materials and methods 127 
Appendix A – Supplementary materials and methods 
Synthesis of Alexa conjugates 
0.3 mg EDC (3.5-fold molar excess) and 0.17 mg s-NHS (2-fold molar excess) were 
added to a solution of 5.4 mg heparin (3.85 x 10-4 mmol) in 0.1 M in borate buffer (pH 
8). The reaction mixture was kept for 15 min at 5 °C. Next, 0.25 mg Alexa 488 (3.9 x 
10-4 mmol) in 0.1 M borate buffer (pH 8) was added. The total volume of the reaction 
mixture was 50 µl. The reaction was run overnight at room temperature. 
The Alexa 488 product was purified by dialysis (membrane with 1 kDa molecular 
weight cut, Spectra/Por, Spectrum Laboratories, Rancho Dominguez, USA) against 
800 ml of 1 M sodium chloride (Sigma-Aldrich) in order to remove any unreacted Alexa 
dye, followed by dialysis against 800 ml of water three times. As a quality control, high 
performance size exclusion chromatography (HPSEC) was performed using a 
combination of a BioSep 2000 (Phenomenex, Torrance, USA) and a PolySep 3000 
(Phenomenex) column with 0.1 M NH4OAc (Sigma-Adrich) as a mobile phase (runtime 
1 h at a rate of 0.5 ml/min). At an absorption of 220 nm, HPSEC chromatogram of the 
purified product showed only one main peak at 17 min which is characteristic for 
heparin. The products displayed a strong absorption at 488 and emission at 530 which 
clearly indicated the presence of Alexa 488 within its structure. 
 
Synthesis of enzymatically cleavable starPEG conjugates 
The MMP cleavable sequence GPQG↑↓IWGQ was included as a bioactive module into 
the peptide NH2-GGPQGIWGQGGCG-CONH2 (in single-letter amino acid code) which 
was synthesized using the solid-phase approach on an Activo P11 (Activotec, 
Cambridge, UK) peptide synthesizer by standard fluorenylmethyloxycarbonyl (Fmoc) 
chemistry. The 0.25 mmol scale protocol with a C-terminal capping protection strategy 
by amide was used. Activation was achieved by O-(Benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate (Sigma-Aldrich), and 1-hydroxybenzotriazole 
(Sigma-Aldrich) in dimethylformamide (Sigma-Aldrich). Deprotection of the amino acid 
side chains and cleavage from the resin was performed by reaction with a mixture of 
trifluroacetic acid (85 % [v/v]; Sigma-Aldrich), phenol (5% [v/v]; Sigma-Aldrich), 
dithiothreitol (2.5 % [v/v]; Sigma-Aldrich), triisopropylsilane (2.5 % [v/v]; Sigma-Aldrich) 
and water (5 % [v/v]) for 2.5 h at room temperature. The crude peptide was then 
precipitated in cold anhydrous diethyl ether (Sigma-Aldrich), collected by vacuum 
filtration and dried under vacuum. Final purification was achieved by preparative 
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reversed-phase HPLC using a XBridge Prep C18 column (10 µm particle size, 19 × 
250 mm, Waters GmbH, Eschborn, Germany). A linear gradient of water/acetonitrile 
(Sigma-Aldrich) containing 0.1 % [v/v] trifluroacetic acid was used as the mobile phase. 
The HPLC runs were performed over 30 min using a flow rate of 10 ml/min for the 
preparative columns. For HPLC separations, the monitoring wavelengths were set to a 
wavelength range of 210-278 nm. A two-pump system (Agilent Technologies 1200 
Series) equipped with an UV/Vis diode array detector/spectrophotometer having a 1-
cm path length cell was used. The collected peptides were lyophilized (LYOVAC GT2, 
GEA Lyophil GmbH, Hürth, Germany) and the purity of the collected peptide was 
verified analogously by analytical HPLC using a XBridge BEH300 C18 column (5 µm 
particle size, 2.1 × 250 mm, Waters GmbH). 
For the preparation of maleimide terminated starPEG, 0.1 g (1 x 10-5 mol) of amino 
terminated starPEG was dissolved in 0.5 ml of CH2Cl2, (Sigma-Aldrich). Next, 112 mg 
(4.2 x 10-5 mol) of 3-Maleimidopropionic acid N-hydroxysuccinimide ester (Sigma-
Aldrich) was added. The reaction was stirred overnight under N2, following double 
precipitation from 150 ml of diethyl ether. The collected white precipitate was dried 
under vacuum overnight and kept under -20 °C, while  the success of the 
functionalization was verified using 1H nuclear magnetic resonance (NMR; resolution 
of 500 Mz, Bruker BioSpin, Rheinstetten, Germany) spectroscopy with deuterated 
chloroform as a solvent. Via NMR, the conversion rate of PEG terminal amino groups 
could be calculated from the ratio between the signals of maleimide group residue and 
PEG core (100 % corresponds to the ratio 1:2; for detailed parameters of NMR analysis 
see [Chwalek et al., 2011]) 
The maleimide-functionalized starPEG was converted into the starPEG-MMP 
conjugates by simple mixing of the stoichiometrical amounts of the peptide and 
functionalized starPEG (10 % [w/v]) in phosphate buffer pH 7. A small amount of tris(2-
carboxyethyl)phosphine chloride (Sigma-Aldrich) was added to the reaction mixture in 
order to prevent oxidation of the cysteine residue. The reaction mixture was stirred 
overnight and purified by dialysis (molecular weight cut of 2 kDa, Spectra/Por, 
Spectrum) against water. White fluffy remnants were collected after lyophilizing the 
dialyzed solution. The purity of the formed starPEG-MMP conjugates was evaluated by 
single peak analysis in analytical reverse phase HPLC as it was explained in detail by 
[Tsurkan et al., 2010]. 
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Desulfation of heparin 
 
Preparation of pyridinium salt of heparin [Inoue et al., 1976; Ayotte et al., 1986; 
Baumann et al., 1996]: 35 g of Amberlite IR-120 H+ ion exchange resin (Rohm and 
Haas, Philadelphia, USA) were filled in a glass column and washed with deionized 
water, regenerated for 30 minutes with 10 % aqueous HCl, and washed with water until 
neutral pH. A solution of 1 g heparin (sodium salt) in 45 ml deionized water was 
applied. The combined filtrate and washings were adjusted to pH 6.0 with pyridine 
(Sigma-Aldrich). After solvent removal by evaporation, the product was lyophilized 
(1240 mg). Subsequently, the pyridinium salt of heparin served as the starting 
compound for the N- and 6-O-desulfation procedure. 
 
N-desulfated, N-acetylated heparin [Inoue et al., 1976; Ishihara et al., 1997]: 25 ml 
DMSO containing 5 % water were added to the pyridinium salt of heparin and the 
mixture was stirred for 1.5 h at 50 °C. After dilut ion with 25 ml water, the pH was 
adjusted to pH 9.5 with 1 N aqueous NaOH (Sigma-Aldrich). The mixture was dialyzed 
(molecular weight cut of 8 kDa, Spectra/Por, Spectrum) against deionized water for 3 d.  
20 ml 10 % methanol (Acros Organics) containing 50 mM Na2CO3 (Sigma-Aldrich) 
were added to the reaction mixture. While stirring, 200 µl acetic anhydride (Sigma-
Aldrich) were added at 0°C. The pH was adjusted to 7-8 with saturated Na2CO3 
solution. Every 30 min, 200 µl acetic anhydride were added for 3 h. The reaction 
mixture was dialyzed (molecular weight cut of 8 kDa) against deionized water for 3 d, 
concentrated and lyophilized. 
 
2-O-desulfation procedure [Ishihara et al., 1997]: 500 mg heparin (sodium salt) were 
dissolved in 10 ml 0.4 M aqueous NaOH. The solution was frozen and lyophilized over 
night. Dissolving and lyophilizing was done twice. The pH was adjusted to 9.0 with 
20 % acetic acid. After dialysis (molecular weight cut of 8 kDa) against deionized water 
for 3 d, the reaction mixture was concentrated and lyophilized.    
 
6-O-desulfation procedure [Baumann et al., 1996]: 420 mg of the pyridinium salt of 
heparin were dissolved in 50 ml N-methyl-2-pyrrolidone (Sigma-Aldrich) containing 10 
% water. The reaction was carried out for 24 h at 90 °C. After cooling to room 
temperature, 50 ml deionized water were added and the pH was adjusted to 9.0 by 
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addition of 1 M aqueous NaOH. The reaction mixture was dialyzed (molecular weight 
cut of 8 kDa) against deionized water for 3 d, concentrated and lyophilized. 
 
 
Degradation studies of enzymatically cleavable hydrogels 
5 µl gel droplets were used for degradation experiments. After gelation overnight, the 
hydrogel drops were washed 3 times with PBS and swollen in PBS overnight. To 
determine the kinetics of degradation, gel drops were placed in plastic UV cuvettes 
(PlastiBrand, Brand GmbH + Co KG, Wertheim, Germany) with 2 ml of PBS ± 1 U/ml 
collagenase. The UV absorption was determined at 278 nm using a spectrophotometer 
(DU800, Beckman Coulter, Brea, USA) and was recorded for all samples every 15 min 
for a time period of 2500 min in total.  
 
 
Characterization of the sulfate content after heparin desulfation procedures 
 
Polyelectolyte titration [Müller et al., 2005]: The anionic charge of the different 
heparin samples (non-desulfated, N-, 2-O-, 6-O- + N- and completely desulfated 
heparin; 1 mg/ml in MilliQ, pH adjusted to 10) was determined by the Particle Charge 
Detector (PCD, Mütek GmbH, Herrsching, Germany) via titration with PDADMAC 
(poly(diallyldimethylammonium chloride), respectively. Based on the exact charge 
compensation of the polyelectrolyte heparin by dropwise added PDADMAC solution (as 
indicated by streaming potential mesurements), the titration of the heparin samples 
reveals a quantitative and reproducible estimation of its charges. To determine the 
heparin sulfate content, all the data were corrected for the charge contribution of the 
carboxylic acid group by subtracting one quarter of the overall charge of the non-
desulfated heparin from all measured values (considering only the major sequence of 
heparin, see Fig. 9). Finally, the decrease of the anionic charge for the different 
desulfated heparins indicated the sulfate removal so that the remaining sulfate content 
could be expressed with respect to the non-desulfated heparin, which served as the 
control sample (set to a sulfate content of 100 %). 
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Infrared (IR) spectroscopy [Müller et al., 2005]: IR measurements on the different 
heparin samples (non-desulfated, N-, 2-O-, 6-O- + N- and completely desulfated 
heparin; 1 mg/ml in MilliQ) were performed on an IFS 55 (EQUINOX, Bruker-Optics 
GmbH, Ettlingen, Germany) Fourier transform IR (FTIR) spectrometer in the attenuated 
total reflection (ATR) mode. The ATR-FTIR spectra were recorded on a special mirror 
setup using the “single-beam sample reference” concept. For that, the particular 
heparin solution was spread on the upper half (sample) of the silicon internal reflection 
element (50 x 20 x 2 mm3) and the lower uncoated half was used as the reference. 
Shuttling the two halves repeatedly in the IR beam, recording the respective intensity 
spectra (IReference(v), ISample(v)), and computing A(v) = -log(ISample(v)/IReference(v)) resulted in 
well-compensated ATR-FTIR absorbance spectra (A(v)). For determination of the 
heparin sulfate content, the intensity peaks of the sulfate and the carboxylic acid group 
were recorded and their ratio was calculated. The decrease of this ratio for the different 
desulfated heparins indicated the sulfate removal, so that the remaining sulfate content 
could be determined with respect to the non-desulfated heparin, which served as the 
control sample (set to a sulfate content of 100 %). 
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Supplementary results and discussion for chapter 4.1: 
“Method establishment for analyzing the interaction of growth 
factors with starPEG-heparin hydrogels” 
 
Growth factor binding studies 
For a first qualitative analysis of the protein uptake and distribution within the starPEG-
heparin hydrogels, representative gel samples were analyzed using CLSM and 
fluorescently labeled FGF-2 or VEGF (Fig. B1A and B). Generally, it could be 
demonstrated that both proteins were able to diffuse into the networks. A 
homogeneous fluorescence intensity of TAMRA-FGF-2 (Fig. B1A, top and B1B, left) 
within the hydrogel could be observed immediately (~ 1 min) after applying the protein. In 
contrast, for TAMRA-VEGF (Fig. B1A, bottom and B1B, right) a complete penetration 
could be observed only after 30 min (~ 65 % for 0.02 h and 80 % for 0.5 h; p < 0.05 when 
comparing the different time points). This fact could be explained by the larger diameter of 
VEGF (~ 6 nm; 38.2 kDa) [Muller et al., 1997] compared to that of FGF-2 (~ 3 nm; 
17.2 kDa) [Eriksson et al., 1991], which might result in a slower diffusion of this 
cytokine through the gel pores. After initial penetration, neither protein showed an 
increase in the relative fluorescence intensity inside the gel networks (after 24 h ~ 60 % for 
FGF-2 and ~ 90 % for VEGF) and no corresponding decrease in the supernatants (after 24 h ~ 
40 % for FGF-2 and ~ 10 % for VEGF) over the course of the experiment. The lower 
fluorescence intensity of TAMRA-FGF-2 in the hydrogel might result from an increased 
tendency of this protein to attach to non-specific surfaces not originating from the 
starPEG-heparin networks or from a decreased heparin binding affinity due to 
interferences of the attached label with the particular FGF-2 molecular structure as it 
will be discussed later. 
After penetration, both proteins showed a homogenous distribution throughout the 
entire scaffold (Fig. B1A). These findings demonstrate that there were no significant 
structural heterogeneities in the network and that the mesh sizes of the hydrogel did 
not prevent penetration of the rather small FGF-2 and VEGF molecules. In contrast to 
that, proteins with dimensions larger than the pore sizes of the gels could be excluded 
efficiently as shown by [Freudenberg et al., 2009]. This offers the advantage that, 
134 Appendix B – Supplementary results and discussion 
besides the stabilizing effect that heparin exerts on FGF-2 and VEGF and the low 
tendency of starPEG to allow for unspecific protein adsorption, the penetration of some 
proteases known to degrade FGF-2 or VEGF such as neprilysin (~ 86 kDa, 
degradation of FGF-2) [Goodman et al., 2006], MMP3 (~ 54 kDa, degradation of 
VEGF) [Lee et al., 2005] or human plasmin 1 (~ 91 kDa, degradation of FGF-2 and 
VEGF) [Saksela et al., 1988; Keyt et al., 1996] is prevented by the particular gel 
structure. In summary, these findings show that the matrices could act as supportive 
carriers maintaining the biological activity of the bound cytokines. Moreover, CLSM 
seems to be an efficient qualitative method to follow uptake of FGF-2 or VEGF in situ. 
Fig. B1 Qualitative FGF-2 or VEGF uptake experiments performed by CLSM studies. B1A: representative 
fluorescence microscopy images of FGF-2 (top) or VEGF (bottom) uptake into starPEG-heparin 
hydrogels); adapted from [Zieris et al., 2010a]. Alexa 488-labeled gel scaffolds (green) were incubated with 
TAMRA-labeled FGF-2 or VEGF (red). White dashed lines indicate the upper and lower boundary of the 
gel network (bar: 10 µm). X-Z-confocal laser scanning of the gel networks was performed at different time 
points after immobilization. B1B: average fluorescence intensity of TAMRA-labeled FGF-2 (left) or VEGF 
(right) in the gel and in the corresponding supernatant at different time point. Measurements were 
performed using confocal laser scanning microscopy. All data are presented as average over three X-lines 
from at least two different gel samples ± root mean square deviation. * indicates statistically significant 
differences (p < 0.05; ANOVA). 
B 
A 
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The quantitative analysis of FGF-2 or VEGF binding to starPEG-heparin scaffolds was 
performed utilizing four different methods (for experimental parameters see Tab. 2, 
chapter 4.1). Due to the detection limits of these approaches, protein concentrations 
used for loading had to be varied. However, in order to compare the different methods 
used here directly, the starPEG-heparin gels have to have the capacity to take up all 
the FGF-2 or VEGF that is applied during these experimental approaches, which was 
proven by radiolabeling studies (125I-studies, respectively), amino acid analysis via 
HPLC and ELISA (see chapter 4.2.2) within a protein concentration regime between 
0.5 to 50 µg/ml. Consequently, within the range of growth factor concentration applied 
in this study, the data generated by the four different methods used to quantify FGF-2 
or VEGF binding to starPEG-heparin hydrogels can be compared directly. 
 
After ensuring that the growth factor binding capacity of starPEG-heparin hydrogels 
does not limit the methodological evaluation, the FGF-2 or VEGF immobilization to the 
matrices was compared among detection via radiolabeling studies, CLSM, amino acid 
analysis via HPLC and ELISA. As shown in Fig. B2, for analysis of FGF-2, except for 
the comparison of CLSM experiments and amino acid analysis via HPLC (p > 0.05), 
there were significant differences between the results obtained with the different 
approaches (p < 0.05). While ELISA data showed almost no protein remaining in the 
Fig. B2 Comparison of the FGF-2 or VEGF immobilization efficiency as obtained by CLSM experiments, 
radiolabeling studies, amino acid analysis via HPLC or ELISA; adapted from [Zieris et al., 2010a]. Values 
are expressed as percentage of FGF-2 or VEGF bound to the starPEG-heparin hydrogels based on the 
initially applied protein amount. All data are presented as mean ± root mean square deviation from n = 2-4. 
* indicates statistically significant differences (p < 0.05; ANOVA). For statistical comparisons apart from the 
illustrated significant differences, see text. 
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supernatant (immobilization efficiency of ~ 99 %), only about 38 % of the deployed FGF-2 was 
detected in the scaffold by radiolabeling studies. Immobilization efficiencies obtained by 
fluorescence labeling and amino acid analysis were ~ 61 % and 68 %, respectively. In 
contrast, when considering results determined for VEGF immobilization, significant 
differences between the data generated by all the different methods (p < 0.05) were 
found except for comparing CLSM studies and ELISA (p > 0.05). Here, immobilization 
efficiencies were ~ 91 % (CLSM), 46 % (radiolabeling studies), 60 % (amino acid analysis 
via HPLC) and 99 % (ELISA), respectively. 
As an explanation, due to the different principles of protein quantification in the gel 
body or the supernatant, all of these four approaches require specific experimental 
conditions. To detect FGF-2 or VEGF by radiolabel and fluorescence sensitive 
methods, the protein has to be converted before the immobilization process. The 
disadvantage of this approach is that the growth factor has to undergo a labeling 
procedure which may alter its characteristics. Although a certain fraction of the protein 
might be already unable to bind to heparin before the labeling procedure (e.g. due to 
structural changes during bacterial synthesis [Linemeyer et al., 1987]), all of these 
treatments, as well as the presence of the label itself increase the probability of 
structural alterations of the growth factor [Bos et al., 1999]. This might of course affect 
the interaction with heparin during the immobilization procedure. Moreover, weakly 
attached label may become released from the protein [Bos et al., 1999] during uptake 
and release studies and thus influence the results of the analytical experiments. Given 
these drawbacks of methods that require a labeled protein, one could explain the low 
FGF-2 immobilization efficiency observed in both radioisotope and fluorescence based 
detection. However, as the VEGF binding efficiency was slightly increased for 
radiolabeling studies and significantly higher for analysis by CLSM (p < 0.05 for comparing 
the immobilization efficiency for FGF-2 and VEGF), this protein seems to be less affected by any 
labeling procedure or the modification itself. Consequently, depending on the particular 
characteristics of the protein of interest, the high sensitivity and the possibility to detect 
the labeled molecule in presence of multicomponent biofluids make these approaches 
nevertheless attractive. 
A second issue that becomes important during binding and release studies with both 
labeled and native protein is the problem of non-specific adsorption to surfaces not 
originating from the actual material that is being analyzed [Edelman et al., 1991]. Any 
relative quantification of FGF-2 or VEGF either in the gel body or in the supernatant 
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would be negatively affected by a certain protein fraction that is simply inaccessible to 
detection. In order to decrease the contact of FGF-2 or VEGF with such areas 
significantly, custom-made incubation chambers were used in the present study for 
performing radiolabeling experiments and ELISA. With this arrangement, the protein 
solution is almost exclusively applied to the material of interest and additionally 
contacts a small rubber ring only that separates the walls of the chamber and prevents 
leaking of the solution. Consequently, any interaction with the bottom of the glass cover 
slip used to prepare surface-bound hydrogels or with the plastic walls of the incubation 
system is avoided.  
Unfortunately, these chambers cannot be used for fluorescence studies as the 
dimensions of the chamber do not allow for any usage within a microscopic setup. For 
amino acid analysis, which offers the possibility to quantify high concentrations of non-
labeled protein, the problem arises that in the immobilization chambers a defined 
volume of the gel body outside of the rubber ring cannot be exposed to the FGF-2 or 
VEGF solution. As after hydrolysis the analyzed HPLC peaks originate from the whole 
sample surface (loaded and non-loaded regions of the scaffold), signals coming from 
unloaded gel disturb the quantification of the protein. Due to these restrictions, in the 
case of CLSM- and HPLC-based detection, alternative setups had to be used for FGF-
2 or VEGF immobilization. Within these configurations, the protein could stick to large 
areas originating from the bottom of the glass cover slip used to prepare surface-bound 
hydrogels or to the plastic walls of the incubation system. Such unspecific protein 
adsorption on ’foreign’ materials could therefore particularly account for the low FGF-2 
immobilization efficiency determined by detection of fluorescently labeled protein and 
amino acid analysis after hydrolysis as it was already identified as the major source of 
physical FGF-2 loss in the studies of [Edelman et al., 1991]. However, since CLSM 
experiments performed under similar conditions, but not the amino acid quantification 
via HPLC, delivered high VEGF immobilization rates, loss of protein due to unspecific 
adsorption might not be the only effect influencing the determined binding efficiency. As 
one indication, the high standard deviation obtained by amino acid analysis by HPLC 
might point to an error that could be rather associated with the method used for 
quantification than with the experimental setup during protein immobilization. Although 
the analysis of bound growth factor was based on corresponding FGF-2 and VEGF 
standards similarly subjected to hydrolysis, both proteins could behave differently 
during this treatment in the presence of the gel components. This could result in 
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incomplete cleavage and, therefore, determination of immobilized protein amounts that 
were too low. Moreover, the presence of peaks originating from hydrolysis of heparin or 
starPEG which partially overlaid the signals coming from the amino acids might have 
also led to inaccuracies in growth factor quantification. 
 
Parts of the text and the figures of this chapter were adapted with kind permission from 
[Zieris et al., 2010a]. Copyright 2009 Springer Science and Business Media. 
 
Growth factor release studies 
After analyzing the FGF-2 or VEGF uptake into starPEG-heparin hydrogels, 
experiments on the release of the proteins were performed. For these studies, CLSM 
and amino acid analysis could not be used since these methods were not sensitive 
enough to detect the small protein quantities in the pico- to nanogram range that were 
sequestered by the gels. For CLSM, the low decrease in the fluorescence intensity 
during release of TAMRA-FGF-2 or -VEGF from the gel body was hard to quantify 
precisely due to interfering processes like photobleaching or -degradation. In the case 
of amino acid analysis via HPLC, depending on the particular molecular composition, 
the method is not sufficient for the quantification of protein amounts below 0.8-0.2 µg 
[Salchert et al., 2003]. Consequently, it could not be applied for analysis of FGF-2 or 
VEGF release within the scope of concentrations used for immobilization to starPEG-
heparin hydrogels in this study and results were only obtained from 125I- studies and 
ELISA.  
Fig. B3 Cumulative amount of hydrogel-released FGF-2 or VEGF as determined by analysis via 
radiolabeling studies or ELISA. Plotted are the cumulative amounts of FGF-2 (left) or VEGF (right) 
released per cm² scaffold area as quantified by radiolabeling studies or ELISA (p < 0.05 for the 
determination of the protein release by the different methods; ANOVA). All data are presented as mean ± 
root mean square deviation from n = 2-4. 
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Fig. B3 illustrates the cumulative release of FGF-2 or VEGF measured within a time 
period of 96 h for gel matrices loaded with a protein concentration of 1 µg/ml. Similar 
qualitative conclusions concerning the release kinetics of both proteins could be drawn 
from results obtained by both methods. However, once again there were significant 
differences in the quantities of FGF-2 or VEGF delivery determined by the two different 
approaches (26.9 or 31.5 ng as determined by radiolabeling studies for FGF-2 or VEGF; 1.4 or 0.82 ng 
as determined by ELISA for FGF-2 or VEGF; p < 0.05 for the comparison of the two methods). Although 
in any case experiments were performed under conditions minimizing the contact area 
for non-specific protein interactions with glass or plastic surfaces, higher amounts of 
released FGF-2 or VEGF were detected via radiolabeling studies. One explanation for 
that could be that the presence of the label might weaken the interaction of FGF-2 or 
VEGF with heparin, thereby leading to a faster release compared to the native protein 
which was used for ELISA studies.  
 
 
Supplementary results for chapter 4.2.1: 
“Uptake and release of FGF-2 or VEGF depending on the physico-
chemical network properties” (for discussion see particular chapter) 
Fig. B4 Amount of hydrogel-immobilized FGF-2 or VEGF determined gel types as quantified via 
radiolabeling studies or amino acid analysis via HPLC; adapted from [Zieris et al., 2010b]. Plotted is the 
amount of electrostatically bound FGF-2 or VEGF per cm² scaffold area for the different gel types γ = 1.5; 
3 or 6 (low, intermediate and high crosslinking degree, p > 0.05; ANOVA) determined by radiolabeling 
studies (left) or amino acid analysis via HPLC (right). All data are presented as mean ± root mean square 
deviation from n = 2 (HPLC) or n = 2-4 (radiolabeling studies). 
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Fig. B5 Cumulative amount of hydrogel-released FGF-2 or VEGF determined for different gel types as 
quantified via radiolabeling studies. Plotted is the cumulative amount of electrostatically bound FGF-2 (left) 
or VEGF (right) released by the different gel matrices γ = 1.5; 3 or 6 (low, intermediate and high 
crosslinking degree, p > 0.05; ANOVA). All data are presented as mean ± root mean square deviation from 
n = 2. 
 
 
Supplementary results for chapter 4.2.2:  
“Uptake and release of FGF-2 and/or VEGF depending on the protein 
concentration” (for discussion see particular chapter) 
Fig. B6 Amount of hydrogel-immobilized FGF-2 or VEGF determined for different protein concentrations as 
quantified via radiolabeling studies or amino acid analysis via HPLC; adapted from [Zieris et al., 2010b]. 
Plotted is the uptake of FGF-2 or VEGF in dependence on the protein concentration in the immobilization 
medium determined by radiolabeling studies (left) or amino acid analysis via HPLC (right); linear 
regression, R² (FGF-2; radiolabeling studies) = 0.99973; R² (VEGF; radiolabeling studies) = 0.99941; R² 
(FGF-2; HPLC) = not definable (immobilization with only 10 µg/ml FGF-2 could not be resolved by HPLC); 
R² (VEGF; HPLC) = 0.99991. All data are presented as mean ± root mean square deviation from n = 2 
(HPLC) or n = 2-4 (radiolabeling studies). 
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Fig. B7 Amount of hydrogel-immobilized FGF-2 and/or VEGF as quantified via radiolabeling studies; 
adapted from [Zieris et al., 2011]. Plotted is the amount of electrostatically bound FGF-2 and/or VEGF per 
cm² scaffold area (p > 0.05 for the immobilized amount of single FGF-2 or VEGF and the corresponding 
concentration used in the combination; ANOVA). All data are presented as mean ± root mean square 
n = 2-4. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. B8 Cumulative amount of hydrogel-released FGF-2 or VEGF determined for different protein 
concentrations types as quantified via radiolabeling studies. Plotted is the cumulative release of FGF-2 
(left) or VEGF (right) in dependence on the protein concentration used for immobilization. All data are 
presented as mean ± root mean square deviation from n = 2. 
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Supplementary results for chapter 4.3.2: 
“Influence of the FGF-2 and/or VEGF delivery” (for discussion see 
particular chapter) 
Fig. B9 FGF-2 and VEGF uptake and release experiments in dependence on the RGD functionalization of 
starPEG-heparin hydrogels as quantified via ELISA; adapted from [Zieris et al., 2011]. top: amount of 
electrostatically bound FGF-2 and VEGF per cm² scaffold surface (p > 0.05 for the immobilized amount of 
growth factors in pure or RGD-functionalized gels; ANOVA). bottom: cumulative percentage of 
electrostatically bound FGF-2 (left) or VEGF (right) released into SF ECGM + 1 mg/ml BSA by gels which 
were loaded with a combination of 1 µg/ml FGF-2 + 1 µg/ml VEGF (p > 0.05 for the released amount of 
growth factors by pure or RGD-functionalized gels; ANOVA). All data are presented as mean ± root mean 
square deviation from n = 3. 
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Supplementary results for chapter 4.5.1: 
“Incorporation of cleavable peptide linkers” (for discussion see 
particular chapter) 
Fig. B10 FGF-2 or VEGF uptake experiments in dependence on the functionalization of starPEG-heparin 
hydrogels with MMP-cleavable peptide sequences as quantified via radiolabeling studies. Plotted is the 
amount of electrostatically bound FGF-2 and VEGF per cm² scaffold surface (p > 0.05 for the immobilized 
amount of growth factors in non-cleavable or MMP-cleavable gels; ANOVA). All data are presented as 
mean ± root mean square deviation from n = 2. 
 
 
Supplementary results for chapter 4.5.2: 
“Selective desulfation of heparin binding sites” (for discussion see 
particular chapter) 
 
Tab. B1 Physico-chemical properties of hydrogels prepared from heparin with different degrees of 
sulfation. 
            
 
desulfation 
  
none N 2-O 6-O; N complete 
volume swelling [-] 30 24 48 29 42 
storage modulus [Pa] 7300 14800 1900 6800 1300 
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Supplementary results for chapter 4.5.3: 
“Application of competing highly heparin-affine polyelectrolytes” 
(for discussion see particular chapter) 
Fig. B11 Cumulative amount of hydrogel-released FGF-2 or VEGF in dependence on the presence of 
chitosan in the release medium at different time points as quantified via ELISA. Plotted is the cumulative 
release of FGF-2 (left) or VEGF (right) in dependence on the temporally defined addition of chitosan. The 
red symbol indicates the first addition of chitosan (rhomb: application after 0 h; square: application after 3 
h; pentagon: application after 24 h). All data are presented as mean ± root mean square deviation        
from n = 3. 
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